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SUMMARY
In a detailed study, the effect of sensitizing tissues to insulin with a thiazolidinedione 
(pioglitazone) on postprandial lipid metabolism was compared to a group of type 2 
diabetic patients treated with sulphonylurea (glibenclamide) in a treatment regime 
designed to achieve equivalent glycaemic control (HbAlc) in both groups. An oral fat 
tolerance test was administered after a 6 week treatment with diet and after 20 weeks 
treatment with glibenclamide or pioglitazone.
Glycaemic control in both groups was unchanged by either treatment but in the 
fasting state, insulin sensitization caused a significant reduction in plasma total 
triglyceride content due to a significant reduction in total VLDL and, in particular, 
VLDL-2 present. The overall triglyceride response to the fat test showed a significant 
improvement to control clearance levels in the pioglitazone group that was not observed 
in the glibenclamide group. Chylomicron and chylomicron remnant clearance improved 
with insulin sensitization. IDL and LDL-TG was significantly higher in the diabetic 
patients than the controls and after treatment with thiazolidinedione the triglyceride 
content of these lipoproteins was reduced by contrast to glibenclamide treatment. 
Cholesterol content did not change significantly over the postprandial period either 
overall or in lipoproteins. There were only small effects on the enzymes of lipoprotein 
remodelling (LCAT, CETP, PLTP, HL or LPL) by insulin sensitization.
Insulin release was reduced over the postprandial period by insulin sensitization 
and a significant reduction of proinsulin and 32-33 split-proinsulin also occurred. The 
results of this study show that sensitizing tissues to the action of insulin causes a 
reduction in insulin resistance (HOMA) and a more rapid clearance of postprandial 
lipoproteins. In addition there is an apparent beneficial effect on P-cell function which is 
manifested by lower levels of incompletely processed insulin species probably caused by 
a less prolonged period of glycaemia.
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CHAPTER 1
1.1 LIPOPROTEINS -  STRUCTURE AND FUNCTION
The insolubility of lipid in aqueous media has led to the evolution of complex 
mechanisms that allow the distribution of lipid to tissues for anabolic or catabolic 
purposes. In the blood, the majority of lipids are transported to the site of their uptake 
by tissues in the form of lipoprotein complexes (Table 1). The lipoproteins are 
spherical particles containing protein (usually one or more of the apolipoprotein 
family) and neutral lipids, such as cholesterol and triglyceride, and polar 
phospholipids. The lipids are packaged together in such a way that hydrophobic 
lipids (triglyceride and cholesteryl ester) form a central core surrounded by a 
monolayer consisting of polar phospholipids, free cholesterol and apolipoproteins. 
The apolipoproteins have three main functions:
o They solubilize insoluble lipids such as cholesterol, cholesteryl esters
and triglyceride.
o They regulate enzyme activity such as lecithin:cholesterol acyl 
transferase (LCAT) and lipoprotein lipase (LPL). 
o They act as ligands for cell surface receptors for the uptake of 
lipoproteins and lipid exchange.
The different types of lipoproteins present in plasma are characterised by their 
hydrated buoyant density or for lipoproteins with a density less than 1 by their 
flotation rate defined in terms of Svedberg units of flotation (Sf).
21
Table 1: Major Apolipoproteins: Location and Function
Apolipoproteins Lipoproteins Function
A-I HDL Structural and activator of LCAT
A-II HDL Not known
B-100 VLDL, LDL, LDL, Lp(a) Structural and ligand for LDL receptor
B-48 Chylomicrons Structural
C-II Chylomicrons, VLDL L P L t
C-III Chylomicrons, VLDL LPL 4-
E Chylomicron remnants, 
IDL, LDL, HDL VLDL
Ligand for LDL receptor;
1.1.1 P o s t p r a n d ia l  (In t e s t in a l , G a s t r ic  o r  A l im e n t a r y ) L ip o p r o t e in s
Chylomicrons are the largest of the lipoprotein particles present in plasma varying in 
size from 100 to 1000 nm diameter, and consist mainly of triglyceride, together with 
lesser amounts of phospholipid, free cholesterol (2%), cholesterol ester (1%) and 
protein (apo-B48) (Table 2). After a meal, the ingested triglyceride is hydrolysed in 
the stomach to non-esterified fatty acids (NEFA), di- and monoglycerides by gut 
lipases and taken up by the enterocytes where they are used to synthesise 
triglyceride. Apolipoprotein B48 is the major protein component of chylomicrons 
and is unique to these lipoproteins. Apo-B48 is a short ended protein product 
generated from a full length apo-B m-RNA by the introduction of a premature stop 
codon in triplet 2153 by a specific apo-B 100 m-RNA enzyme (Scott et al., 1994). 
The polypeptide consists of the amino-terminal half of apolipoprotein B100 and has 
a molecular weight about 48% of that of the apolipoprotein B100 polypeptide but,
22
importantly, it is not a ligand for the B/E receptor. In intestinal cells, the transfer of 
lipids into nascent chylomicrons (or VLDL in hepatocytes) is mediated by 
microsomal triglyceride transfer protein (MTP) (Wetterau et al., 1992).
Newly-synthesised chylomicrons are secreted into the lymphatic system and 
enter the systemic circulation through the thoracic duct. Once in the blood they 
receive apo-C and apo-E from HDL in exchange for apo-AI and are acted on by 
lipases that hydrolyse the triglyceride component releasing NEFA with the result that 
the particles become smaller, less buoyant particles known as chylomicron remnants 
(Erkelens et al., 1981). The rate of removal of chylomicrons from plasma is rapid, 
with a half-life of less than 1 hour, and normally they are undetectable after a 12- 
hour fast. Peak chylomicronaemia normally occurs between 3 to 6 hours after 
ingestion of a fatty meal.
In normal subjects, chylomicron remnants clearance starts within 30 minutes 
after the meal (Berr et al., 1992) and they are usually taken by the liver, through a 
process mediated primarily by receptors that recognise apolipoprotein E (apo-E) 
(Windier et al., 1996). Apo-E is also found in VLDL, IDL, and HDL. It serves 
several functions, including the receptor-mediated transfer of cholesterol between 
tissues and plasma. It is the principal apolipoprotein in the central nervous system 
(CNS), and it serves as the major apolipoprotein that is capable of lipid transport and 
regulation of lipid metabolism through known receptor-mediated processes. There 
are 3 common isoforms of the protein: E2, E3 and E4, arising from 2 alleles. The 
most common phenotype is apo-E3/3 (55%), with apolipoprotein E3/4 the next most 
common (26%). The least frequently occurring phenotype is apo-E2/2 (1%), which 
in some instances is associated with type III hyperlipidaemia. Apo-E mediates
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binding of chylomicron remnants to the hepatic B/E receptor where its greater 
affinity for the receptor in part ensures their rapid removal from the circulation.
In patients with type III hyperlipoproteinaemia, chylomicron remnants 
accumulate in the plasma and have been linked to the development of accelerated 
atherosclerosis (Hussain., 1995, 1997; Mahley et al., 1999, 1997, 1994, 1991). The 
clearance of chylomicron remnants by the liver is a process that involves three steps. 
It begins with sequestration of the remnants within the space of Disse (Figure 1). 
Chylomicron remnant enter the space of Disse through the fenestrated sinusoidal 
endothelium, that allows the smaller remnants to enter (Fraser et al., 1995). The 
space of Disse is rich in heparan sulphate proteoglycan (HSPG) that has an important 
role in remnant catabolism by attaching the triglyceride-rich lipoproteins and 
bringing them in close proximity to lipases (Williams et al., 1997). Treatment of a 
variety of cells with heparinase, which removes heparan oligosaccharides from 
HSPG in the liver, significantly inhibits the binding and uptake of apo-E enriched 
remnant lipoproteins (Ji et al., 1993, 1995). HSPG may serve as a reservoir for apo- 
E, allowing the particles to be enriched in apo-E and so enabling their interaction 
with receptors (Hamilton et al., 1990; Huang et al., 1998; Raffai et al., 2003). Several 
approaches have shown that apo-E is critical ligand for the clearance of remnant 
lipoproteins in animal and human studies (Mahley et al., 1989, 1998; Shimano et al., 
1994). More recently, it has been demonstrated that over expression of human apo-E 
prevented diet-induced remnant accumulation and also accelerated remnant clearance 
from the plasma (Fan et al., 1998).
24
Remnant Lipoprotein Clearance Pathways
Sinusoid
HSPGML SpaceSequestration
Lipolytic
Processing LPL LPL
HL'
Uptake HSPG
(3)
HSPG Alone
LRP Complex
HSPGLRPLDL?
HSPG
dependent
LRP
dependent
+
+
+
+
Figure 1: Remnant lipoprotein uptake by the LDL receptor, HSPG-LRP pathway, and 
HSPG alone. HSPG are abundant in the space of Disse and on the surface of hepatocyte. 
Apo-E and HL, secreted by the hepatocytes, appear to bind to the HSPG and be available to 
enrich the remnant lipoproteins, the HSPG/apo-E appear to fulfils a critical role in the 
sequestration or capture of the remnants. Three major pathways for internalization are 
illustrated: 1) direct uptake by LDL receptor; 2) HSPG-LRP pathway: (a) remnants 
transferred to LRP for uptake or (b) HSPG-LRP complex internalized; and 3) HSPG alone 
mediating direct uptake. (Adapted from Atherosclerosis, Vol. 141 suppl 1. Dec 1998).
The space of Disse contains hepatic lipase (Sanan et al., 1997) and also LPL, 
which is carried to the space of Disse with the remnants (Skottova et al., 1995). The 
LDL receptor is a critical participant in the uptake and endocytosis of remnants, but 
other molecules are involved, including LDL Related Protein (LRP). LRP a very 
large molecule, expressed predominantly on hepatocytes and has multiple ligands, 
including apo-E, HL, LPL, a2-macroglobulin (Herz et al., 1995). LRP is synthesised 
in the cell and transported with receptor-associated protein (RAP), which serve as a
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chaperone to usher LRP to the cell surface (Willnow et al., 1996). Interestingly, 
when RAP is isolated and injected intravenously, it blocks the binding of all the 
ligands to the LRP (Kounnas et al., 1995) and can also bind to cell-surface HSPG 
(Mahley et al., 1994). On the other hand, RAP, which is known to be a heparin- 
binding protein and the hepatic HSPG are rich in heparin-like domains. Therefore, it 
is likely that RAP binds to hepatic HSPG in vivo and that RAP can inhibit remnant 
lipoprotein binding to the LRP and HSPG as well as LDL receptor. In summary, 
under normal physiological conditions, the LDL receptor and the LRP mediate 
endocytosis by the liver of chylomicron remnant.
Table 2: Lipoprotein Classification
Lipoprotein Density
(g/ml)
Flotation
(Sf)1
Major Function
Chylomicrons <0.95 >400 Transport of exogenous triglyceride.
Chylo. Remnants <0.95 40-400 Transport of exogenous triglyceride.
VLDL-1 0.95-1.006 60- 400 Transport of endogenous triglyceride.
VLDL-2 0.95- 1.006 20- 60 Transport of endogenous triglyceride.
IDL 1.006- 1.019 12- 20 Intermediate in the transformation of 
VLDL to LDL.
LDL 1.019- 1.063 0- 12 Transport cholesterol and 
phospholipid to peripheral cells.
HDL 1.063- 1.21 __2 Transport cholesterol and other lipids 
from peripheral tissues to the liver.
1 Expressed in Svedberg units for solvent density of 1.006.
2 HDL sediment at 1.063g/ml salt solution.
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1.1.1.1 Metabolism of exogenous cholesterol
Exogenous cholesterol arising from the diet or bile, contributes, in part, to the plasma 
cholesterol concentration. The remainder is endogenously synthesized mainly by the 
liver. A daily western diet contains around 400 mg of cholesterol, derived from 
animal sources, and about 200- 400 mg of non-cholesterol sterols, derived mostly 
from plants (Nair et al., 1984). On average, about 55% of the dietary cholesterol is 
absorbed and retained on a daily basis, but almost none of the non-cholesterol sterol 
are retained (sterol, sitosterol, campesterol, etc.) (Salen et al., 1970).
In the intestinal lumen, esterified cholesterol is cleaved by pancreatic 
cholesteryl ester hydrolase into free cholesterol and fatty acid. Free cholesterol, along 
with other lipids and fat-soluble vitamins, is then solubilized by bile acids into 
micelles which interact with the intestinal brush border and enter the enterocyte by a 
transport process the mechanism of which is not completely understood. After 
absorption, the free cholesterol is re-esterified by acyl CoAxholesterol 
acyltransferase (ACAT) and is packaged along with other lipids, into chylomicrons 
which are secreted into the lymph and ultimately into plasma, as described 
previously. The excess remaining free cholesterol and plant sterols are presumed to 
be pumped out of the enterocyte back to the intestinal lumen by the complex of ATP- 
binding cassette transporters (ABCG5/ABCG8). These transporters somehow work 
as pumps in the intestine and liver to move selectively cholesterol and non­
cholesterol sterols from the enterocyte/bile canaliculus back to the lumen (Small et 
al., 2003; Wittenburg et al., 2002).
Ezetimibe, a novel, potent and selective inhibitor of cholesterol absorption 
(Van Heek et al., 1997). It reduces plasma cholesterol concentrations by up to 15- 
20% (Davidson et al 2002) and has been found to lower plasma plant sterol
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concentrations in sitosterolaemic subjects. This suggests that this drug may be 
inhibiting the activity of a putative sterol permease in the brush border membrane of 
the enterocyte (Klett et al., 2003). It does not, however, affect the absorption of bile 
acids, fatty acids, triglyceride and fat-soluble vitamins (Van Heek et al., 2000).
1.1.2 HEPATIC LIPOPROTEINS
1.1.2.1 Very Low Density Lipoprotein (VLDL)
VLDL is similar to chylomicrons in structure and composition but the particles are 
smaller in size ranging from 25-100 nm. Compared to intestinal lipoproteins, it 
contains relatively less triglyceride but more cholesterol, phospholipid and protein. 
Apo-BlOO is the main structural protein present in VLDL and remains with the 
particles from secretion into and clearance from plasma through the apo-B/E 
receptor. Other lipoproteins present in VLDL are a mixture of apo-C and apo-E. 
VLDL is mainly synthesised in the liver and its chief function is the transport of 
endogenously synthesised triglyceride to peripheral tissues where they are a substrate 
for the lipases that release NEFA for storage or oxidization as an energy source. As 
the triglyceride is removed the particle becomes smaller and denser ultimately 
becoming intermediate-density lipoprotein (IDL). Further lipolysis leads to the 
production of low-density lipoprotein (LDL) ultimately taken up from the circulation 
by specific hepatic receptors that recognise the apo-BlOO (LDL receptor or apo-B/E 
receptor). Partially lipolysed VLDL and IDL can also be taken up by the so-called 
remnant receptors which are structurally different from the apo-B/E receptors.
One of the substrates for VLDL-triglyceride synthesis is NEFA released from 
adipose tissue stores by the action of a hormone sensitive lipase. This enzyme is 
inhibited by insulin and thus in the fasting state, when insulin levels are low,
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lipolysis proceeds at a maximum rate, releasing NEFA into the plasma. VLDL 
synthesis is promoted by an increase in the supply of NEFA to the liver or in an 
increase in the rate of hepatic synthesis of endogenous fatty acids as occurs during 
periods of high carbohydrate intake.
VLDL exists in two forms differing in flotation rate (Sf): VLDL-1 (Sf 60-400) and 
VLDL-2 (Sf 20-60), according to size and composition. VLDL-1 are larger particles 
and contain relatively more triglyceride than VLDL-2. The key observation has been 
made that the large VLDL-1 particles (Sf 60-400) and small VLDL-2 (Sf 20-60) 
particles exhibit distinct pattern of metabolic behaviour and that their production is 
independently regulated (Demant et al., 1996; Packard et al., 1997). There is 
evidence that a greater proportion of VLDL-2 particles are converted into LDL via 
IDL as compared with VLDL-1, which are converted to EDL that is removed from 
plasma before undergoing conversion to LDL. The VLDL-1 production rate shows a 
close positive correlation with plasma triglyceride levels and the current theory is 
that VLDL-1 overproduction causes elevation of plasma triglyceride whilst VLDL-2 
overproduction results in raised LDL concentrations (Packard et al., 1997).
1.1.2.2 Intermediate Density Lipoprotein (IDL)
IDL is the intermediate density particle formed during lipolytic conversion of VLDL 
to LDL. Apo-BlOO is the predominate apolipoprotein present but IDL contain 
relatively less triglyceride and more cholesterol ester than VLDL and is present in 
about one tenth of the concentration of LDL in plasma. LDL particles have one of 
two fates: the particles can be removed from blood, by virtue of apo-E binding to the 
hepatic apo-B/E receptor or they can be further hydrolysed to LDL.
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1.1.2.3 Low Density Lipoprotein (LDL)
LDL is the major carrier of cholesterol, and cholesterol ester, triglyceride and 
phospholipid in plasma. A typical LDL molecule is composed of 75-80% lipid and 
20-25% protein. Apolipoprotein B100 constitutes more than 95% of the protein 
content of LDL. LDL shows some variation in particle size and composition and can 
be separated by density gradient ultracentrifugation or gradient gel electrophoresis 
into 3 main subclasses dependant on their size and density (see Chapter 3 for a 
detailed discussion of LDL sub classes). LDL is taken up by hepatic and extra- 
hepatic tissues by a specific receptor mediated process. This receptor, known as the 
LDL receptor (apo-B/E), recognises both apo-BlOO and apo-E as ligands with the 
latter having a greater affinity than apo-BlOO and is, in part, responsible for the 
clearance of the VLDL-derived lipoproteins from the blood (Hersberger et al., 2003; 
Slowik et al., 2003).
1.1.2.4 Lipoprotein (a)
Another lipoprotein, very similar to LDL, is also found in plasma and known as 
Lipoprotein (a) (Lp(a)). This lipoprotein is slightly denser than LDL because of the 
presence of an extra protein called apolipoprotein ‘a’ that is covalently attached to 
the apolipoprotein B 100 by a disulphide bond. This extra protein is synthesised in the 
liver, and has a close structural homology to plasminogen. The function of Lp(a), if 
any, is not known but excess levels in blood are a risk factor for CHD probably 
caused by similarities of apo (a) to plasminogen that interferes with clot dispersion 
(Buchler et al., 2003).
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1.1.2.5 High Density Lipoprotein
HDL are the smallest and densest of the lipoproteins and is also the most 
heterogeneous. HDL is mainly synthesised by the liver and to a lesser extent by the 
small intestine. Apolipoprotein Al is the major apolipoprotein of HDL and its 
functions include mediating removal of cholesterol from cells, including 
macrophages through interaction with ATP-binding cassette protein (ABCA1); 
promoting selective uptake of cholesteryl ester in liver, binding to SR-B1 receptor on 
the surface of liver and steroidogenic tissues, such as, adrenal, and ovary (Remaley et 
al., 2001). Apo-AI also serves as cofactor for the enzyme, lecithin:cholesterol acyl 
transferase (LCAT) responsible for the esterification of free cholesterol derived from 
peripheral tissues with a fatty acid from phospholipid to yield cholesteryl ester. This 
ester-rich form of HDL is known as HDL2. Newly synthesised ester is exported from 
the HDL to other lipoproteins by a specific transfer protein (cholesteryl ester transfer 
protein; CETP) in exchange for triglyceride. As the triglyceride progressively 
accumulate it causes the HDL to become a less dense more spherical form called 
HDL3 . Triglyceride-rich HDL3 is lipolysed by the hepatic lipase and results in the 
formation of small HDL2  particles available for further esterification of free 
cholesterol (Rader et al., 2003).
The mechanism of the protective effect of HDL against the development of 
CHD is complex. Much research in this field has centred on the lipid transport 
function of HDL, particularly reverse cholesterol transport, and whether any 
component of HDL aids the efflux of cholesterol from the artery wall and peripheral 
tissues. Another area of interest, however, has emerged in recent years concentrating 
on antioxidant function and how HDL protects LDL and cell membranes against
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lipid peroxide-induced damage, which is thought to mediate the initiation and 
progression of atheromatous lesions. The chief mechanism is through the action of 
the enzyme paraoxonase which detoxifies the product of lipid peroxidation such as 
hydroperoxide. This prevents further oxidation of lipids and protects against the 
formation of oxidized LDL which is known to be atherogenic (Mackness et al, 2002).
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Figure 2: HDL cycle and reverse cholesterol transport. The triglyceride present in HDL3 
is acted on by hepatic lipase releasing NEFA into the blood & returning the particle to a small 
dense HDL2 form ready to receive more free cholesterol via the ABC1 receptor or cholesterol 
efflux regulatory protein (CERP) to be esterified by LCAT. The ester formed is exchanged for 
triglyceride from TRL by the action of CETP. The HDL accumulate the TG and is then acted 
on by the HL and the cycle continue. (Adapted from Lipids and Lipid Disorders, MD Feher & 
W Richmond, Excerpta Medica Publications, 2003).
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1.2 LIPOPROTEIN REMODELLING, ROLE IN CHOLESTEROL 
HOMEOSTASIS AND RECEPTOR-MEDIATED UPTAKE
Three enzymes: lipoprotein lipase (LPL), hepatic lipase (HL) and lecithin:cholesterol
acyl transferase (LCAT), are of physiological importance in lipoprotein metabolism. 
In addition, two specific transfer proteins: cholesteryl ester transfer protein (CETP) 
and phospholipid transfer protein (PLTP), facilitate the interchange of these lipids 
between lipoproteins (they will be discussed in detail in Chapter 5).
1.2.1 Lecithin Cholesterol Acyltransferase (LCAT)
LCAT enzyme is secreted by the liver and is present in plasma, lymph, and 
cerebrospinal fluid and is tightly associated with HDL. It is responsible for the 
formation of most of the esterified cholesterol present in plasma. The action of 
LCAT is described in the preceding section (1.1.2.5).
1.2.2 Cholesterol Ester Transfer Protein (CETP)
CETP mediates the transfer of cholesteryl ester from HDL to triglyceride-rich 
lipoproteins (TRLs) and of triglyceride in the reverse direction. By this means an exit 
route is provided for cholesterol ester, accumulating in HDL as a result of the action 
of LCAT, thus maintaining continuity of movement of cholesterol from cells into 
plasma.
1.2.3 Phospholipid Transfer Protein (PLTP)
Phospholipid transfer protein (PLTP) plays an important role in plasma lipoprotein 
metabolism. PLTP facilitates the in vivo transfer of phospholipids from triglyceride- 
rich lipoproteins to HDL during lipolysis by LPL. These phospholipids are released
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from chylomicrons and VLDL during lipolysis, and are important precursors of 
plasma HDL (will be discussed in Chapter 5).
1.2.4 Lipoprotein Lipase (LPL)
Lipoprotein lipase is a key enzyme that is present in a number of tissues, including 
muscle, adipose tissue, lung, brain and breast tissue. LPL is present primarily on the 
luminal surface of endothelial cells in tissue capillary beds, where it is bound to 
heparan-sulphate proteoglycan component of plasma membrane. It is also present in 
very low concentrations as a free form in the plasma.
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Figure 3: Lipoprotein remodelling by lipoprotein lipase. The primary role of LPL is 
to hydolysed TG in TRL releasing NEFA and forming smaller remnant particles that can be 
taken up by hepatic receptors or in the case of VLDL remnants further lipolysed to form LDL. 
(Adapted from Lipids and Lipid Disorders, MD Feher & W Richmond, Excerpta Medica 
Publications, 2003).
LPL has several distinct physiological functions including 1) hydrolysis of the 
triglyceride component of triglyceride-rich lipoproteins, chylomicron and VLDL. 2) 
LPL has a bridging function in which it serves to anchor the lipoprotein to the vessel 
wall and facilitate triglyceride hydrolysis and particle uptake. 3) LPL acts as a ligand
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for the LDL receptor, VLDL receptor and LDL related protein. 4) LPL can mediate 
the uptake of lipophilic vitamins (vitamin A, E) and the uptake of lipoprotein 
associated lipid (Stein et al., 2003).
1.2.5 Hepatic Lipase (HL)
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Figure 4: The functions of 
hepatic lipase. (Adapted from 
Lipids and lipid Disorder, MD 
Feher & W Richmond, 
Excerpta Medica 
Publications, 2003)
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Hepatic lipase is a glycoprotein that catalyzes the hydrolysis of lipoprotein 
triacylglycerols and phospholipids in LDL, HDL and triglyceride-rich lipoproteins 
remnant particles (see Figure 4). The majority of hepatic lipase is synthesised and 
secreted by the liver. Its catalytic activity contributes to the remodelling of LDL
35
HDL resulting in smaller, denser particles. In addition to its lipolytic activity, hepatic 
lipase participates with surface proteoglycans, the scavenger receptor B1 (SR-B1) 
and the LDL receptor-like-protein in promoting hepatic uptake of lipoproteins, 
including triglycerides-rich lipoprotein remnants, LDL and HDL particles and 
nascent HDL particles. Unlike lipoprotein lipase human HL does not require the 
presence of apo-CII for its function. HL is known to be important in the generation 
of small dense LDL (Cheung et al., 2003).
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1.3 EFFECTS OF DIABETES AND INSULIN ON LIPOPROTEIN 
METABOLISM
1.3.1 Pathophysiology of Type 2 Diabetes
The pathophysiology of type 2 diabetes involves characteristic defects in three main 
organ systems that act together to produce abnormal glucose metabolism i.e., liver, 
skeletal muscle, and pancreas.
A characteristic trait of type 2 diabetes is the overproduction of glucose by 
the liver. Increased hepatic glucose output correlates with fasting glucose levels and 
is the main cause of fasting hyperglycaemia in type 2 diabetic patients. Increased 
levels of NEFA supplied to the liver contribute to elevated hepatic glucose output. 
The second defect occurs in glucose disposal by skeletal muscle that accounts for 80- 
90% of insulin-stimulated glucose uptake and is significantly reduced in type 2 
diabetic subjects. Finally, impaired pancreatic p-cell function is commonly found in 
established type 2  diabetes, usually coincident with fasting hyperglycaemia. 
Prospective epidemiological studies indicated that insulin resistance may be primary 
defect in type 2  diabetes, since it can be detected long before deterioration of glucose 
tolerance occurs, often at a time when insulin secretion is increased. Thus, in many 
patients, insulin resistance and hyperinsulinaemia precede the development of type 2  
diabetes and can be identified in most pre-diabetic individuals. Moreover, insulin 
resistance can be further exacerbated during the progression of the disease because of 
abnormal lipid and carbohydrate metabolism. The p-cells respond to peripheral 
insulin resistance by increasing basal and postprandial insulin secretion in an attempt 
to maintain normal glucose homeostasis. Eventually, the p-cells are no longer able to 
compensate for insulin resistance by secreting increased amounts of insulin. At this 
stage, glucose-induced insulin secretion falls, allowing glucose homeostasis to
deteriorate and leading to the subsequent development of frank diabetes (De Fronzo 
et al 1997; Chen et al; 1999; Cherrington et al; 1999).
1.3.2 Molecular mechanism of insulin action
Insulin stimulates the cellular uptake of glucose, amino acids and fatty acids, 
promotes the storage of carbohydrate, lipids and proteins and inhibits their 
degradation and release into the circulation.
1.3.3 Receptor signalling pathways
The signal transduction pathway is very complex and only partly understood in spite 
of great progress in the last ten years (Saltiel et al., 2001) (Figure 5). Insulin action 
begins with its binding to highly specific receptors on the plasma membrane of the 
target tissue e.g., muscle or adipose tissue. The insulin receptor is a large 
transmembrane protein consisting of a- and p-subunits. Insulin initiates its cellular 
effects by binding to the a-subunit which leads to phosphorylation of specific 
tyrosine residue of the cytoplasmic tail of the P-subunit (Cheatham et al., 1995). The 
p-subunits themselves possess tyrosine kinase activity and autophosphorylate 
multiple tyrosine residues on the p-subunits. A number of proteins bind with high 
affinity to phosphotyrosine residues present in specific sequence motifs on the 
insulin receptor p-subunit. These proteins include the insulin receptor substrate (IRS) 
proteins, She and Gab-1, which, when bound, became phosphorylated by the insulin 
receptor tyrosine kinase activity.
The IRS serve as docking sites for protein ligands that contain specific 
recognition domains. The divergence of insulin signalling pathways within the cell
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Figure 5 : Simplified scheme for intracellular action of insulin. The insulin receptor is a 
tyrosine kinase. Binding of insulin activates intracellular autophosphorylations of the 
receptors and catalyses the phosphorylation of insulin receptor substrate 1 and 2 (IRS 1,2) 
cellular proteins of the insulin signalling pathway. The various pathways following act in a 
concerted action to co-ordinate translocation of Glut-4- containing vesicles into the plasma 
membrane, enzyme activation involved in the regulation of glucose, lipid, and protein 
metabolism and gene expression (involving GRB2 growth factor receptor-bound protein and 
the Ras complex).
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may reside at the level of the IRS docking proteins that have been referred to as the 
metabolic switches of the cell.
Insulin receptor activation is upstream of diverse intracellular signalling 
pathways including activation of phosphoinositide-3-kinase (PI-3-kinase), Akt B and the 
MAP kinase (Cheatham et al., 1995; Kim et al., 1999; White et al., 1997). The effect of 
insulin on glucose uptake involves activation of the enzyme PI-3 kinase which is 
necessary for insulin action on glucose transport (Hara K et al., 1994. Okada T et al.,
1994), glycogen synthesis, protein synthesis (Mendez et al., 1996), antilipolysis (Okada 
et al., 1994), and gene expression (Sutherland et al., 1998).
Although activation of PI-3 kinase is crucial for transducing the metabolic 
effects of insulin, it is not sufficient in itself to account for the glucose uptake process. A 
number of other growth factors stimulate PI-3 kinase to the same extent as insulin, but 
they do not stimulate glucose transport.
In summary, current evidence suggests that IRS proteins in their phosphorylated 
form, act as a docking site for a variety of second messenger kinases that allow the 
insulin signal to diverge throughout the target cell
1.3.4 Glucose uptake and disposal
PI-3 kinase activation ultimately leads to the translocation of cytoplasmic Akt to the 
plasma membrane where it is phosphorylated to an activated form responsible for the 
translocation of vesicles containg glucose transport proteins (GLUT) to the cell 
membrane where they are incorporated and allow the entry of glucose into the cell. 
Glucose transporters consist of at least four transmembrane proteins (Glut-1, -2, -3, -4). 
These GLUT proteins have distinct specificities, kinetic properties, and tissue 
distribution that define their role (Shepherd et al., 1999). Two major glucose transporters 
(Glut-1 and 4) have been identified in skeletal muscle. Glut-1 is mainly involved in basal
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glucose uptake. Glut-4 is predominantly expressed in insulin target tissue (skeletal 
muscle, adipose tissue, and cardiac muscle), and it is the major insulin responsive 
glucose transporter. In muscle Glut-4 is recycled between the plasma membrane and an 
intracellular storage pool with approximately 90% sequestered intracellularly in the 
absence of insulin. This polarised intracellular distribution is unique to Glut-4. After 
insulin stimulation, Glut-4 moves from intracellular stores to the plasma membrane, 
resulting in glucose transport into the cell (Shepherd et al., 1999). The fate of glucose 
entering the cell is determined too by Akt phosphorylation. In its activated form, Akt 
inhibits glycogen synthase 3 (GSK-3) and so directs the glucose to catabolic energy- 
producing pathways.
1.3.5 Fatty acids and insulin action
A role for fatty acids in the regulation of insulin sensitivity has been proposed by Randle 
and termed the “fatty acid-glucose cycle” (Randle et al., 1963). They speculated that it is 
increased fat oxidation that causes the insulin resistance associated with obesity. The 
proposed mechanism is that increase in fatty acids causes an increase in the 
intramitochondial acetyl CoA with subsequent inactivation of pyruvate dehydrogenase 
(Figure 6 ). This in turn would cause the intracellular citrate concentration to increase, 
leading to inhibition of phosphoffuctokinase, a key rate-controlling enzyme in 
glycolysis. Subsequent accumulation of glucose-6 -phosphate would inhibit hexokinase 
activity resulting in an increased intracellular glucose concentration and decreased 
glucose uptake.
A recent series of studies proposed an alternative mechanism for fatty acid 
induced insulin resistance in human skeletal muscle (McGarry et al., 2002).
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Figure 6: Features of the glucose fatty acid cycle. Fatty acids are taken up from the plasma 
either as the NEFA or by action of LPL and carried to the mitochondria (FABPs). The NEFA are 
transported into the mitochondria by the carnitine palmitoyl transferase (CPT) system, where they 
undergo B-oxidation to produce acetyl CoA that enters the krebs cycle. Accumulation of acetyl 
CoA and citrate inhibits PDH and phosphofructokinase (PFK), respectively. This lead to buildup of 
glucose-6-P and inhibition of hexokinase, resulting in reduced glucose uptake. FABP (fatty acyl 
binding protein), F-Ac (fatty acyl); HADH (hydroxyacyl-CoA dehydrogenase cytosolic fatty acid 
binding protein). (Adapted from Diabetes, Vol. 49, May 2000).
It has been proposed that the excess triglyceride or NEFA in muscle in insulin resistant 
states might lead to increased long-chain acyl CoA (LCCoA) concentrations. An 
increase in fatty acyl CoAs can lead to increased diacylglycerol (DAG) concentrations, 
which could also result from partial lipolysis of intracellular triglyceride. DAG, in turn, 
activates many isoforms of protein kinase C (PKC). Activation of PKC can 
phosphorylate and inhibit tyrosine kinase activity of the insulin receptor as well as 
tyrosine phosphorylation of insulin receptor substrate IRS-1 and thereby inhibit its 
interaction with PI-3 kinase (Figure 7). As a consequence insulin mediated glucose 
uptake becomes impaired. The relevant concentration of LCCoA is on the other hand 
dependent on malonyl-CoA, which regulates the activity of carnitine
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palmitoyltransferase 1 and thereby the rate of fatty-acid oxidation. The synthesis of this 
important regulator and “metabolic sensor” is mediated by AMP-kinase. 
Phosphorylation and activation of this enzyme causes an inhibition of acetyl-CoA 
carboxylase, but an activation of malonyl-CoA decarboxylase resulting in a fall of 
malonyl-CoA and an acceleration of fatty-acid oxidation. Up-regulation of relevant 
phosphatases as observed in experimental diabetes leads to inactivation of AMP-kinase 
and subsequently to an increased level of malonyl-CoA, a reduced rate of fatty-acid 
oxidation and accumulation of LCCoA and triglycerides favouring the development of 
an insulin-resistant state.
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Figure 7: Potential interaction between lipids and insulin signalling. Potential inhibitors; 
potential activators. ACC, acetyl-CoA carboxylase; PKB, protein kinase B. (Adapted from 
Diabetes, VOL. 49, May 2000).
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There are likely to be multiple factors that contribute to impairment of both glucose 
and fatty acid metabolism. An impaired functional capacity of mitochondria is one 
factor that might contribute to perturbations in the metabolism of both substrates. A 
reduction in the activity of marker enzymes of oxidative pathways has been observed 
in skeletal muscle obtained from individuals with obesity and type 2  diabetes and 
correlates with the severity of insulin-resistant glucose metabolism (Simoneau et al.,
1997).
Reduced mitochondrial capacity for fat oxidation during fasting conditions, as noted 
in obesity and type 2 diabetes (Kelley et al., 2000), could lead to insulin-resistance 
through the accumulation of lipid intermediates (Schmitz-Peiffer et al., 1999). It has 
also been postulated that impaired mitochondrial function could directly contribute to 
insulin-resistance due to insufficient provision of ATP for the phosphorylation of 
glucose by hexokinase as well as other reactions requiring phosphorylation (Gerbitz 
et al., 1996).
Skeletal muscle is richly endowed with mitochondria and strongly reliant on 
oxidative phosphorylation for energy production. In a previous study using electron 
microscopy to assess skeletal muscle mitochondrial size and morphology as a 
monitor of the activity of electron transport chain demonstrated perturbations in type 
2 diabetes and, to a lesser degree, in obesity. Activity of rotenone-sensitive 
NADH : 0 2  oxidoreductase was found to be reduced by 40% in skeletal muscle from 
patients with type 2 diabetes. Skeletal muscle mitochondria were also smaller in 
obesity and type 2  diabetes, and in some instances, particularly in type 2  diabetes, 
there was evidence of severely damaged mitochondria. Both findings correlated with 
the degree of insulin resistance (Kelley et al., 2002). Others had earlier reported 
reduced activity of mitochondrial tricarboxylic acid cycle enzymes in skeletal muscle
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from type 2 diabetic subjects (Vodra et al., 1977; Lithell et al., 1981). Disturbances 
of mitochondrial function in muscle and other tissue can lead to lipid accumulation 
(Vogel et al., 1999), which in turn can cause or aggravate insulin resistance.
There are at least several potential mechanisms by which impaired mitochondrial 
function might contribute to insulin resistance of skeletal muscle.
• Insulin resistance could be related to lipid accumulation within myocytes. 
Previous studies have found that increased lipid accumulation in muscle is 
associated with insulin resistance and that, in turn, lipid accumulation in skeletal 
muscle in obesity and type 2  diabetes is related to reduced oxidative enzyme 
capacity (He et al., 2001; Kelly et al., 2002).
• Disturbed oxidative phosphorylation capacity has been proposed to be a direct 
cause of insulin resistance (Gerbitz et al., 1996).
• An excess of long-chain fatty acid CoA, could damage the mitochondria either 
directly or by channeling of palmitoyl-CoA to increased ceramide synthesis 
(Basu et al., 1998).
• Mitochondria DNA (mtDNA) is more susceptible than nuclear DNA to damage 
and has a less efficient repair mechanism. Increased mtDNA mutations have been 
reported in type 2 diabetic patients (Liang et al., 1997). One source of injury to 
mtDNA could be reactive oxygen species, and increased free radical damage to 
mtDNA has been reported for other tissues in type 2 diabetic patients (Nishikawa 
et al., 2 0 0 0 ).
In summary current evidence suggest that there is an impaired bioenergetic capacity 
of skeletal muscle mitochondria in type 2  diabetes.
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1.3.6 Insulin resistance syndrome
Insulin resistance is characterised by an abnormally low response of the target cells to 
insulin. The sensitivity and the responsiveness, or both, of the cell to the hormone can be 
decreased depending on the severity of the syndrome (Olefsky et al., 1981). The term 
'Insulin resistance' was originally used to indicate impaired insulin action on glucose 
uptake and metabolism in skeletal muscle, adipose tissue, and the liver. More recently 
the term has been used to indicate abnormal insulin activation or inhibition of other 
pathways such lipolysis, LPL activity and hepatic metabolism (Frayn et al., 1993). The 
term Syndrome X was introduced in 1988 by Reaven who suggested that insulin 
resistance and compensatory hyperinsulinaemia, underlie clustering of cardiovascular 
risk factors including impaired glucose tolerance, type 2  diabetes, hypertension and 
dyslipidaemia. Several other components have subsequently been added, including 
obesity especially abdominal obesity, microalbuminuria, abnormalities in fibrinolysis 
and coagulation and the presence of small dense atherogenic LDL particles (Bjomtorp et 
al., 1994; Groop et al., 1993; Yudkin et al 1999). It has also been described as the Insulin 
Resistance Syndrome (IRS) (Haffner et al., 1997). A positive association between insulin 
resistance and CHD has been shown in different studies. (Reaven et al., 1988; DeFronzo 
et al., 1991; Ferrannini et al., 1991; Frayn et al., 1992; Howard et al., 1996).
A defect in the insulin signalling transduction cascades, will lead to a reduced 
biological activity of the hormone i.e. insulin resistance. In vivo and in vitro studies 
suggest that only those parts of the signalling cascade involved in glucose disposal are 
affected in insulin resistance, whereas the MAP-kinase pathways appear to be 
undisturbed. Thus insulin resistance is most often described as a functional defect 
causing an inappropriate disposal of glycaemia as a consequence.
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1.3.7 Assessment of Insulin Resistance
A variety of procedures have been developed to detect the presence of clinical insulin 
resistance. The most widely accepted and specific measure is a technique called the 
euglycaemic hyperinsulinaemic clamp; however, this technique has a number of 
limitations, primarily in the procedure's complexity and expense. A second, less invasive 
method is the frequently sampled intravenous glucose tolerance test (FSIVGTT) and can 
be applied to larger populations (Del Prato et al., 1999; Ferrannini et al., 1998). Both of 
these procedures require a well-staffed clinical research setting and are unrealistic for 
clinical practice or large population-based studies (Del Prato S, 1999; Ferrannini et al.,
1998).
The homeostasis model assessment (HOMA) of insulin sensitivity is a 
mathematical model that provides a measure of insulin resistance based on the fasting 
glucose and insulin content of the plasma. (Bonora et al., 2000; Mathews et al., 1985). 
This parameter was proposed 10 years ago as a simple, inexpensive alternative to more 
sophisticated techniques. Specifically, an estimate of insulin resistance by HOMA score 
is calculated with the formula: [fasting serum insulin (pU/ml) x fasting plasma glucose 
(mA/)]/22.5 (Mathews et al., 1985). The HOMA method has been shown to correlate 
strongly to glucose disposal methods as assessed by clamp studies (Bonora et al., 2000). 
Furthermore, the HOMA model of insulin resistance showed a significant association 
with risk of CHD over 8 -year follow-up of the San Antonio Heart Study, after 
adjustment of multiple covariates (Anthony et al., 2002). The convenience of the HOMA 
models has led to its being used in numerous large scale studies and research projects in 
which the clamp methods are impractical because of the nature of the study.
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1.4 LIPID METABOLISM IN TYPE 2 DIABETES
The most common lipid abnormality present is moderate hypertriglyceridaemia 
associated with reduced levels of HDL cholesterol and is seen in up to one third of type 2 
diabetes patients, including those with good glycaemic control (Barrett-Connor et al., 
1982; Taskinen et al., 2003). By contrast, total plasma cholesterol concentrations and in 
particular LDL cholesterol concentrations are little different from normal subjects 
(Ginsberg et al., 2000).
1.4.1 Effects on VLDL
A variety of factors have been implicated in the aetiology of diabetic dyslipidaemia 
including: hyperinsulinaemia (Reaven et al., 1981, 2003) insulin resistance (Malmstrom 
et al., 1997) hyperglycaemia and disturbed fatty acid metabolism (Lewis et al., 1995). 
An important function of insulin is to maintain a state of balance between intestinally 
derived triglyceride containing lipoproteins (chylomicron) and triglyceride containing 
lipoproteins of hepatic origin (VLDL). In type 2 diabetes, insulin resistance impairs the 
normal suppression of NEFA release from adipose tissue by a failure in the mechanisms 
that lead to suppression of hormone sensitive lipase activity. Consequently plasma 
concentrations of NEFA are greater and the influx of NFFA to liver is increased 
(Bjomtorp et al., 1994). This is coupled with diminished inhibitory effect of insulin on 
hepatic apo-BlOO synthesis which results in excess VLDL production. It is this excess 
VLDL which is responsible for hypertriglyceridaemia in particular large VLDL-1 
(Malmstrom et al., 1997).
The key observation has been made that the large VLDL-1 particles (Sf 60-400) 
and small VLDL-2 (Sf 20-60) particles exhibit distinct patterns of metabolic behaviour 
and that their production is independently regulated (Demant et al., 1996; Packard et al., 
1997). VLDL-1 production rate shows a close positive correlation with plasma
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triglyceride levels and VLDL-2 overproduction results in raised LDL concentrations 
(Packard et al., 1997).
VLDL synthesis appears to be regulated by insulin since it correlated positively 
with plasma insulin concentration (Chirieac et al., 2000; Reaven et al., 1987) and with 
insulin resistance as measured by the euglycaemic hyperinsulinaemic clamp technique 
(Abbott et al., 1987). In this scenario, insulin resistance results in compensatory 
hyperinsulinaemia, which in turn stimulates further VLDL production in the liver and the 
end result is elevation of plasma triglyceride. The opposite effect has been shown in in 
vitro studies showing that insulin acutely suppresses VLDL apo-B production in cultured 
hepatocytes and also increases the intracellular degradation of newly synthesised Apo-B 
(Sparks et al., 1992). Furthermore, it has been shown that in healthy men acute 
hyperinsulinaemia suppresses VLDL apo-B and triglyceride production (Cumming et al.,
1995). In Type 2 diabetes , the principal finding was that, by contrast to the suppression 
of VLDL-1 apo-B production observed in normal subjects, insulin failed to decrease 
VLDL-1 apo-B production (Malmstrom et al., 1997). This lack of inhibition of VLDL-1 
production by insulin is a feature of insulin resistance (Taskinen et al., 1998).
In the postprandial state insulin has a physiological action to regulate the balance 
between liver-derived and intestinally-derived triglyceride-rich particles, and should 
suppress the secretion of large VLDL-1 particles. This would relieve postprandial 
competition between chylomicrons and VLDL-1 for lipolysis and other remodelling 
processes and prevent prolonged alimentary lipaemia. The failure of insulin to suppress 
VLDL-1 particle release in type 2 diabetes is likely to contribute to a major cause of the 
raised triglyceride levels and exaggerated postprandial lipaemia (Malmstrom et al., 
1997).
The metabolism of the remnant particles may also be influenced by low LPL activity 
associated with type 2 diabetes and insulin resistance. Evidence from in vitro studies
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showed that LPL enhances the binding of lipoprotein remnants to the LRP (Beisiegel et 
al., 1991). In insulin resistance, the binding of remnant particles to LPL and/or LRP is 
diminished, resulting in decreased elimination of remnants by peripheral tissues 
(Beisiegel et al., 1996). This leads to a greater exposure of the vessel wall to triglyceride- 
rich lipoproteins remnants, secondary to reduced elimination which is thought to 
promote atherogenesis.
1.4.2 Effects on LDL
Hypertriglyceridaemia in diabetic subjects results in compositional changes in all 
lipoprotein particles. There is increased neutral lipid exchange resulting in triglyceride 
enrichment of both HDL and LDL (Bagdade et al., 1990). This is probably a 
consequence of both CETP over-activity and the expanded VLDL pool (Elchebly et al.,
1996). Furthermore, triglyceride-rich HDL and LDL particles undergo increased 
lipolysis due to the over-activity of hepatic lipase present in type 2 diabetes (De-Man et 
al., 1996; Syvanne et al, 1995, 1997). This results in generation of smaller, more dense 
lipoprotein particles with altered physiological function.
Small dense LDL particles are a characteristic of the dyslipidaemia of type 2 
diabetes (Taskinen et al., 1996) and are related to hypertriglyceridaemia rather than 
diabetes per se (Syvanne et al., 1997). The Strong Heart Study Shows observed a 
stepwise decrease in LDL-size according to diabetic status from normal through 
impaired glucose tolerance, to full diabetes. This association is more striking in women 
than in men (Howard et al., 1998). Small dense LDL is mainly generated when there is 
an elevation of triglyceride-rich lipoproteins, both VLDL and chylomicron particles, that 
remain in the circulation for longer periods than normal; this allows for an increased 
exchange of cholesterol ester from LDL in return for triglyceride, resulting in 
triglyceride-rich LDL, that are then lipolysed by hepatic lipase to small dense particles.
50
Small dense LDL particles are a strong risk factor for coronary heart disease and 
is considered to be highly atherogenic (Austin et al., 1998). It is easily oxidised and 
binds more readily to arterial wall proteoglycans. It has been shown to be an independent 
determinant of intima-media thickness (IMT) and an independent predictor of coronary 
artery disease in healthy men (Skoglund-Andersson et al., 1999). Small dense LDL also 
seems to be associated with very early signs of endothelial dysfunction, particularly in 
diabetic patients (Tan et al., 1999). The size of small, dense LDL correlates with flow 
mediated dilatation independent of other variables (HbAlC, blood pressure). It has also 
been shown to exhibit an increased toxicity to endothelial cells, increased tendency to 
absorption by macrophages to form foam cells and increased susceptibility to oxidative 
and glycative modification (Sattar et al., 1998). Furthermore, small LDL particles have 
an increased tendency to induce free radical production (Heinecke et al., 1998).
1.4.3 Effects on HDL
In diabetic dyslipidemia, not only is the concentation of HDL reduced, but also the 
distribution and the composition is changed. Levels of HDL2 are reduced and there is a 
shift towards smaller HDL-particles that are reported to have diminished reverse 
cholesterol transfer capacity and reduced antioxidant potential hence reducing the anti­
atherogenic potential of HDL (Syvanne et al., 1995). The mechanisms underlying the 
lowering of HDL in diabetes may be due to any one or combination of the following. 1) 
Small HDL particles, which are a product of the lipolysis of triglyceride-enriched HDL 
are cleared more rapidly from the circulation. 2) Triglyceride-enriched HDL are more 
unstable in the circulation, with apo-AI loosely bound. 3) Lipolysis of triglyceride- 
enriched HDL may lower HDL particle number by causing apo-AI to be shed from the 
HDL particles and cleared from the circulation through the kidney. 4) LPL activity is 
impaired in diabetes and may contribute to the lowering of HDL levels by reducing the
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availability of the surface components (phospholipid and apolipoproteins) of 
triglyceride-rich lipoproteins for transfer to the HDL fraction (Rader et al., 2002).
I 4.4 Lipoprotein lipase dependent effects
Decreased activity of LPL has been observed in type 2 diabetes compared with age 
matched non-diabetic subjects (De-Man et al., 1996). The reduction of LPL activity is 
more striking in diabetic patients with cardiovascular disease (De-Man et al., 1996). In 
vitro and in vivo studies have suggested a regulatory role for NEFA in LPL-mediated 
lipolysis since high concentrations of NEFA have been shown to inhibit LPL activity by 
weakening the binding of the enzyme to its substrate and to the endothelium-bound 
heparan sulphate (Lewis et al., 1995).
1.4.5 Hepatic lipase dependent effects
Increased activity of hepatic lipase is a feature in type 2 diabetes (Syvanne et al., 1997) 
and results in generation of small dense LDL particles with altered physiological 
function (De-Man et al., 1996) and which are a strong risk factor for cardiovascular 
disease (Austin et al., 1998) as discussed previously.
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1.5 TRIGLYCERIDE-RICH LIPOPROTEINS IN ATHEROSCLEROSIS
Triglyceride-rich lipoproteins have been implicated in clinical coronary disease events 
for over 40 years. Gofman was the first to show an increase in triglyceride-rich 
lipoproteins (Sf 12-400) in men with myocardial infarction (Gofman et al., 1954). 
Grundy proposed two hypotheses to understand the atherogenicity of triglyceride-rich 
lipoproteins, applicable to both diabetic and non-diabetic subjects (Grundy et al., 1991).
The first view is that triglyceride-rich lipoproteins (such as VLDL remnants), are 
directly atherogenic. The second hypothesis is that triglyceride-rich lipoproteins act 
indirectly by influencing the concentration and composition of other lipoproteins. There 
is considerable evidence, both clinical and experimental, supporting the role of 
triglyceride-rich lipoproteins in atherogenesis. This evidence includes in vitro and animal 
experiments showing that remnants can induce foam-cell formation, and can infiltrate 
the arterial wall (Karpe et al., 1995; Rapp et al., 1994). Lipoprotein analysis from the 
Monitored Atherosclerosis Regression Study (MARS) demonstrate that VLDL remnants 
and IDL are strong predictor of carotid intima-media thickness, implying the importance 
of triglyceride-rich lipoproteins in the early stages of atherogenesis (Hodis et al., 1998; 
Mack et al., 1996).
Miesnbok and Patsch have proposed the concept of “triglyceride or lipid 
intolerance” whereby ineffective triglyceride removal for any reason prolongs the 
plasma residence time of triglyceride-rich lipoproteins. These lipoproteins are 
atherogenic because of their potential to extract cholesteryl ester from HDL and LDL, 
resulting in cholesterol deposition into the arterial wall by these particles whose normal 
function is to carry triglyceride into the peripheral tissue (Miesnbok et al., 1992; Patsch 
et al., 2000; Tannock et al., 2002).
The third hypothesis proposed that the effect of hypertriglyceridaemia also 
renders LDL itself more atherogenic because it is associated with presence of small LDL
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(pattern B). Small dense LDL are reported to be more susceptible to oxidative 
modification (Chait et al., 1993; Chmura et al., 2002). The presence of this small, dense 
LDL is closely associated with coronary heart disease (Austin et al., 1998; Hokanson et 
al., 2 0 0 2 ).
An expanded pool of circulating cholesteryl ester may be an important factor in 
the formation of small, dense LDL because of an increased transfer of cholesteryl ester 
from LDL to those lipoproteins. A similar increase in the transfer of cholesteryl ester 
from HDL to triglyceride-rich lipoproteins also contribute to the low HDL cholesterol, 
frequently associated with hypertriglyceridaemia.
HDL particles in type 2 diabetes also have some special characteristics. In a 
cross sectional study (Syvanne et al., 1995), low levels of apo-AI: All (particles carrying 
both apo-AI and apo-AII) particles were a striking feature of in type 2 diabetic subjects, 
especially in those who had coronary disease. This finding is supported by in vitro 
studies; diabetic sera had low capacity to induce cholesterol efflux from cells, and this 
related to apo-AI: All concentration (Syvanne et al., 1996). These results suggest that 
impaired reverse cholesterol transport may also play an important role in the enhanced 
atherogenesis in type 2  diabetes.
There is considerable evidence, both clinical and experimental, supporting the 
role of triglyceride-rich lipoproteins in atherogensis, as Zilversmit postulated in 1979 
(Zilversmit et al., 1979). The rise in plasma triglycerides and triglyceride-rich 
lipoproteins concentrations after a test meal is significantly greater in type 2  diabetic 
patients than in controls (De Man et al., 1996). Fasting hypertriglyceridaemia is 
predictive of exaggerated postprandial lipid excursions (Lewis et al., 1991; Tan et al.,
1995). Several studies suggested that the postprandial increase in hepatic triglyceride- 
rich VLDL particles result from an increased flow of substrates to the liver as a result of 
insulin resistance (Heath et al., 2003; Francone et al., 1992). A second explanation is a
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postprandial saturation of the lipolysis system, due to competition of VLDL particles 
with chylomicrons or their remnants for the common removal pathway. The close 
correlation between the increment in apo-B48 and apo-BlOO containing triglyceride-rich 
lipoproteins in the postprandial state confirms that the clearance of chylomicrons and 
VLDLs is closely related (Demant et al., 1998; Packard et al., 2000).
Remnant particles have also been shown to be toxic to both endothelial cells and 
macrophages, and triglyceride-rich apolipoprotein B containing lipoproteins have been 
isolated in excess from atherosclerotic plaque (Rapp et al., 1994). Recently, it has been 
noted that the postprandial state is associated with impaired endothelium-dependent 
vasodilatation, which is generally considered to be an early marker of cardiovascular 
disease (Anderson et al., 2001; Evans et al., 1999; Muntwyler et al., 1999).
1.5.1 Triglyceride-rich lipoproteins and haemostatic abnormalities-relation to CHD
Several lines of evidence suggests that triglyceride-rich lipoproteins may be directly or 
indirectly thrombogenic and/or antifibrinolytic. An increase in factor VII coagulant 
activity (VII c) has been observed in type lib and type IV hyperlipidaemia.
The Nothwick Park Heart Study demonstrated an independent association between factor 
VII activity and CHD in middle aged men. Both cholesterol and triglyceride 
concentrations are related to factor VII (Meade et al., 1993).
Demonstrable changes have been observed in postprandial haemostasis including 
an increase in factor VII when fat is added to the diet (Miller et al., 2002). In addition 
factor VIIc and factor VII antigen levels are strongly correlated with each other and both 
were significantly increased in patients who exhibited abnormal postprandial triglyceride 
level after a test meal, compared to those who displayed normal triglyceridaemia (Miller 
et al., 1998). A possible explanation for these observations might be that the increase in 
activated VII activity represents an acute response of the haemostatic system to
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postprandial lipolytic activity, and in particular the appearance of negatively charged 
surface lipoproteins, such as remnant particles that activate the intrinsic pathway 
(Silveira et al., 1996).
Elevated plasminogen activated inhibitor 1 (PAI-1) levels have recently been 
included as a component of the insulin resistance syndrome and are strongly associated 
with body mass index , insulin and triglyceride levels (Dichtil, et al., 2000; Juhan-Vague 
et al., 1996). Plasma PAI-I activity is considered to be a major determinant of plasma 
fibrinolytic activity, it is a specific inhibitor of t-PA and is synthesised in the liver and 
endothelial cells. The concentration of PAI-I is partly dependent on a common 
polymorphism discovered in the promoter region of the PAI-I gene (Panahloo et al., 
1996). Fatty acids derived from triglycerides in VLDL can interact with the promoter 
region of the PAI-1 gene, leading to increased transcription of PAI-I in human 
endothelial cells. The molecular mechanism is related to a VLDL-responsive element in 
the promoter region in PAI-1 gene (Eriksson et al., 1998). Importantly, the influence of 
VLDL triglycerides on PAI-1 seems to be genotype-dependent. PAI-1 levels are more 
strongly correlated with levels of triglycerides in 4G/G subjects than in 5G/G subjects 
(Ossei-Geming et al., 1997; Fu et al., 2001; Stegnar et al., 1998). Genotypic-specific 
regulation of plasma PAI-1 by VLDL is due to competition of these two proteins for 
overlapping binding sites.
1.5.2 Diabetes mellitus and Coronary Heart Disease
Elevated levels of plasma triglyceride have long been associated with an increased risk 
of cardiovascular disease in diabetic patients. Type 2 diabetes is associated with high 
risk of premature morbidity and mortality from atherosclerosis-related disease including 
coronary heart disease (Sniderman et al., 2001), cerebrovascular and peripheral vascular 
disease (Letho et al., 2000; Manolio et al., 1996). Diabetic patients without previous
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myocardial infarctions have been found in same studies to have a high risk of myocardial 
infarction as non-diabetic patients who have had a previous myocardial infarction 
(Haffher et al.} 1998). Diabetic patients also have high mortality rate from first 
myocardial infarction.
The aetiology of vascular disease is likely to be multifactorial with factors 
associated with the diabetic state such as hyperglycaemia and factors associated with 
concomitant metabolic syndrome particularly dyslipidaemia, hypertension, thrombotic 
and inflammatory factors. In addition the glycosylation of proteins may also affect 
arterial wall physiology and risk of disease (Zhang et al., 1998).
In a review of previous studies that examined the role of triglyceride as a risk 
factor for cardiovascular disease, it was noted that most analyses showed a relation 
between triglyceride and coronary artery disease (Austin et al., 1991). However, a 
number of studies found that this association did not remain statistically significant after 
controlling for other risk factors, especially HDL cholesterol. Data from Lipid Research 
Clinics Follow-up Study demonstrated that triglyceride was related to 12-year coronary 
artery disease mortality both in men and women (Criqui et al., 1993) and after 
adjustment for covariates, including HDL, the relative risk was no longer statistically 
significant. This finding led the National Institute of Health Consensus Panel to question 
whether triglyceride is a risk factor for coronary artery disease, independent of HDL.
To address the role of triglycerides in cardiovascular disease using all available 
data, meta-analysis of the existing epidemiological literature has shown that increased 
plasma triglyceride is associated with significant increase in risk of incident 
cardiovascular disease among both men and women. In men, an increase of 1 mmol/L 
was associated with 32% increase in risk of disease. A greater increase in risk (76%) was 
found in women. After adjustment for HDL cholesterol the risks were decreased but 
remained statistically significant (Hokanson et al., 1996).
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Recent studies have demonstrated the importance of triglyceride as a risk factor for 
atherosclerosis. The Physician Health Study showed that both triglyceride and LDL 
particle size were significant predictors of future coronary artery disease.
In summary both cross sectional and prospective studies have highlighted the 
strong association between increasing plasma triglyceride concentration and 
cardiovascular disease and knowledge is increasing concerning the potential atherogenic 
effects of hypertriglyceridaemia. It is likely that some triglyceride-rich lipoproteins 
particles such as remnant particles are directly atherogenic and contribute to arterial lipid 
deposition. Furthermore, postprandial hypertriglyceridaemia is prolonged because of 
competition for lipoprotein lipase between chylomicrons and continued hepatic VLDL 
secretion which is not suppressed postprandialy in type 2  diabetes. 
Hypertriglyceridaemia is also associated with important alterations in other lipoproteins. 
HDL is reduced and the distribution of LDL is shifted to smaller denser particles which 
are thought to be more atherogenic partly through increased susceptibility to oxidation. 
Important additional determinants of these changes are increased lipid exchange between 
lipoproteins via cholesterol ester transfer protein and increased activity of the enzyme 
hepatic lipase. It is likely that triglyceride-enriched LDL and HDL are substrates for 
hepatic lipase which hydrolyses triglyceride and phospholipid leading to smaller denser 
LDL and HDL. Small dense HDL is more rapidly catabolised, contributing to reduced 
plasma HDL concentrations.
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1.6 MANAGEMENT OF TYPE 2 DIABETES
Over the last four decades, oral therapies for type 2 diabetes have focused on 
sulphonylureas and metformin, with acarbose introduced in 1990.
Sulfonylureas
This class of drugs lowers blood glucose by stimulating insulin secretion from pancreatic 
p-cells. Their molecular effect is characterised by binding to and blocking an ATP- 
sensitive potassium (K+) channel (K+(ATP)) of the P-cells. The precise binding target is 
the sulfonylurea receptor (SUR1) subunit of this channel. Reduced K+ conductance 
causes membrane depolarization followed by an influx of calcium through a voltage 
sensitive calcium channel. The increased intracellular calcium concentration then 
triggers insulin secretion. Glibenclamide is a member of this group, it blocks channels 
containing SUR1 and SUR2 (in heart and in smooth muscle cell). However, 
glibenclamide administration has no effect on the insulin sensitivity of peripheral tissues.
Metformin
Metformin belongs to the biguanide class. It acts as an antihyperglycaemic by decreasing 
hepatic glucose secretion through inhibition of gluconeogensis and delaying enteric 
resorption of glucose. Metformin does not influence the secretion of insulin, but it 
appears to increase insulin action in peripheral tissues.
Acarbose
Acarbose competitively and reversibly inhibits a-glucosidase, a brush border enzyme in 
the lumen of the small intestine which hydolyszes disaccharides. This inhibition causes a 
decrease in carbohydrate absorption, because disacharides are not broken down into 
absorbable monosaccharides.
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In summary the benefits of these drugs on glycaemic levels, as monotherapy and in 
combination are well documented. However, current antidiabetic agents can claim only a 
modest impact against the progressive nature of diabetes and its chronic microvascular 
and macro vascular complications.
Insulin Sensitizers
Thiazolidindiones (TZDs) are a new class of oral antidiabetic agents. They selectively 
enhance or partially mimic certain effects of insulin on carbohydrate and lipid 
metabolism in type 2 diabetes mellitus and other conditions of insulin resistance* The 
next section will discuss the detailed mechanism of action of this new class of drug.
1.6.1 Peroxisome Proliferator-Activated Receptors and Thiazolidinediones
The peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
transcription factors and are members of the nuclear hormone receptor superfamily. 
Activated PPARs form a heterodimer with the retinoid receptor (RXR) and bind to 
specific response elements in the promoter region (PPREs) of target genes (Figure 8  ). 
An additional “co-repressor” protein in this complex may serve to maintain the receptor 
in an inactivated state (Desveme and Whali et al., 1999).
PPAR ligands may be natural such as saturated and unsaturated fatty acids or 
synthetic such as fibric acid derivatives and thiazolidinedione (TZDs). After binding 
with ligand, the activated PPAR undergoes conformational change, displacing the co- 
repressor or allowing for the binding of a coactivator that leads to enhanced transcription 
of the target gene (Auwerx et al., 1999). PPARs control several genes involved in 
carbohydrate and lipid metabolism (Table3) (Desvergne and Wahli et al., 1999; 
Schoonjans et al., 1996).
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Three isotypes of PPARs a, p/ 8  and y have been described. They are a subgroup of the 
family of nuclear receptor which include retinoid receptor (RXR), thyroid receptor and 
vitamin D receptor (Schoonjans et al., 1996). In humans, each PPAR gene is located on 
different chromosomes and is expressed differently in various organs (Braissant et al., 
1996). PPARa is located on chromosome 22 and expressed predominantly in the liver 
and less in the heart, kidney, skeletal muscle and large intestine, PPAR p / 8  is on 
chromosome 6  and is found at moderate levels in all tissues tested, with high expression 
in placenta, large intestine and heart.
The PPARy gene located on chromosome 3, can encode for two proteins by the 
use of an alternative splice site. PPARy2 contains an additional 28 amino acids at the 
amino terminus. Both isoforms PPARyj, 7 2  are expressed primarily in adipose tissue and 
to a lesser extent in colon, the immune system, skeletal muscle, and the retina.
1.6.2 Function of PPARs at the cellular level
PPARs play key roles in different aspects of lipid metabolism and homeostasis. PPARy 
influences the storage of fatty acids in adipose tissue, and is part of the adipocyte 
differentiation program that induces the maturation of pre-adipocytes into mature 
adipocyte. PPARy target genes encode enzymes involved in peroxisomal mitochondrial 
B-oxidation, ketone body synthesis, lipoprotein lipase (LPL), adipocyte fatty acid 
binding protein (A-FABP or Ap2), Acyl- CoA synthase and fatty acid transport protein 
(FATP).
In adipose tissue, even under high catabolic conditions such as fasting, 
lipogenesis continues and is dependent upon PPARy while some of the released fatty 
acids are re-esterified to triglycerides in a reaction which requires synthesis of glycerol 
in a rate-limiting step which requires phosphoenolpyruvate carboxykinase, whose 
transcription is positively controlled by PPARy.
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A heterozygous knockout mouse for PPARy deficiency has been generated by gene 
targeting. Surprisingly these animals were shown to have enhanced insulin sensitivity in 
peripheral tissues (measured by glucose disposal rate) and liver (suppression of glucose 
production) and lower insulin concentrations during glucose tests than wild type mice 
(Miles et al., 2000). The investigators concluded that the genetic reduction in PPARy 
gene expression is associated with increased insulin sensitivity and under normal 
conditions full PPARy activity may have a role in the development of insulin resistance. 
In other studies heterozygous PPARy deficient mice were shown to be resistant to the 
effects of a high fat intake on glucose homeostasis (Kubota et al., 1999).
These animals, unlike wild type mice, did not become obese and insulin resistant 
and maintained expression of Glut-4 in white adipose tissue when fed a high fat diet. 
Furthermore leptin expression was increased in the PPARy deficient mice due to partial 
suppression of PPARy-mediated inhibition of leptin gene expression, possibly 
accounting for the protective effect. Results from these studies in heterozygous PPARy - 
/+ mice are consistent with a prime role for PPARy in adipocyte differentiation with 
secondary effects on insulin sensitivity.
Further insights into the role of PPARy have come from genetic studies. A 
mutation in the PPARy2 that resulted in the conversion of proline to glutamine at 
position 115 was described in 4 out of 121 obese German subjects (Ristow et al., 1998). 
All the subjects with the mutant allele were markedly obese. Over expression of the 
mutant gene in murine fibroblasts led to the production of a protein, which accelerated 
differentiation of the cells into adipocytes, and greater accumulation of triglyceride. Of 
interest, insulin resistance was less in these subjects. The mean fasting insulin 
concentration was lower in these subjects compared to the obese subjects. Furthermore 
two different heterozygous mutation in the ligand-binding domain of PPARy have been
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reported in three subjects with severe insulin resistance. In addition to insulin resistance, 
all three subjects developed type 2  diabetes and hypertension at an unusually early age.
These above findings provide compelling genetic evidence that this receptor is 
important in the control of insulin sensitivity, glucose homeostasis and blood pressure in 
man. PPARy is likely to be an important regulator of monocyte/macrophage function 
with relevance for human atherosclerotic disease (Roberts et al., 2003). PPARy is present 
in macrophages and in human atherosclerotic lesions and may regulate expression and 
activity of matrix metalloproteinases (MMP s) particularly MMP-9, an enzyme 
implicated in plague rupture (Marx et al., 1998). PPARy has also been demonstrated in 
high concentrations in atherosclerotic lesions localised with oxidised LDL in both 
experimental animal and human atherosclerotic lesions (Ricote et al., 1998; Tontonoz et 
al., 1998).
1.6.3 Thiazolidinediones
Thiazolidinediones represent a new class of oral antidiabetic drugs, that are chemically 
and functionally unrelated to other oral antidiabetic agents. A thiazolidine-2-4-dione 
nucleus is common to all agents of this class, but they differ in side-chain modification 
that influences their pharmacological actions and potential for adverse effects.
The TZDs: troglitazone, rosiglitazone and pioglitazone have already been used in 
clinical practice (troglitazone has been withdrawn in the UK and USA because of liver 
toxicity). TZDs have been shown to be insulin sensitizers acting particularly in muscle 
and adipose tissue, TZDs reduce hyperglycaemia and insulin levels through a variety of 
mechanisms, and they increase insulin mediated glucose disposal
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1.6.4 Mechanism of action of thiazolidinediones
Thiazolidinediones appear to enhance insulin action without directly stimulating insulin 
secretion. They reduce hyperglycaemia in genetically insulin-resistant animals such as 
KKA, ob/ob, and db/db mouse (Chang et al., 1983; Fujiwara et al., 1995). This has been 
confirmed by glucose clamp procedures in non genetic models of insulin resistance, 
including both fructose-fed and high fat diet-adapted rats (Khoursheed et al., 1995; Lee 
et al., 1994;).
Table 3: Metabolic Effects of TZDs
Target gene Adipose tissue
tGLUT-I 
Tg l u t -4 
T Glucokinase
TPhosphoenolpyruvate Carboxykinase 
TPhosphodiesterase 3B 
TLipoprotein lipase
TGlucose uptake 
TGlucose uptake 
TGlucose utilisation 
TGluconeogensis 
Tlntra-adipocyte lipolysis 
tTG  clearance
The improvement in insulin sensitivity seen with TZD treatment generally involves both 
increased peripheral glucose disposal and reduced hepatic glucose production in models 
with hyperinsulinaemia (Bowen et al., 1991; Oakes et al., 1994). In severely insulin- 
dependent diabetic states induced by streptozotocin or 90% pancreatectomy, TZDs have 
little or no effect on hyperglycaemia, confirming that their glucose-lowering activity is 
dependent upon the presence of adequate amounts of insulin (Fujii et al., 1997; Inoue et 
al 1995). However, chronic administration of TZDs caused regranulation of islet beta- 
cells in 90% pancreatectomised rats and ob/ob and db/db mice, without increasing 
plasma insulin concentrations (Fujiwara et al., 1995; Inoue et al., 1995). This may be
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related to the sparing effect of TZDs which indirectly assist restoration of the beta-cell 
insulin reserve.
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Figure 8: Molecular mechanism of thiazolidinedione TZDs. TZDs bind to PPARy, one of 
the family of transcription factors. PPARy is known to heterodimerize with another 
transcription factor, the RXR, enabling PPAR to interact with DNA sequences controlling 
insulin -sensitive genes. The effects of TZDs appear also to require that insulin-regulated 
transcription factors bind to insulin response elements. PPARy activation is linked to 
increased levels of CCAAT/ enhancer binding protein-a(C/EBP-a), a transcription factor 
involved in the differentiation of preadipocytes to adipocytes.
1.6.4.1 Increasing glucose transporters and uptake
In vitro studies have demonstrated that TZDs act directly on adipocyte and skeletal 
muscle to increase glucose transport. In the case of pioglitazone, this has been attributed
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to increased production of the glucose transporter (Table 3) isoforms Glut-1 and Glut-4 
and translocation of Glut-4 into the plasma membrane (Ciaraldi et al., 1995, 2002; El- 
Kebbi I et al., 1994; Sandouk et al., 1993). This effect was evident without added insulin, 
and it is possible that TZDs mimic certain effects of insulin and directly increase muscle 
glycogen synthesis. In cultured hepatocytes (HepG2 cells), TZDs increased glycogen 
synthesis and decreased gluconeogensis (Ciaraldi et al., 1991).
KKA mice is a model of insulin resistance with reduced Glut-4 in adipose tissue 
and skeletal muscles. Treatment of these mice with pioglitazone for 4 days increased 
Glut-4 in skeletal muscle and adipose tissue (Hofmann et al., 1991).
In humans, euglycaemic hyperinsulinaemia clamp studies have demonstrated an 
increase in insulin-stimulated glucose disposal in patients with type 2  diabetes treated 
with pioglitazone (Mahankali et al., 2000).
1.6.4.2 Enhancing Insulin Signalling
TZDs do not appear to act directly on insulin receptor binding in cultured cells, although 
the improved metabolic environment after administration of TZDs in vivo can increase 
the number of insulin receptors without altering affinity (Bonini et al., 1995). Wistar 
fatty rats are an animal model of insulin resistance. They have decreased activity of IRS- 
1 and low activity of PI-3-kinase (Hayakawa et al., 1996). Pioglitazone administration 
for 2 weeks altered the activity of the (3-subunit of the insulin receptor, increasing 
autophosphorylation and tyrosine kinase activity with improvement of hyperglycaemia 
and hyperinulinaemia.
KKA mice have low levels of PI-3-kinase and IRS protein in adipose tissue and 
liver. There is also evidence that pioglitazone can increase PI-3-Kinase activity which 
increases the responses of the cell to insulin (Bonini et al., 1995; Kobayashi et al., 1992).
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6.4.3 Lowering plasma NEFA content
TZDs generally reduce circulating concentrations of triglyceride and NEFA in a number 
of diabetic rodent models (Oakes et al., 1994; Young et al., 1995). These effects are 
observed in both insulin resistant and insulin deficient animals, thus the lipid-lowering 
effect of TZDs appears to be independent of their glucose-lowering and their insulin- 
lowering effects. The lipid lowering effect is usually greater in the hyperlipidaemic 
animals, this has been attributed to decreased hepatic VLDL synthesis and increased 
peripheral clearance, together with reduced lipolysis (Oakes et al.,1994; Lee et al.,1994).
Insulin resistance is often associated with increased concentrations of plasma 
NEFA due to increased intra-adipocyte lipolysis caused by decreased inhibition of the 
hormone sensitive lipase (Reaven et al., 1988). Insulin exerts its anti-lipolytic effect by 
activating phosphodiesterase (PDE-3B), which in turn inactivates hormone sensitive 
lipase activity. Pioglitazone treatment in people with type 2 diabetes can restore both 
PDE-3B level, in this way result in decreased lipolysis and lower plasma NEFA (Bajaj et 
al., 2003; Kaneko et al., 1997; Miyazaki et al., 2000).
1.6.4.4 Reduction of hepatic glucose output
KKA mice have an increased activity and expression of phosphoenolpyruvate 
carboxykinase (PEPCK), the rate-limiting enzyme in gluconeogenesis. Treatment of 
these mice with pioglitazone normalised the activity of PEPCK and decreased blood 
glucose concentration (Ikeda et al. 1990).
In fructose-fed insulin-resistant rats, pioglitazone treatment for 2 weeks reduced 
glucose output by perfused liver, and insulin perfusion caused a greater decrease in 
glucose output in the pioglitazone treated group (Ikeda and Fujiyama, et al., 1998). In a 
perfused rat liver model, addition of pioglitazone decreased gluconeogensis by around
67
70% after 20 minutes (Nishimura et al., 1997). These studies indicate that pioglitazone 
inhibits gluconeogensis in the liver.
1.6.4.5 Adipocyte Differentiation
PPARy is a pivotal coordinator of the adipocyte differentiation process enhancing the 
expression of adipocyte-specific genes and promoting adipocyte differentiation 
(Hallakou et al., 1997; Hutley et al., 2003; Fajas et a l ., 1998). Treatment of preadipocyte 
cultures for 7 days with pioglitazone and insulin resulted in nearly 100% differentiation 
of cells to lipid-accumulating adipocytes, and such adipocytes showed a markedly 
increased expression of cellular glucose transporter (Glut-1, Glut-4).
When 3T3-L cells are treated with pioglitazone, a marker of adipocyte 
differentiation glycerol 3-phosphate increases, with an increase in insulin receptor m- 
RNA and total number of insulin receptors (Swanson et al., 1995; van Harmelen et al., 
2002).
1.6.4.6 Reduction of Tumour Necrosis Factor-alpha (TNFa )
Tumour Necrosis Factor-alpha has been shown to have certain catabolic effects on fat 
cells. Recent studies in animal models indicated that TNFa may play a role in mediating 
insulin resistance in obesity and diabetes through its ability to inhibit PI-3-kinase 
downstream in the insulin signalling pathway the tyrosine kinase activity of the insulin 
receptor (IR). TNF-a causes phosphorylation of serine sites in the IRS and thereby 
reduces the interaction between the insulin receptor and its ligands (Hotamisligil et al., 
1999).
Incubation of 3T3-L1 cells with TNFa completely inhibits adipocyte conversion 
and expression of fatty acid-binding protein m-RNA. However, co-incubation of TNFa-
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treated cells with pioglitazone blocked these effects (Souza et al., 2003; Szalkowski et 
al., 1995).
1.6.4.7 Increase of adiponectin/ACRP30/adipoQ
Adiponectin is also known as an adipose-specific plasma protein adipoQ (Hu et al.,
1996). It is synthesised in adipose tissue, but acts primarily on skeletal muscle by 
increasing the expression of proteins involved in fatty acid transport, combustion and 
energy dissipation (CD36, acyl CoA oxidase). By increasing the influx and combustion 
of fatty acids it reduces the muscle content of triglycerides, the amount of free fatty acids 
in serum, and lowers liver triglycerides. The adiponectin gene has been mapped to a 
diabetes susceptibility locus at the human chromosome 3q27. This locus is strongly 
linked to the “metabolic syndrome” (Berg et al., 2002).
Circulating adiponectin concentrations are decreased in obese individuals (Arita 
et al., 1999) and the reduction was proposed to have a role in the pathogenesis of 
arteriosclerosis and cardiovascular disease associated with obesity and other components 
of the metabolic syndrome (Kishida et al., 2003; Kojima et al., 2003; Matsuzawa et al., 
1999).
Thiazolidinedione administration significantly increased plasma adiponectin 
concentration in insulin resistant humans and rodents. The expression of adiponectin m- 
RNA was normalized or increased by TZDs in the adipose tissue of obese mice, and in 
the 3T3 LI adipocyte. These effects were mediated through the activation of the 
promoter by TZDs. On the other hand, TNF-a, which is produced more in insulin- 
resistance, reduced the expression of adiponectin in adipocytes by suppressing its 
promoter activity. TZDs restored this inhibitory effect by TNF-a (Ruan et al., 2003).
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1.6.4.8 Decreased expression of tissue resistin
Resistin was recently identified as a hormone secreted by adipocytes, which leads to 
insulin resistance in vivo and in vitro (Fasshauer et al., 2001; Steppan et al., 2001).
It has been reported recently that resistin expression is significantly increased in adipose 
tissue in several different animal models of obesity (Ahima et al., 2001; Baneijee et al., 
2003). In response to TZDs, adipose tissue resistin expression is decreased in both ob/ob 
mice and Zucker rat (Amer et al., 2003).
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1.7 AIMS OF THE STUDY
The overall aim of this study was to establish if any beneficial metabolic effects are 
evident in type 2  diabetic patients after 2 0  weeks tissue sensitisation to insulin through 
the PPARy nuclear receptor with pioglitazone compared to augmentation of insulin 
output by sulphonylurea in regimes designed to maintain glycaemic control constant. 
Maintenance of glycaemic control stabilised this factor known to perturb metabolism by 
a variety of mechanisms and so allow a less complicated analysis of the results. A group 
of control subjects was also studied to assess if any changes that occur in diabetic 
patients improve known defects in metabolism such as delayed clearance of dietary fat to 
that of normal situation.
Specifically, the following parameters were investigated in a detailed study of 
the fasting and postprandial state:
Fasting State
The effect of insulin sensitisation with pioglitazone on:
• Fasting dyslipidaemia including analyses of total triglyceride, subfractionation of 
fasting plasma lipoproteins into VLDL and its subfractions (VLDL-1 & VLDL-2) 
IDL, LDL, HDL (HDL2 & HDL3), apoliproteins A-I & B, Lp(a) and NEFA.
• Fasting glycaemia and p-cell function as measured by plasma insulin content and 
the presence of insulin precursors.
• Assessment of insulin resistance using the HOMA model.
• Proteins and enzymes responsible for lipoprotein remodelling processes: LPL, HL, 
LCAT, CETPand PLTP.
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Postprandial State
• Postprandial lipaemia after a high fat meal including analyses of total triglyceride 
and the cholesterol and triglyceride content of subfractions of plasma lipoproteins 
including chylomicrons and chylomicron remnants labelled with retinyl palmitate, 
IDL, LDL, HDL (HDL2 & HDL3), and the insulin-dependent suppression of NEFA 
release from adipose tissue.
• The effect of insulin sensitisation with pioglitazone on postprandial glucose and p- 
cell function as measured by the release of insulin and insulin precursors (proinsulin 
and 32-33 split proinsulin).
• The effects of insulin sensitisation with pioglitazone on postprandial cholesterol 
esterification by LCAT and lipid exchange by CETP and PLTP.
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CHAPTER 2: MATERIALS AND METHODS
2.1 SUBJECTS, INSULIN SENSITISATION AND POSTPRANDIAL LIPID 
METABOLISM PROTOCOLS
2.1.1 DIABETIC PATIENTS
Twenty-two patients with type 2 diabetes were recruited from the diabetic clinic at 
University College London and North Middlesex Hospital. All patients exhibited 
modest glycaemic control, (mean HbAlC 7.3%), with diagnosis of type 2 diabetes 
based on WHO criteria. The group consisted of 17 males and 5 females with mean age 
of 56.2 year (age range 30-75 years). All of these patients had a total plasma triglyceride 
level > 1 .7  mmol/L and were receiving no lipid lowering treatment, or taking drugs 
known to directly affect lipid metabolism. Mean duration of diabetes was 2.5 years. 
Patients with abnormal hepatic, thyroid or renal function test, and excessive 
consumption of alcohol were excluded., inclusion and exclusion criteria shown in Table 
4. All females in the study were not taking any hormonal therapy. All subjects were 
euthyroid and had normal liver and kidney functions.
Table 4: Inclusion and exclusion criteria
INCLUSION CRITERIA EXCLUSION CRITERIA
Fasting TG > 1.7-5 mmol/1 Insulin therapy, acrabose
HbAlC < 9% Statin, fibrate, hormonal therapy.
Glibenclamide <10 mg/d ALT, AST > 2.5 above normal
Metformin< 2500 mg/d LDL >4.1 mmol/L
Gliclazide < 240 mg/d C-peptide < 1 ng/ml
Age 25-75 years Creatinine >150 pmol/1, macroalbuminuria
BM I25- 35 kg/m2 Heart failure, uncontrolled blood pressure
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2.1.2 CONTROL SUBJECTS
Ten healthy control subjects ( 6  male, 4 female) matched for age and body mass index 
(BMI) with the diabetic subjects were recruited into the study. No control subject was 
taking any medication, and no family history of diabetes mellitus.
2.1.3 DOUBLE-BLIND, DOUBLE-DUMMY PROTOCOL FOR SENSITIZING THE 
DIABETIC SUBJECTS TO INSULIN WITH THIAZOLIDINEDIONE
Diabetic patients recruited into the study were, at that time, treated with either 
sulphonylurea or metformin as a mono-therapy. Drug therapy was withdrawn from the 
subjects for a period of 6  weeks and during which they were given dietary advice. 
Subjects were monitored during that period for fasting glucose and HbAlC to check 
that they were suitable to continue on the study.
One week prior to the end of the wash out period subjects attended for 
preparation of post-heparin plasma (PHP) lipase measurements (see Chapter 5 ). At the 
completion of the washout phase the subjects attended for the baseline test meal (see 
section 2.1.4.1). Patients then were allocated to either receive glibenclamide 5 mg/d or 
pioglitazone 45 mg/d in a double- blind double-dummy protocol designed to maintain 
the same glycaemic control for 20 weeks. To achieve the same glycaemic control an 
open label glibenclamide 5 mg could be added to any subjects (only one patient required 
this intervention and at the end of the study, when the code was broken, was found to 
have been in the group taking glibenclamide therapy).
During the treatment period all subjects were monitored regularly for their 
glycaemic control, liver and kidney function and full blood count. One week prior to the 
end of the treatment period subjects attended for preparation of another post-heparin 
plasma (PHP) for lipase measurements. At the completion of the treatment period the
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subjects received an identical test meal as described previously. Two weeks after the 
end of the study, patients attended for a final full clinical and biochemical check up 
visit.
Control individuals participating in the study received no drug therapy nor 
placebo prior to the test meal. Post-heparin plasma was prepared one week before the 
test meal.
The study was fully approved by local ethics committee and all subjects gave 
informed written consent prior to commencing the study.
VISIT 1 (week -  8  to - 6 ): Consent and Admission to Trial. Physical examination 
(height, weight, blood pressure BP), screening for fasting lipid profile, full blood count 
(FBC), liver function test (LFT), urea and electrolyte, C-peptide, glucose, HbAlC, urine 
protein dipstick test.
VISIT 2 (week - 6 ): W ashout period started. Patients’ diabetic medication withdrawn 
and replaced with placebo tablets and instructed concerning their diet.
VISIT 3 (week -1): Physical examination (body weight, BP), fasting lipid profile, 
FBS, HbAlC, urine protein dipstick test.
VISIT 4A ( 4 days after visit 3): Post heparin HL/ LPL.
VISIT 4 (day 0): Baseline test meal. FBC, LFT, urea & electrolyte, urine protein 
dipstick test. (Randomization start next day).
VISIT 5 (week 4): Body weight, documentation of adverse events or changes in 
concomitant medication.
VISIT 6  (week 8 ): Vital signs, body weight, documentation of adverse events or 
changes in concomitant medication. Fasting lipid profile, FBS, HbAlC, FBC, LFT, urea 
& electrolyte, dipstick urine analysis.
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VISIT 7 (week 12):_Vital signs, body weight, HbAlC, FBS, fasting lipid profile, 
dipstick urine analysis. Documentation of adverse events or changes in concomitant 
medication.
VISIT 8 A (4 days before visit 8 ): Post-Heparin HL/ LPL.
VISIT 8  (week 20): Post-treatment test meal. FBC, LFT, urea & electrolyte, urine 
protein dipstick test.
VISIT 9 (week 22): Vital signs, body weights. FBC, LFT, urea & electrolyte, urine 
protein dipstick test.
2.1.4 ORAL FAT TOLERANCE TEST
2.1.4.1 The high-fat content meal
A mixed-meal with a high-fat content was administered to the patients for the 
measurement of postprandial lipid and glucose metabolism after a 6  week washout 
period during which the subjects received placebo. A second mixed-meal with a high- 
fat content was administered following 2 0  weeks treatment with pioglitazone or 
glibenclamide.
Patients were asked to refrain from alcohol for the preceding 24 hours and to fast 
for 14 hours prior to the test. The meal was eaten within 20 minutes and the subject 
remained fasting for the following 8  hours but was allowed water ad libitum. No 
smoking was allowed during the test. The test meal was given at 8.00 am and consisted 
of 110 g of fat (P/S ratio 0.4), 46 g of protein, 70 g of carbohydrate, and 729 mg of 
cholesterol. The ingredients were incorporated as a milkshake, scrambled eggs and 
cheese sandwich. 300,000 IU of vitamin A (retinyl palmitate - Roche Ltd) was included
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with the milkshake to label the intestinally derived lipoprotein. After ingestion, vitamin 
A is incorporated into the newly-synthesised chylomicrons as retinyl palmitate (RP)
( Hazzard and Bierman et al., 1976; Goodman et al., 1980) and is finally taken up by the 
liver after lipolysis to chylomicron-remnant particles. Retinyl palmitate is then 
hydrolysed to retinol and either released into the plasma bound to retinol-binding 
protein or re-esterified and stored in the liver. Since RP is not re-secreted by the liver 
(Lenich and Ross et al., 1987), and the exchange of RP among lipoproteins is minimal 
(Berr et al., 1985; Cortner et al., 1987; Sprecher et al., 1991; Wilson et al., 1983) the 
measurement of RP content reflects the concentration of chylomicrons and their 
remnants in the circulation.
2.1.4.2 Blood sampling
Blood samples were drawn from an indwelling venous catheter into an appropriate 
anticoagulant (plasma) or plain tube (serum); the first sample was taken immediately 
before eating the test meal and then at 30 minutes intervals for the first 2 hours and then 
hourly for the further 6  hours. Plasma or serum was separated by centrifuge at 3000 x g 
for 10 minutes. Cholesterol, triglyceride, NEFA, phospholipid, insulin, proinsulin and 
split proinsulin were measured on these samples. Individual lipoproteins (chylomicron, 
chylomicron remnants, IDL, LDL, HDL2 , HDL3 ) were isolated from plasma sample 
taken at 0, 1, 2, 4, 6 , 8  hr. LCAT, CETP and PLTP activities were measured on the 
plasma samples taken in the fasting state and 4 hr postprandial. Apo-AI, apo-B, LP(a), 
VLDL and LDL subfractions were measured only in the fasting state of each test meal. 
Blood sampling for measurements of total cholesterol, triglyceride and their 
subfractions (VLDL, IDL, LDL, HDL), chylomicron and chylomicron remnants retinyl 
palmitate, NEFA, phospholipid, glucose, CETP, LCAT, LPL, HL were done by me.
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Measurements of serum insulin, proinsulin and 32-33 split proinsulin were done in the 
department of Clinical Biochemistry, Addenbrookes Hospital ( Professor C. N. Hales).
Measurements of LDL subfractions were performed at the Institute of Biochemistry, 
Surrey University (Dr. B. Griffin). Measurements of PLTP mass were done at the 
University of Lille, France (Professors B. Staels and G. Luc).
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LABORATORY TECHNIQUES
2.2 ISOLATION OF LIPOPROTEINS AND LIPOPROTEIN SUBTRACTIONS
2.2.1 INTESTINAL LIPOPROTEINS
2.2.1.1 Chylomicrons
Chylomicrons (Sf > 1,000) were separated from plasma by sequential flotation, (Dole 
and Hamlin et al., 1962; Grundy and Mok et al., 1976; Lindgren et al., 1972).
2.5 ml of plasma was overlaid with 0.5 ml of 0.15 M sodium chloride solution. 
Tubes were balanced and centrifuged at 417,000 x gaverage for 5 minutes at 16°C in a 
Beckmann TLA 110 rotor. Under these conditions, chylomicrons migrate into the saline 
layer, which was carefully aspirated, and the volume made up to 1 ml with saline. 
Fractions were stored at -20°C for subsequent lipid analyses and the assay of retinyl 
palmitate content.
2.2.1.2 Chylomicron Remnants
0.5 ml of saline was overlaid into the plasma infranatant obtained after removal 
of intact chylomicrons described above. The tubes were centrifuged at 417,000 x gaverage 
for a further 30 minutes at 16°C. The upper saline layer containing the chylomicron- 
remnants was aspirated and made up to 1 ml with saline. Fractions were stored at -20°C 
for subsequent lipid analyses and the assay of retinyl palmitate content.
2.2.2 HEPATIC LIPOPROTEINS
2.2.2.1 Very Low-density Lipoproteins 1 and 2 (VLDL-1 and VLDL-2 )
Fasting levels of VLDL-1 and VLDL-2 were determined by sequential flotation of the 
lipoproteins from plasma at densities of 2.006 g/ml and 2.019 g/ml respectively (Hatch
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and Lees et al., 1968). Total VLDL was isolated from 2.5 ml of plasma overlaid with 
0.5 ml sodium chloride (0.15 M). Samples were ultra-centrifuged at 417,000 x gaverage 
for 30 minutes at 16°C. Under these conditions total VLDL (VLDL-1 and VLDL-2) 
floats into the saline layer which was aspirated and made up to 1 ml with saline. The 
remaining plasma infranatant was retained and used for IDL and LDL separation.
To subfractionate the total VLDL into VLDL-1 and VLDL-2, 170 mg/ml of 
solid sodium chloride was added to the VLDL preparation and mixed thoroughly. The 
samples were overlaid with 1 ml of a KBr solution (density 2.0852 g/ml). The sample 
was centrifuged at 417,000 x gaverage for 10 minutes at 16°C. The upper supernatant 
containing VLDL-1 was removed and made up to a volume of 1 ml with saline. The 
infranatant was overlaid with 0.5 ml saline and centrifuged at 417,000 x gaverage for 45 
minutes at 16°C and the VLDL-2 was aspirated from the top of the tubes and then made 
up to a volume of 1 ml with saline for VLDL-2 measurement. Samples were stored at - 
20°C prior to lipid analyses.
2.2.2.2 Intermediate Density Lipoproteins (IDL)
IDL was isolated from the infranatant obtained after removal of VLDL as described 
above 127 pi of a high-density KBr/NaCl solution, (KBr 2.97 mol/L, NaCl 2.62 mol/L, 
EDTA 240 pmol/L; 2.33 g/ml density) was added and mixed well. An aliquot (0.5 ml) 
of KBr solution (2.019 g/ml density) was overlaid on to the samples and centrifuged at 
417,000 x gaverage for 45 minutes at 16°C. Under these conditions DDL floats into the 
upper non-plasma layer which was then aspirated and made to 1 ml volume with saline. 
Samples were stored at -20°C prior to lipid analyses.
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2.2.2.3 Low-Density Lipoproteins (LDL)
LDL was isolated from the infranatant obtained after removal of IDL.
525 pi of KBr heavy solution, (KBr 2.97 mol/L, NaCl 2.62 mol/L, EDTA 240 pmol/L;
2.33 g/ml density) was added and mixed well. An aliquot (0.5 ml) of KBr solution 
(2.063 g/L density) was overlaid on the samples which were centrifuged at 417,000 x 
gaverage for 45 minutes at 16°C. Under these conditions LDL floats into the upper non­
plasma layer which was then aspirated and made to 1 ml volume with saline. Samples 
were stored at -20°C prior to lipid analyses.
2.2.2.4 Low-Density Lipoprotein subfractions (LDL)
Isolation of LDL subfractions was achieved by density gradient ultracentrifugation 
using a discontinuous salt gradient (Griffin et al., 1990). Plasma was adjusted to a 
density of 2.09 g/ml with solid KBr (0.38 g per 3 ml plasma). The samples and 6 -step 
salt gradient were introduced sequentially into polyvinyl alcohol-coated polyallomer 
SW-40 tubes by peristaltic pump. The gradient was prepared and centrifugation was 
carried out at 23°C. All densities were checked using a digital densitometer (PAAE 
Scientific Ltd, UK). The rotor was accelerated to 170 r.p.m over 4 minutes in Beckman 
L8-60 ultracentrifuge and then centrifuged at 40,000 r.p.m for 24 hours. The gradient 
containing the separated LDL fractions was displaced upwards from the tube in an 
apparatus similar to that devised by Groot et al (1982). A dense, hydrophobic material 
(Maxidens, 2.9 g/ml, Nyegaard Ltd) was introduced under the plasma layer by a 
constant infusion pump at a flow rate of 0.69 ml/min. The elute was passed through a 
UV detector (MSE/Fisons, UK) and continuously monitored at 280 nm. The elution 
times of the first, least dense, LDL fraction and the appearance of plasma proteins were
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identified by peak maxima that occurred between hydrated density interval of 2.025-
2.034 g/ml (LDL-1), 2.034-2.044 g/ml (LDL -II), or 2.044-2.060 g/ml (LDL-III).
The individual subtraction areas beneath the LDL profiles were quantified using a 
Beckman "Data Graphics" software (Beckman "Data Leader", Beckman, UK). 
Integrated areas were adjusted by specific extinction coefficients calculated previously 
for LDL-I, II, and III to give their percentage abundance (% LDL). The total LDL mass 
(lipid and protein mass) of sequentially prepared LDL (density 2.019-2.063) was then 
subdivided in proportion to the adjusted percentage values. This gave rise to 
concentration values for each LDL subfraction in mg of lipoprotein per 100 ml of 
plasma. LDL sub fractions were therefore expressed in terms of adjusted percentage 
abundance and plasma concentration.
2.2.2.5 High-Density Lipoproteins and subfractions (HDL2 and HDL3)
It is well established that the traditional heparin/Mn2+ method used for determination of 
HDL in fasting plasma samples cannot be used for lipaemic samples (Demacker et al., 
1980). This is because of the presence of lipid rich particles that do not react or 
sediment with heparin/Mn2+ treatment and lead to an overestimation of HDL 
cholesterol. The polyethylene glycol technique, which correlates well with results 
obtained on fasting plasma with the heparin/Mn2+ technique, relies instead on 
dehydrating the lipoproteins causing them to become insoluble. The addition of 
polyethylene glycol solution of different concentrations and pH results in the selective 
precipitation of different lipoproteins fractions.
To remove triglyceride-rich lipoproteins, which would otherwise interfere with 
HDL determination, samples of fasting and postprandial plasmas (1 ml) were overlaid 
with a 0.5 ml saline and centrifuged at 204,000 x gaverage at 16°C for 45 minutes.
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Triglyceride-rich lipoproteins float into the saline layer, which was carefully aspirated 
and discarded.
Total HDL cholesterol content of the remaining plasma was determined by selective 
precipitation of VLDL and LDL (Quantolip Reagent A; Technoclone, UK). Followed 
by determination of the cholesterol content of the supernatant (see section 2.2.3.2). 
HDL3 cholesterol content was determined by selective precipitation of VLDL + LDL + 
HDL2  (Quantolip Reagent B; Technoclone, UK). Followed by determination of the 
cholesterol content of the supernatant (see section 2.2.3.2).
2.2.3 LIPID DETERMINATIONS
2.2.3.1 RETINYL PALMITATE MEASUREMENTS
Sample extraction and High Pressure Liquid Chromatography (HPLC)
Retinyl palmitate present in chylomicron and chylomicron-remnant fractions was 
extracted by Folch's procedure using an internal standard of retinyl acetate (RA) to 
monitor and correct for variations in recovery (Folch et al., 1957). An aliquot of the 
preparation (600 pi) was mixed with 50 pi of RA (48.68 pmol/L) internal standard 
followed by 7 ml of CHCL3 /CH3 OH (2:1 v/v) in a 10 ml screw-top glass tube. After 
vigorous shaking at room temperature for 1 0  minutes, the sample was filtered through a 
glass fibre filter (Whatman glass microfibre filter Grade GF/A), into a 10 ml stoppered 
conical glass centrifuge tube. The filter was washed twice with 0.7 ml CHCL3 /CH3 OH 
(2 : 1  v/v) and distilled water (2 . 6  ml) was added to the filtrate and thoroughly mixed. 
After centrifugation at 2000 x g for 5 minutes, the upper aqueous phase was aspirated 
and the lower organic phase evaporated to dryness under nitrogen with gentle warming 
(50°C) under subdued light. The residue was dissolved in 150 pi of CHCL3 /CH3 OH (1:4
83
v/v) and an aliquot (100 pi) of the extract was injected on to a HPLC system (Waters 
Ltd) equipped with a 150 x 4.6 mm reversed phase column (3 p octadecyl Spherisorb). 
The column was eluted with HPLC grade methanol (1 ml/min). The effluent was 
monitored at 340 nm for RA and RP with a UV detector (Waters Ltd). The RA eluted 
after about 3 minutes followed by the RP, 25 minutes later. The detector response for 
RP was linear between 0.05 and 2.2 mmol (DeRuyter and Leenheer et al., 1978; Wilson 
et al., 1983).
Quantification of Chylomicron and chylomicron remnants retinyl palmitate
A standard solution containing RP (3.8 pmol/L) and RA (48.68 pmol/L) in 
CHCL3 /CH3 OH (1:4 v/v) was injected on to the column monitored at 340 nm and eluted 
as described for the chylomicron and chylomicron remnant extracts. The peak heights 
were accurately measured for the standards and for the samples. By comparing the ratio 
of RA present in the standard and the samples to that of the RP present in standard and 
samples, the concentration of RP in the samples can be calculated using the following 
formula:
[RP sample] [RP standard] x ( RP sample / RA sample) x ( RA std /RP std) where RP sample 
peak height of RP in sample, RA sample =peak height of RA in sample, RP std = peak 
height of RP standard, RA std = peak height of RA in standard. The inter-assay 
coefficient of variation was 7.0%.
2.2.3.2 Determination of cholesterol
The total cholesterol content of plasma and lipoprotein fractions were measured by an 
enzyme-linked calorimetric method (CHOD-PAP; Sigma Infinity Cholesterol reagent, 
Sigma Chemical Co., UK). The inter-assay coefficient of variation was 2.6%. In brief,
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an aliquot of sample was measured with a reagent containing: detergent, cholesterol 
esterase, and cholesterol oxidase. H2 O2  produced as a result of cholesterol oxidase 
activity was used to oxidise aminoantipyrene to give a pink product the absorption of 
which was measured at 500 nm.
2.2.3.3 DETERMINATION OF TRIGLYCERIDE
The total triglyceride contents of plasma and lipoprotein fractions were measured by an 
enzymatic-calorimetric method (GPO-PAP, Sigma Infinity Triglyceride reagent, Sigma 
Chemical Co. UK). The inter-assay coefficient of variation was 3.7% for triglyceride. In 
brief, an aliquot of sample was measured with a reagent containing a lipoprotein lipase 
causing the liberation of glycerol from triglycerides present, which was then determined 
after enzymatic conversion to glucose-1 -phosphate and its subsequent oxidation by 
glucose phosphate oxidase. The resultant H2 O2 was coupled to the formation of a
coloured dye with horseradish peroxidase to give a pink product the absorption of which
was measured at 500 nm.
2.2.3.4 DETERMINATION OF NON-ESTERIFIED FATTY ACIDS (NEFA)
NEFA concentrations in plasma were measured using an enzyme-linked calorimetric 
assay (Roche Diagnostics, UK). In brief, NEFAs were quantitatively converted to Acyl 
Co A (Reaction 1) that were then quantitatively oxidised by Acyl CoA oxidase causing 
the liberation of H2 O2  (Reaction II). The H2 O2 was used to oxidise 2, 4, 6-tribromo-3- 
hydroxy-benzoic acid (TBHB) to yield a red dye the absorbance of which was measured 
at 546 nm (Reaction III). The inter-assay coefficient of variation was 4.6 %.
(I) NEFA + CoA + ATP -» Acyl-CoA + AMP + pyrophosphate
(II) Acyl- CoA + O2  -> enoyl-CoA + H2 O2
(III) H2 0 2 + 4-AA + TBHB -> red dye + 2 H20  + HBr76
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2.2.3.5 DETERMINATION OF PLASMA PHOSPHOLIPD
A sample of heparin plasma was mixed with a reagent containing phospholipase D 
(Roche Diagnostic, UK). Phospholipase D cleaves the choline from phosphatidylcholine 
which is acted on by choline oxidase releasing H2 O2 which is used to oxidise a 
chromogenic dye to give a coloured product catalysed by peroxidase. The absorbance at 
500 nm was measured and the concentration of phospholipid present in the sample was 
determined from a standard curve prepared with pure phosphatidylcholine.
The inter-assay coefficient of variation was 4.3 %.
2.3 TECHNIQUES FOR ASSESSING LIPOPROTEIN REMODELLING
2.3.1 CHOLESTERYL ESTER TRANSFER PROTEIN (CETP)
The rate of net cholesteryl ester transfer in plasma was determined by measuring the 
rate of decrease of cholesteryl ester present in HDL after inhibition of LCAT activity. 
Ten ml of blood was collected into citrate (0.2 M citrate, pH 7.2) at a ratio of 1 part 
citrate to 19 parts blood and centrifuged at 3000 x g for 15 minutes, at 4°C to obtain the 
plasma. An aliquot (25 pi) of 1M Tris-HCl buffer (pH 7.4) was added to 2.5 ml of 
plasma and LCAT activity in the plasma inhibited by the addition of N-ethylmaleimide 
(NEM) at a final concentration of 2.5 mmol/L.
Ester transfer activity was measured over 3 hours at 37°C. After 5 min 
equilibration at 37°C, an initial (0 hour) sample (100 pi) was taken and added to 200 pi 
PEG (Quantolip HDL Reagent A-Technoclone Ltd, UK), mixed and incubated 10 min 
at room temperature. Non-HDL lipoproteins precipitated by this procedure and were 
then sedimented by centrifugation at 3000 x g for 10 minutes. The HDL-containing 
supernatant was carefully aspirated and retained for analysis for free and esterified
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cholesterol. Further samples were taken from the NEM-treated plasma at hourly 
intervals and treated in an identical fashion (Fielding et al., 1981).
2.3.1.1 Assay of HDL total cholesterol and free cholesterol:
HDL free and esterified cholesterol content was measured by a fluorometric 
method using a 96 well plate. For the assay of free cholesterol present, the samples were 
diluted 1:10 with saline and aliquots (10 pi) added to 100 pi of a solution containing: 50 
mmol/L NaH2 PC>4 pH 7.4, 0.17 mmol/L polyethylene Glycol 6000 (mol. wt); 5 mmol/L 
sodium taurocholate; 5 mmol/L EDTA (tetrasodium salt); 0.25 v/v Triton X-100; 2.5 
umol/L p-hydroxyphenyl acetic acid; 30 p/ml horseradish peroxidase; 0.08 p/ml 
cholesterol oxidase and incubated at room temperature for 30 minutes with occasional 
mixing. The fluorescence of the oxidized p-hydroxyphenyl acetic acid was stabilised by 
the addition of 0.2 ml of Tris buffer (0.3 mol/L, pH 9.0) and left for 5 minutes and then 
fluoresence determined using a fluorimetric plate-reader set to an excitation wavelength 
of 325 nm and 415 nm emission. All samples were assayed in quadruplicate. The 
amount of free cholesterol in the sample was quantitatively derived from the standard 
curve (0 pmol/L, 25 pmol/L, 50 pmol/L, 100 pmol/L cholesterol) obtained in the same 
test run. The assay was linear up to 100 pmol/L and the inter-assay coefficient of 
variation of free cholesterol was 3.8%. The mean of quadruplicate measurements of 
plasma free cholesterol sampled at 0, 1, 2, 3 hours were determined and plotted against 
time. LCAT activity was calculated as the gradient determined by least-squares method. 
In general the correlation obtained by regression analysis was r2> 0.998. The total 
cholesterol (free cholesterol + cholesteryl esters) content of the HDL was similarly 
determined with the exception that cholesterol esterase (0.8 U in lOpl) was added to the 
reagent.
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2.3.1.2 HDL cholesteryl ester content and calculation of CETP activity
At each time point, HDL cholesteryl ester content was obtained by calculating the 
difference between total and free cholesterol concentrations and plotted against time. 
The gradient of the curve was determined by the least-squares method and taken to be 
the rate of transfer of cholesteryl ester from HDL to endogenous plasma triglyceride- 
rich lipoproteins. The inter-assay coefficient of variation of HDL free cholesterol and 
HDL total cholesterol were 6 % and 4.8% respectively. The reaction was linear over 3 
hours (i^= 0.85); the inter-assay coefficient of variation was 6.5 %.
2.3.2 PHOSPHOLIPID TRANSFER PROTEIN (PLTP)
PLTP activity was measured in total plasma as the transfer of radio-labelled 
phosphatidylcholine from [1 4C]-phosphatidylcholine liposomes to an excess of 
exogenous human HDL3 (Damen et al., 1982). Briefly, 10 pmol of [,4 C]-L- 
phosphatidylcholine (PerkinElmer Life Sciences) and 0.1 pmol of butylated 
hydroxytoluene were mixed, and the lipids were dried under nitrogen, suspended in 1  
ml of 150 mM NaCl, 10 mM Tris-HCl, 1 mM EDTA (pH 7.4), sonicated, and 
centrifuged to remove lipid aggregates and metallic debris. Plasma samples were 
incubated for 1 hour at 37°C with radiolabeled liposomes (50 nmol of phospholipid) and 
isolated human HDL3 (250 fig of protein) in a final volume of 400 pi with 150 mM 
NaCl, 10 mM Tris-HCl, 1 mM EDTA (pH 7.4). At the end of the incubation, liposomes 
were precipitated with dextran sulphate. The supernatant (0.5 ml) was used for 
radioactivity determinations. Plasma volumes were chosen to keep PLTP activity in the 
linear range of the assay. PLTP activity was expressed as pmoles of 
phosphatidylcholine transferred from liposomes to exogenous human HDL3 per ml of 
plasma (Bouly et al., 2001).
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2.3.3 LECITHIN:CHOLESTEROL ACYL TRANSFERASE (LCAT)
The decrease in free cholesterol content of incubated plasma, (Heider and Boyett et al., 
1978) reflects the rate of plasma cholesterol esterification by LCAT and was determined 
as follows. Blood (9.5 ml) was collected into 0.5 ml of sodium citrate (0.2 mol/L 
sodium citrate pH 7.2) and centrifuged at 3000 x g for 15 minutes at 4°C to obtain 
plasma. An aliquot (25 pi) of 1M Tris buffer (pH 7.4) was added to 2.5 ml of fresh 
plasma and incubated for 3 hours at 37°C. Aliquots (250 pi) were taken from the 
incubation at hourly intervals and N-ethylmaleimide (15 mmol/L saline) was added to 
stop the reaction. Samples were kept at 4°C until analysed.
The free cholesterol content of the samples was determined as described in the 
assay of CETP activity (see section 2.3.1). The mean of quadruplicate measurements of 
plasma free cholesterol sampled at 0, 1, 2, 3 hours were determined and plotted against 
time. LCAT activity was calculated as the gradient determined by least-squares method. 
In general the correlation obtained by regression analysis was !*> 0.998; the inter-assay 
coefficient of variation was 3.9 %.
2.3.4 LIPASE ACTIVITIES
2.3.4.1 Preparation of post-heparin plasma (PHP)
Both lipoprotein lipase and hepatic lipase are released from the proteoglycans by an 
injection of heparin. Baseline and post-treatment post-heparin plasma samples were 
collected from the subjects for measurement of lipoprotein lipase and hepatic lipase 
activity. Heparin (60 U/Kg) was administered intravenously and blood was taken 15 
minutes later into heparin tube. Plasma was separated immediately and stored at -  8 6 °C 
until assayed for lipase activities.
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2.3.4.2 Hepatic Lipase Activity
Hepatic Lipase (HL) activity in post-heparin plasma was carried out by the method of 
Henderson et al 1993. HL activity was discriminated from LPL activity by conducting 
the assay at the pH optima for HL (pH 8 .8 ) in the presence of high salt concentrations 
and in the absence of apo-CII (an essential co-factor for LPL activity). Twenty-five pCi 
of glycerol tri [9, 10 (n)-3H] oleate (specific activity 1 pCi/nmol; TRA 191 Amersham 
Ltd., UK) was added to 100 mg (113 pmoles) of triolein (Sigma Ltd) in 1 ml of toluene. 
This was dried under nitrogen and then washed with 2 ml heptane. After evaporation,
17.5 ml of gum arabic (5% w/v in 0.2 M Tris buffer, pH 8 .8 ) and 8.25 ml fatty acid free 
BSA (200 mg/ml 0.2 M Tris pH 8 .8 ) were added and the mixture sonicated for 4 
minutes in an ice bath until it was milky with no visible oil droplets. The salt 
concentration was raised by the addition of 7.74 ml 3.24 M in 0.2 M Tris buffer, pH 8 .8 .
Samples of PHP (30 pi) were incubated with 0.5 ml of the substrate for 1 hour at 
37°C. A blank incubation was performed to compensate for non-specific hydrolysis. 
The reaction was stopped by the addition of 8.125 ml of Belfrage reagent (Methanol 
141: chloroform 125: Heptane 100) and Borate extraction buffer (2.87 ml of 0.14 mol/L, 
pH 10.5) was added to extract selectively the free fatty acids released by the HL and 
mixed for 5 minutes. The phases were separated by centrifugation for 10 minutes at 
3000 x g and 1 ml of upper phase added to 4 ml scintillation fluid (Aquasafe 300+, 
Zinsser Analytic, UK) and mixed well. The radioactivity was determined in a liquid 
scintillation counter with quench correction made by automated external standard (AES) 
to obtain the results as d.p.m (Henderson et al., 1993) .
90
2.3.4.3 Lipoprotein Lipase Activity
Lipoprotein lipase (LPL) activity in post-heparin plasma was carried out by the method 
of Henderson et al. (1993). LPL activity was discriminated from HL activity by 
conducting the assay at the pH optima for LPL (pH 8.2) in the presence of apo-CII (an 
essential co-factor for LPL activity) and of sodium dodecyl sulphate (SDS - an inhibitor 
of HL). Twenty-five pCi of glycerol tri [9, 10 (n)-3 H] oleate (specific activity 1 
pCi/nmol) (TRA 191 Amersham Ltd., UK) was added to 100 mg (113 pmoles) of 
triolein (Sigma Ltd) in 1 ml of toluene. This was dried under nitrogen and then washed 
with 2 ml heptane. After evaporation, 17.5 ml of gum arabic (5% w/v in 0.2 M Tris 
buffer, pH 8.2) was added and the mixture were sonicated for 4 minutes in an ice bath 
until it was milky with no visible oil droplets. Bovine serum albumin (8.25 ml of 200 
g/L defatted BSA) and 0.8 ml of 2.42 mol/L sodium chloride (both in 0.2 mol/L Tris 
buffer pH 8.2) was added and mixed. Aliquots (0.42 ml) of substrate emulsion were pre 
incubated for 90 min at 37°C with 80 pi of heat-inactivated human serum as the source 
of apo-CII. HL activity was inhibited by incubation of the plasma samples for 30 min at 
room temperature with SDS (1:1 v/v PHP:70 mmol/L SDS in 0.2 mol/L Tris buffer, PH 
8.2). An aliquot (60 pi) of the incubated plasma was added to the pre incubated 
substrate and mixed. Following incubation at for 1 hour at 37°C the reaction was 
stopped by the addition of Belfrage reagent and the assay continued as per for HL 
(Henderson et al., 1993).
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2.3.4.4 Lipase activity normalisation and calculation
All assays of the same subject’s PHP for LPL and HL determinations, at both baseline 
and after treatment, were carried out at the same time and using the same batch of 
substrate in order to compensate for variations in the micelle size of the substrate 
emulsion. Inter assay variation was accounted for by assaying a PHP sample from a 
control batch prepared from a healthy volunteer with each group of assays performed. 
Results from the assays were normalised using the control values as standard. The 
specific activity of the substrate was determined and expressed as pmoles triolein per 
d.p.m. This figure was multiplied by 3 to account for the 3 acyl groups on triolein and 
the d.p.m present in the samples were converted to pmoles triolein and the total amount 
present in the upper phase of the free fatty acid extraction step was calculated. A 
correction factor for the efficiency of the Belfrage extraction technique was determined 
using [3 H]-oleic acid was applied to the result. After correction for dilutions, the results 
were expressed as pmoles fatty acid released/h/L plasma. The inter-assay coefficients of 
variation was < 7% for both assays.
2.4 PLASMA INSULIN AND INSULIN PRECURSOR MEASUREMENTS
Plasma insulin, intact proinsulin and 32-33 Split proinsulin concentrations were 
determined by two-site immunoradiometric assays using highly-specific antibodies 
(Sobey et al., 1989). The insulin assay cross-reacted 5.3% and 5.0% with intact 
proinsulin and 32-33 split proinsulin respectively. The proinsulin assay did not cross- 
react with insulin or 32-33 split proinsulin. The inter-assay coefficients of variation was 
< 15% for both assays.
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2.5 GLUCOSE DETERMINATION
Glucose present in EDTA plasma samples was determined using the hexokinase 
reaction in which glucose-6 -phosphate formed by the hexokinase reaction is oxidised by 
glucose-6 -phosphate dehydrogenase in the presence NAD+ yielding NADH and 6 - 
phosphogluconate. NADH produced was measured at 340 nm (Sigma Infinity glucose 
reagent). Glucose present in the plasma was determined from a standard curve that was 
linear up to 20 mmol/L. The inter-assay coefficients of variation was 3.4 %.
2.6 HOMA INSULIN RESISTANCE and 3-CELL FUNCTION
Insulin resistance was calculated from fasting plasma glucose and insulin concentrations 
using the computer-solved homeostasis model assessment (HOMA) method as 
previously described by Mathews et al. (1985). The estimate of insulin resistance 
derived from this method has been shown to correlate with those obtained by the use of 
euglycaemic and hyperglycaemic clamps.
Insulin resistance = fasting insulin (pU/ml) x fasting glucose (mmol/L) / 22.5
2.7 APOLIPOPROTEIN MEASUREMENTS (APO-AI & APO-B)
Apo-AI and apo-B were determined separately by immunoturbidometric methods (Apo- 
AI Direct, Apo-B Direct; Technoclone, UK). Plasma samples were mixed with the 
reagents and mixed briefly. An initial reading of the absorbance was made at 340 nm 
and the sample left to incubate for 10 minutes at 37°C without further stirring. A second 
reading was made at 340 nm. The initial reading was subtracted from the second 
reading and the difference in absorbance determined. A standard curve was prepared 
using apo-AI and apo-B preparations treated identically to the plasma and the
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concentration of apo-AI and apo-B in the plasma were determined from these curves. 
The inter assay coefficient of variation was < 5 %.
2.8 LIPOPROTEIN (a) (Lp(a)) MEASUREMENTS
Lipoprotein (a) was determined on diluted plasma samples using a an Elisa kit in 96- 
well plate format (Immuno-UK). The inter assay coefficient of variation was < 8  %.
2.9 HbAlC
Liver and kidney function tests, full blood count and HbAlC were assayed by at the 
chemical pathology lab at University College London Hospital.
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2.10 POWER OF THE STUDY AND STATISTICAL ANALYSES
The statistical power of the study was greater than 0.85 to detect differences of 20% in 
glucose, triglyceride, insulin, proinsulin, split proinsulin, HOMA, cholesterol, NEFA at 
a level of significance of 0.05.
Statistical analyses were performed using program SPSS version 11 (SPSS UK Ltd, 
Chertsey, UK). Between-group characteristics were compared by unpaired t-test. Within 
group changes were compared by paired t-test. The effect of glibenclamide and 
pioglitazone on postprandial lipoprotein, NEFA, glucose, insulin and insulin precursor 
were analysed using repeated ANOVA (Ludbrook, et al., 1994). Associations between 
variables were analysed using Spearman’s correlation analysis. Variables with skewed 
distribution were log-transformed before the analyses, but the untransformed data are 
shown in the text, figures and tables for ease of interpretation. Postprandial parameters 
over the 8 -hours period were calculated as areas under the curve (AUC). The p value 
<0.05 (two tailed) was considered statistically significant Data are presented as mean ± 
S.D (standard deviation) in text and tables and mean ± S.E.M. (standard error of the 
m ean) in figures.
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CHAPTER 3
THE EFFECT OF INSULIN SENSITIZATION THROUGH THE PPARy 
RECEPTOR PATHWAY IN TYPE 2 DIABETIC AND CONTROL 
SUBJECTS: PLASMA LIPID CONCENTRATIONS IN THE FASTING AND
POSTPRANDIAL STATE.
The objective o f this part of the study was to determine the effect of insulin 
sensitization through the PPARy receptor pathway with pioglitazone and compare it 
with sulphonylurea treatment (glibenclamide) on the fasting lipid concentrations and 
postprandial clearance of lipoproteins in type 2  diabetic patients compared with a 
group of control subjects.
3.1 THE DEMOGRAPHIC DETAILS OF THE STUDY GROUPS
Table 5: Demographic characteristic of controls and diabetic subjects
Control Glibenclamide Pioglitazone
N 1 0 1 1 1 1
Age (years) 52.4 ± 8.9 58.5 ± 9.2 54.5 ± 12.2
Sex 6M/4F 8M/3F 9M/2F
BMI (kg/m"1) 24.7 ±1.5 28.4 ±2.8 28.2 ±3.1
Smoker 2 2 3
Alcohol (unit/week) 8 1 0 1 1
Duration o f DM (years) -
oo1© 0.5- 5.2
Treatment -
Diet & sulphonylurea 5 3
Diet & Metformin 6 8
Hypertension - 4 2
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The clinical and physical characteristics of the patients and control subjects are 
shown in Table 5. It can be seen that the groups of subjects were matched for age 
and sex and no statistical differences were found (ANOVA, p = NS). However, the 
diabetic patients had a trend to have a higher BMI when compared to controls but 
this was not statistically significant. Both diabetic groups had the same duration of 
diabetes and treated with either metformin or sulphonylurea prior to the study. No 
changes in the anti-hypertensive treatment were made during the study period.
3.2 THE EFFECT OF INSULIN SENSITIZATION ON FASTING LIPID 
CONCENTRATIONS IN TYPE 2 DIABETIC SUBJECTS
3.2.1 Baseline fasting lipids in the diabetic groups compared to control subjects
Fasting lipid and lipoprotein concentrations are shown in Table 6 a and 6 b. Total 
plasma triglycerides were significantly higher in both diabetic groups in comparison 
with the control group (p < 0.05). Plasma cholesterol content had a trend to be 
greater in the diabetic subjects compared to control subjects but only in the 
pioglitazone group did this achieve statistical significance.
Total VLDL -TG  concentrations were significantly higher in both groups o f 
diabetic patients compared to control values (p < 0.05). VLDL-1 and VLDL-2-TG 
were also significantly greater in both diabetic groups than in control subjects (p < 
0.05) see Figure 9. Neither total VLDL cholesterol content nor that in its 
subfractions were statistically different between the study groups.
IDL cholesterol levels were also higher in the diabetic subjects in comparison 
with the control group (p < 0.05). This was not the case for triglyceride content 
which was only significantly higher in the glibenclamide group.
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Table 6a: Fasting plasma lipids and lipoproteins (mmol/L)
Glibenclamide Pioglitazone Control
Cholesterol Baseline
Post-treatment
5.02 ± 0.75 
5.15 ± 1.04
5.40* ± 0.94 
4.87 ±1.57
4.44 ±0.58
VLDL (T) CH Baseline
Post-treatment
0.72 ±0.42  
0.72 ± 0.35
0.58 ± 0.22 
0.58 ± 0.46
0.46 ±0.13
VLDL-1 CH Baseline
Post-treatment
0.36 ± 0.24 
0.32 ± 0.24
0.29 ±0.12  
0.29 ± 0.34
0.22 ±0.11
VLDL-2 CH Baseline
Post-treatment
0.35 ± 0.20 
0.40* ± 0.24
0.28 ±0.11 
0.29 ±0.15
0.23 ± 0.05
IDL-CH Baseline
Post-treatment
1.10* ±0.75  
0.99 ± 0.68
0.94* ± 0.22 
0.91 ± 0.63
0.50 ± 0.21
LDL-CH Baseline
Post-treatment
2.19 ±0.51 
1.77 ±0.51
2.13 ±0.48  
1.83 ±0.63
2.0 ± 0.44
HDL-CH Baseline
Post-treatment
1.31 ±0.54  
1.06* ±0.39
1.08 ±0.23  
1.01* ±0.25
1.31 ±0.29
h dl3-ch Baseline
Post-treatment
0.95 ±0.13  
0.66* ± 0.28
0.72 ±0.12  
0.67* ±0.15
0.89 ± 0.24
h dl2-ch Baseline
Post-treatment
0.35 ± 0.85 
0.40 ± 0.26
0.35 ± 0.20 
0.34 ± 0.21
0.41 ± 0.24
Triglyceride Baseline
Post-treatment
1.18* ±0.33  
1.35* ±0.52
1.98* ±1.69  
1.10* ± 0.68
0.82 ± 0.34
VLDL (T) TG Baseline
Post-treatment
0.68* ± 0.38 
0.66* ± 0.34
0.86* ±0.50  
0.55* ± 0.51
0.39 ± 0.25
VLDL-1 TG Baseline
Post-treatment
0.46* ± 0.25 
0.46* ± 0.22
0.54* ± 0.28 
0.37 ± 0.39
0.39 ± 0.25
VLDL-2 TG Baseline
Post-treatment
0.21* ±0.14  
0.22* ± 0.09
0.32* ±0.28  
0.16* ± 0.11
0.12 ±0.07
IDL- TG Baseline
Post-treatment
0.30* ± 0.22 
0.27* ±0.14
0.41 ± 0.46 
0.26 ± 0.26
0.15 ±0.08
LDL- TG Baseline
Post-treatment
0.16 ±0.06  
0.16 ±0.05
0.21 ±0.14  
0.15 ±0.07
0.14 ±0.03
HDL- TG Baseline
Post-treatment
0.12 ±0.06  
0.14 ±0.06
0.14 ±0.06  
0.11 ±0.05
0.13 ±0.05
HDL3- TG Baseline
Post-treatment
0.10 ±0.03  
0.12 ±0.05
0.02 ± 0.28 
0.09 ± 0.04
0.12 ±0.06
HDL2- TG Baseline
Post-treatment
0.01 ± 0.03 
0.02 ± 0.02
0.12 ±0.26  
0.03 ± 0.02
0.01 ± 0.02
Data show the mean ± SD.
Patients groups vs control subjects: * p< 0.05.
Baseline vs post-treatment for each group: t  P< 0.05. 
Glibenclamide vs pioglitazone treated patients: $ p< 0.05.
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LDL cholesterol and triglyceride were also slightly higher in the diabetic groups than 
in the control subjects but, in this case, the difference did not reach statistical 
significance. As shown in Table 6 b, apo-B concentrations were also higher in the 
diabetic groups but this did not reach statistical significance. Lp(a) concentration 
were significantly higher in the glibenclamide group compared to the control (p< 
0.05). Lp(a) was also higher in the pioglitazone group but did not reach statistical 
significance (see Table 6 b).
Total HDL cholesterol and triglyceride content did not differ between the 
diabetics and control subjects. This was also the case when HDL was subfractionated 
to HDL2 and HDL3 . Likewise, no differences were observed for apo-AI.
Both groups of diabetic subjects had a higher concentration o f NEFA than 
controls but this did not achieve statistical significance (Table 5b).
Table 6b: Fasting plasma Lp(a), NEFA and apolipoproteins
Glibenclamide Pioglitazone Control
Lp(a) (mg/dl) Baseline
Post-treatment
19.15* ±19.20  
14.80* ±13.70
16.85 ±17.2  
18.5 ±17.6
8.63 ± 7.06
NEFA (pmol/L) Baseline
Post-treatment
444 ± 161
502* ±208
471 ± 203 
4 0 7 ± 188
373 ± 105
Apo-AI (mg/dl) Baseline
Post-treatment
153 ± 45  
143 ± 33
143± 30 
146 ±35
128 ±17
Apo-B (mg/dl) Baseline
Post-treatment
130 ± 36  
118 ± 30
133 ±36  
121 ±46
105 ±28
HbAlC % Baseline
Post-treatment
7.21* ±0.60  
7.28* ± 0.50
7.40* ± 0.50 
7.29* ± 0.50
5.30 ± 0.20
Data show the mean ± SD.
Patients groups vs control subjects: * p< 0.05.
Baseline vs post-treatment for each group: f  P< 0.05. 
Glibenclamide vs pioglitazone treated patients: t  P< 0.05.
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3.2.2 Fasting plasma lipid and lipoprotein content after treatment
Neither treatment had an effect on the glycaemic control assessed by HbAlC (see 
Table 6 b). Fasting plasma lipid and lipoproteins after treatment with glibenclamide 
or pioglitazone are shown in Tables 6 a and 6 b. Neither the total cholesterol nor 
VLDL-1, VLDL-2, IDL, LDL lipoprotein cholesterol content showed any significant 
changes from the fasting baseline data. There was a fall in total HDL cholesterol and 
HDL3  cholesterol in both groups which both became significantly lower than the 
control subjects, but this was not the case for HDL2  which did not change after 
treatment.
Total plasma triglyceride showed a significant fall in the pioglitazone treated 
group to a level not significantly different from that o f the control subjects. By 
contrast, there was no change in the total plasma triglycerides in the glibenclamide 
treated group which remained significantly higher than the control individuals. In the 
pioglitazone group, there was a significant fall in the total VLDL triglyceride and 
also in VLDL-2 triglyceride; there was also a fall in VLDL-1 triglyceride but this did 
not achieve statistical significance. By contrast treatment with sulphonylurea made 
no changes to triglyceride present in total VLDL and its subfractions. There was a 
trend for a fall in the triglyceride content o f IDL, LDL in the pioglitazone group but 
it did not achieve a statistical significance. Total HDL triglyceride and its 
subfractions showed no significant changes with either treatment.
The concentration o f Lp(a) showed a significant fall from the baseline after 
treatment with glibenclamide, but this was not the situation with the pioglitazone 
group (Table 6 b). No effect of either treatment was observed on the plasma content 
of apo-AI and apo-B (Table 6 b). There was a trend for a fall in the fasting plasma 
NEFA content in the pioglitazone treated group but this was not statistically
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significant. In the glibenclamide group, fasting NEFA concentrations increased and 
became significantly higher than the control subjects.
1.2
o
£
E
Pre and post-treatm ent VLDL-TG
- v -
1
0.8
0.6
0.4
0.2
0
G- pre G-post P-pre P-post
i
□  T -VLDL
□  VLDL-1
□  VLDL-2
Patient groups vs control subjects: p < 0.05.
Baseline vs post-treatment for each group: ^p < 0.05.
Figure 9: The response of total VLDL-TG and its subtractions to treatment with 
pioglitazone or glibenclamide in type 2 diabetic patients compared to control 
subjects.
3.3 THE EFFECT OF INSULIN SENSITIZATION THROUGH THE PPARy 
RECEPTOR PATHWAY ON POSTPRANDIAL LIPAEMIA IN TYPE 2 
DIABETIC PATIENTS AND CONTROL SUBJECTS
3.3 .1  Po s t p r a n d ia l  T r ig l y c e r id e  M e t a b o l ism
Postprandial triglyceride clearance in diabetic groups and controls subjects is shown 
in Figure 10. In the control subjects the effect o f the meal was to cause an increase in
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plasma triglyceride reaching a peak at 4 hr postprandial after which triglyceride 
concentration declined but did not return to the starting value after 8  hours.
In the diabetic subjects at baseline triglyceride levels increased but the peak 
was not achieved until 5-6 hr postprandial and remained elevated till the end o f the 
study period. At the baseline condition the AUC for postprandial plasma TG 
(mmol/L/hr) was similar in both groups o f diabetic patient (Table 7), and 
significantly higher than controls.
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Figure 10: The postprandial triglyceride response to the test meal before and after 
treatment with pioglitazone or glibenclamide in type 2 diabetic patients compared to 
control subjects.
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After the 20 week treatment period, the pioglitazone group showed a significant 
reduction in both the magnitude and duration o f postprandial hypertriglyceridaemia. 
By contrast, the glibenclamide treated group had no significant changes in 
postprandial plasma triglyceridaemia.
Table 7: Postprandial clearance of lipoprotein triglyceride measured as 
Area-Under-the Curve (mmol/L/8 hr)
Glibenclamide Pioglitazone Control
Triglyceride Baseline
Post-treatment
20.8* ±5.1 
21.5* ±7.7
23.5* ±10.7  
14.7* ± 7.4
12.4± 5.9
Corrected TG Baseline
Post-treatment
11.3** ±0.42  
11.1* ± 5.6
8.7* ±3.3  
5.6* * ± 2.1
5.8 ±2.9
Chylomicron RP Baseline
Post-treatment
16.9 ±18.2  
22.6 ± 16.4
19.9 ±12.4  
8.2** ±4.2
12.6 ±4.3
CR-RP Baseline
Post-treatment
26.0* ±24.1 
20.9* ±12.1
25.5* ±19.3  
14.8* ±6.4
11.7 ± 5.7
IDL-TG Baseline
Post-treatment
4.44* ±2.06  
5.78* ± 4.28
5.46** ±3.58  
3.60 ± 2.59
1.89 ± 1.13
LDL-TG Baseline
Post-treatment
2.04* ± 0.77 
2.42* ±1.40
2.58* ±1.80  
1.64 ±0.77
1.22 ±0.26
HDL-TG Baseline
Post-treatment
1.46 ±0.53  
1.21 ±0.44
1.68 ± 1.10 
1.11± 0.36
1.33 ±0.36
h d l3-tg Baseline
Post-treatment
1.05 ±0.46  
0.86 ±0.34
1.22 ±1.08  
0.74 ±0.38
1.13 ±0.50
hdl2-tg Baseline
Post-treatment
0.41 ± 0.29 
0.36 ± 0.21
0.47 ± 0.22 
0.38 ±0.15
0.21 ± 0.24
NEFA Baseline
Post-treatment
3198 ±1289  
3740 ± 1821
3871 ± 1882 
3092 ±1197
4098 ± 1640
Data show the mean ± SD.
Patients groups vs control subjects: * p< 0.05.
Baseline vs post-treatment for each group: t  P< 0.05. 
Glibenclamide vs pioglitazone treated patients: t  P< 0.05.
In order to assess the impact of the fat load present in the test meal in the 
absence o f the endogenous triglyceridaemia present in the subjects, a correction was 
made by subtraction o f the fasting triglyceride concentrations from the postprandial
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data. When the data was corrected in this fashion, the glibenclamide treated group 
still showed an exaggerated lipaemia in response to the test meal (Table 7). By 
contrast a significant reduction in the lipaemic response from that in the baseline 
state was seen in the pioglitazone group and was no longer significantly different 
from control values.
3.3 .2  C h y l o m ic r o n  R e t in y l  P a l m it a t e  C l e a r a n c e
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Figure 11: The postprandial chylomicron RP response to the test meal before and 
after treatment with pioglitazone or glibenclamide in type 2 diabetic patients 
compared to control subjects.
The chylomicron RP content o f postprandial plasma samples from diabetic patients 
and control subjects at baseline and post-treatment is shown in Figure 11. In the 
control subjects, chylomicron RP reached a peak after 4 hours and began to decline 
thereafter. By contrast, both groups of diabetic subjects showed a progressive
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increase in chylomicron RP over the entire 8  hour postprandial period. After 
treatment the postprandial chylomicron-RP content in the glibenclamide treated 
group showed a peak around 5 hours and then started to decline slowly. Nevertheless 
the clearance of chylomicrons was still severely abnormal when compared to the 
control subjects. Pioglitazone treatment, however, caused a significant reduction of 
postprandial chylomicron RP concentrations to that of the controls. This is reflected 
in the AUC for chylomicron RP (see Table 7). Paired t-test analysis showed that the 
reduction in chylomicron RP clearance from baseline was statistically significant (p 
<0.05).
3 .3 .3  C h y l o m ic r o n  R e m n a n t  R e t in y l  Pa l m it a t e  C l e a r a n c e
Post-treatment Chylomicron 
Remnants RP
Baseline Chylomicron Remnants RP
8.0 8.0
7.0 7.0
6.0 6.0
5.0 5.0
3.03.0
2.0 2.0
1.0
0.0 0.0
Time (hr) Time (hr)
Figure 12: The postprandial chylomicron remnant RP response to the test meal before 
and after treatment with pioglitazone or glibenclamide in type 2 diabetic patients 
compared to control subjects.
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At baseline, chylomicron remnant RP clearance showed a similar pattern to 
chylomicron RP, with the diabetic subjects having an exaggerated and delayed 
clearance of the chylomicron remnant-RP (Figure 12 & Table 7). Glibenclamide 
treatment had no effect on the clearance of chylomicron remnants where as 
pioglitazone treatment caused a significant reduction such that there was no longer 
any difference in the clearance (AUC) from that of the control subjects.
3.3.4 P o st p r a n d ia l  IDL a n d  LDL T r ig l y c e r id e  C l e a r a n c e
Baseline postprandial IDL-TG Post-treatment postprandial 
IDL-TG
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Figure 13: The postprandial IDL-TG response to the test meal before and after 
treatment with pioglitazone or glibenclamide in type 2 diabetic patients compared to 
control subjects.
In both groups of diabetic patents the IDL and LDL was significantly enriched with 
triglyceride when compared to control (see Table 7; Figures 13 & 14). The effect of 
the test meal was to cause an apparent progressive increase over the 8  hours in the
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content of triglyceride but this did not achieve statistical significance. Treatment 
with glibenclamide had no effect on the postprandial triglyceride content, expressed 
as AUC, of both IDL and LDL, but treatment with the pioglitazone reduced the 
triglyceride AUC content of both IDL and LDL to the level seen in controls (Table
7).
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Figure 14 : The postprandial LDL-TG response to the test meal before and after 
treatment with pioglitazone or glibenclamide in type 2 diabetic patients compared to 
control subjects.
3.3.5 P o s t p r a n d ia l  HDL T r ig l y c e r id e  C l e a r a n c e
HDL triglyceride content in both diabetic groups were similar to that of control 
subjects. The changes observed after treatment with either glibenclamide or 
pioglitazone were small and did not reach statistical significance (Table 7). HDL2  
and HDL3 triglyceride also showed no effects of either treatment (Table 7).
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Figure 15: The postprandial HDL-TG response to the test meal before and after 
treatment with pioglitazone or glibenclamide in type 2 diabetic patients compared to 
control subjects.
3.3.6 Postprandial Cholesterol Metabolism
There were no significant postprandial changes in plasma total cholesterol content in 
any o f the group studied (Table 8 ). No statistically significant changes were 
observed in the plasma concentrations of IDL and LDL cholesterol in the diabetic 
patients or control group (Table 8 ).
At baseline, the clearance (AUC) o f cholesterol in total HDL, HDL2  and 
HDL3 were not statistically different from that o f the control group (Table 8 ). After 
20 weeks treatment, the HDL3 AUC was reduced in both diabetic groups and became 
significantly less than the control values. There were no significant differences in the 
AUC o f HDL2 between the control subjects and both diabetic groups patients after 
treatment.
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Table 8: Postprandial clearance of total and lipoprotein cholesterol 
measured as Area-Under-the Curve (mmol/L/8 hr)
Glibenclamide Pioglitazone Control
Cholesterol Baseline
Post-treatment
38.0 ± 6.4 
37.6 ± 6.8
36.6 ±12.0  
35.9 ±10.0
34.4± 4.6
IDL-CHO Baseline
Post-treatment
6.1 ±1.3  
6.8 ±3.1
6.6 ±1.9
5.6 ±2.1
4.7 ±1.2
LDL-CHO Baseline
Post-treatment
14.2 ±2.5  
12.6 ±2.7
15.4 ±4.1 
13.2 ±4.8
13.1 ±2.9
HDL-CHO Baseline
Post-treatment
9.1 ±3.1 
7.4 ±1.9
7.7 ±2.1 
7.6 ±2.2
10.2 ±2.5
HDL3-CHO Baseline
Post-treatment
5.2 ±1.5  
4.7* ±1.0
5.8 ± 1.8 
4.7* ±1.4
7.1 ±2.1
HDL2-CHO Baseline
Post-treatment
3.3 ±2.1 
2.7 ±0.9
2.5 ±1.8  
2.9 ±1.6
1.22 ±0.26
Data show the mean ± SD. Patients groups vs control subjects: * p< 0.05.
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Figure 16: The postprandial cholesterol response to the test meal before and after 
treatment with pioglitazone or glibenclamide in type 2 diabetic patients compared to 
control subjects.
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Figure 17: Postprandial changes of IDL-Cholesterol pre- and post-treatment.
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Figure 18: Postprandial changes of LDL-Cholesterol pre- and post-treatment.
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Figure 19: Postprandial changes of HDL-Cholesterol pre- and post-treatment.
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3 .3 .7  P o st p r a n d ia l  N o n -E s t e r if ie p  F a t t y  A c id  M e t a b o l ism
In control subjects there was a fall in plasma NEFA concentrations reaching a 
minimum between 30 minutes and one hour after the test meal. In the diabetic groups 
this fall was not as pronounced and the minima occurred later between 1 - 2  hours. 
After treatment with pioglitazone the AUC for NEFA was reduced by 20% from the 
baseline. By contrast glibenclamide treatment increased the AUC for NEFA by 17% 
(Table 7).
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Figure 20: The postprandial NEFA response to the test meal before and after 
treatment with pioglitazone or glibenclamide in type 2 diabetic patients compared to 
control subjects.
3 .3 .8  P o s t p r a n d ia l  P h o s p h o l ip id  M et a b o l ism
The phospholipid content of postprandial plasma samples from diabetic patients and 
control group at baseline and in the post-treatment condition are shown in Figure 21.
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Figure 21: The postprandial plasma phospholipid response to the test meal before 
and after treatment with pioglitazone or glibenclamide in type 2 diabetic patients 
compared to control subjects.
At baseline, the AUC of total plasma phospholipid content in the diabetic groups 
were not statistically different from the control individuals. The changes after 
treatment with either glibenclamide or pioglitazone were minimal and did not reach 
statistical significance and neither did they differ from the control subjects.
3 .3 .9  LDL S u b f r a c t io n s  a n d  t h e ir  R e l a t io n  t o  P o s t p r a n d ia l  L ipa e m ia
The purpose of this part of the study was to assess the effect of pioglitazone 
treatment on the LDL density profile in the diabetic subjects. Furthermore, the 
significance of postprandial lipaemia, lipolytic enzymes, CETP, plasma insulin and 
insulin resistance as determinants of LDL heterogeneity was examined by statistical
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means. The subfractions are defined by their hydrated buoyant density as follows: 
LDL-1 (1.025-1.034 g/ml), LDL-II (1.034- 1.044 g/ml) and LDL-III (1.044- 1.060 
g/ml). The percentage distribution o f the major LDL subfractions in the diabetic 
group are shown in Table 9. At baseline, LDL-II was the predominant subfraction 
present in both groups of diabetic patients and the control subjects. There was a trend 
for small dense LDL (LDL III) to be a greater percentage o f total LDL than in the 
control subjects but this did not achieve statistical significance. Treatment with 
pioglitazone or glibenclamide made no difference to the distribution (Figure 22).
Table 9: Percentage distribution of LDL subfractions
Glibenclamide Pioglitazone Controls
Baseline Post­ Baseline Post­
treatment treatment
LDL I % 1 2  ± 6 1 1  ± 1 0 10 ± 9 1 2  ± 8 15 ± 13
LDL II % 55 ±14 52 ± 9 55 ±22 51 ± 21 58 ± 10
LDL HI % 33 ±16 36 ±16 34 ±27 37 ± 25 27 ± 14
Data show the mean ± SD.
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Figure 22: The distribution of LDL subtractions before and after treatment with 
pioglitazone or glibenclamide in type 2 diabetic patients compared to control subjects.
3.3.9.1 Correlation between LDL subfractions and fasting and postprandial 
measurement
The relationships between the percentage distribution o f LDL subfractions with 
fasting and postprandial lipid measurements, CETP, PLTP, LCAT and lipases 
activities are shown in Table 10. LDL-I levels correlated negatively with fasting 
triglyceride, overall triglyceride clearance (AUC), total VLDL and VLDL-1 
triglyceride. The opposite was found for LDL-III and correlated positively with 
these parameters. Percentage LDL-III correlated inversely with HDL cholesterol, 
when data for all subjects were analysed together. There was no significant 
correlation between any o f the LDL subfractions and HL, LPL activity nor with 
CETP, LCAT and PLTP.
A significant correlation were found between LDL subfractions and fasting 
insulin and pro insulin and split pro insulin levels. LDL-I correlated negatively with 
fasting insulin, proinsulin, split proinsulin, and LDL-III correlated positively with 
fasting insulin. Insulin resistance (estimated by the HOMA model) correlated
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negatively with LDL-I and positively with LDL-III when the data from all subjects 
were analysed together (Table 10).
Table 10: Relationships between % LDL subfractions and fasting, postprandial 
lipaemia, CETP, LCAT, lipases and insulin parameters in all diabetic patients 
at baseline
LDL-I LDL-H LDL-III
Fasting TG (mmol/L) - 0.46* -0.08 0.27
Total VLDL TG (mmol/L) -0.43* - 0.45* 0.52*
VLDL-1 TG (mmol/L) - 0.55* -0.24 0.43*
VLDL-2 TG (mmol/L) -0.29 -0.15 0.27
TG AUC (mmol/L/8 hr) - 0.49* -0.07 0.24
HDL (mmol/L) 0.30 0.37 - 0.43*
HOMA-IR - 0.65** -0.30 0.46*
Insulin (pmol/L) - 0.57** -0.37 0.52*
Proinsulin (pmol/L) - 0.43** -0.19 0.29
32-33 split proinsulin (pmol/L) - 0.47* -0.32 0.40
CETP (pinole cholesterol ester transferee!/ L/hr) -0.02 -0.02 0.06
PLTP (Arbitrary unit) -0.19 0.01 0.13
LCAT (pinole free cholesterol esterified/L/hr) 0.14 0.33 -0.34
HL (pmol NEFA released/ml/hr) -0.28 -0.09 0.23
LPL ((pmol NEFA released/ml/hr) 0.15 -0.19 0.12
Values are Spearman rank correlation coefficients. *P < 0.05, **p < 0.01.
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DISCUSSION
3.4 THE EFFECT OF INSULIN SENSITIZATION WITH PIOGLITAZONE 
ON PLASMA LIPID AND LIPOPROTEIN CONCENTRATION IN TYPE 2 
DIABETIC PATIENTS COMPARED TO CONTROL SUBJECTS.
3.4.1 The Fasting State
Dyslipidaemia is common in type 2 diabetes and in the fasting state, is normally 
manifest as hypertriglyceridaemia and reduced HDL cholesterol content. Previous 
reports have shown that TZDs can modify lipid metabolism in insulin resistant 
animals and humans (Nozue et al., 1999; Sunayama et al., 2000; Crawford et al., 
1999). In this study insulin sensitization with pioglitazone caused a fall in the total 
plasma triglyceride which was most evident in the VLDL triglyceride and 
subfractions, in particular the smaller VLDL-2 species. Glibenclamide treatment had 
no effect on total circulating triglyceride nor on VLDL and its subspecies which 
remained present in significantly higher concentrations than in the control subjects. 
No changes were seen in the cholesterol content of VLDL and its subfractions 
suggesting that it is the incorporation o f triglyceride into lipoprotein in the liver that 
is reduced by treatment by pioglitazone. Reduced VLDL triglyceride content could 
be brought about by a restriction in the supply o f NEFA to the liver for a use as a 
substrate for triglyceride synthesis. Some evidence in support of this hypothesis is 
given by the finding that apo-BlOO concentrations did not alter and that it can be 
inferred that the particle number was not changed by either treatment. However, 
other mechanisms involved in the assembly o f  VLDL such as the microsomal 
triglyceride transfer protein can not be excluded (Zoltowska et al., 2003).
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We have found that insulin sensitization caused a fall in the plasma concentration o f 
NEFA of a similar order of magnitude (18%) as other reports (Gomez-Perez et al., 
2002). However in our study the fall was not statistically significant probably 
because of the small sample size of the patient groups studied and the large variation 
in the normal range o f NEFA concentration 250-700 pmol/L (Perseghin et al., 2001).
Less VLDL in plasma would be thought to be reflected in reduced IDL and 
LDL content but this was not the situation and we did not find any significant 
changes in either the triglyceride or cholesterol concentrations o f IDL. This suggests 
that the fall in VLDL and its sub species is associated with a more rapid uptake of 
by the hepatic remnant receptors rather than them proceeding down the lipolytic 
cascade to IDL and LDL. Pioglitazone treatment has not been reported to cause an 
increase in LDL cholesterol content by contrast to treatment using a different TZD 
(rosiglitazone) that is reported to increase in LDL cholesterol (Lacivita et al., 2002; 
Van Wijk et al., 2003).
Insulin resistance is reported to be associated with lower plasma 
concentrations of Lp(a) (Gomez-Perez et al., 2002). In agreement with this finding 
we have found that treatment with glibenclamide caused an increase in insulin 
resistance as estimated by the HOMA model (see Chapter 4) and was associated with 
a significant fall in Lp(a) concentrations. By contrast, treatment with pioglitazone 
which reduced the insulin resistance showed a trend to increase the plasma Lp(a) 
concentrations but this did not achieve statistical significance. These finding need to 
be interpreted with caution because o f the relatively small number o f patients studied 
and also because the subjects were not genotyped for Lp(a) polymorphism. The 
mechanism by which these changes are brought about by insulin sensitization are not 
known and likewise the physiological importance of the results.
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We did not find that sensitization to insulin through the PPARy pathway increased 
the amount of HDL cholesterol present in the fasting state. However, from the outset, 
the patient groups did not have a significantly lower HDL cholesterol level than the 
control subjects. This is likely also to be the reason why we did not observe any 
differences in the distribution o f HDL into HDL2  and HDL3 particles when 
compared to control subjects. Previous studies with TZDs have reported a small but 
significant increase in total HDL cholesterol (Aronoff et al., 2000; Gomez-Perez et 
al., 2002; Herz et al., 2003; Nolan et al., 2000). In these studies a larger number of 
patients were recruited and were more severely hypertriglyceridaemic than those in 
our study. In addition it may be that long term treatment with the insulin sensitizer is 
required to induce significant changes in total HDL and its subfractions.
The synthesis o f apo-AI is thought to be directed through the PPARa 
receptor (Linden et al., 2002) and not PPARy. Beneficial effects of TZDs are thus 
likely to be through indirect mechanisms that lead to a decrease in the turnover of 
HDL species or a more general effect caused by the improvement in insulin 
resistance. Recent evidence has been presented that suggest that the increase in 
plasma HDL content is mediated, at least in part, through PPARy activators that 
induce expression o f the gene encoding for the ABCA1 transporter (Chinetti et al., 
2001). The effect of this is to allow a greater efflux of free cholesterol from 
peripheral tissues to nascent HDL and hence accelerate the reverse cholesterol 
transport without increasing the amount of apo-AI present. While this mechanism 
may improve the effectiveness o f HDL in reverse cholesterol transfer it does not 
explain why the overall amount o f HDL (apo-AI) is increased. Our finding that apo- 
AI concentration did not change with treatment with pioglitazone, is in agreement
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with this hypothesis, but additional studies are required for describing the detailed 
effects of TZDs on HDL kinetics.
Both diabetic group were found to have fasting triglyceride > 1 . 7  mmol/1 on 
screening. However after the washout period and on the baseline test meal patients 
founds to have triglyceride level within normal range ( < 1.7mmol/l), and those 
patient were mainly in the glibenclamide group ( see table 6 A, 6 B), also their NEFA 
were not significantly different from the control subjects and this is not unexpected 
since this group are not very hypertriglyceridaemic.
3.4.2 The Postprandial State
3.4.2.1 Baseline postprandial lipaemia in type 2 diabetic patients compared to 
normal subjects
This study is the first to investigate the effect of insulin sensitization through the 
PPARy/TZD pathway using pioglitazone on postprandial lipid clearance compared to 
the effect o f sulphonylurea treatment (glibenclamide) in a group of patients with type 
2 diabetes. The treatment regimes were designed to maintain the long-term 
glycaemic control of the patients, as measured by HbAlC, at the same level. The 
reason for this was to be able to rule out the impact of any change in glycaemic 
control on the metabolism o f lipids.
In the baseline test both groups of diabetic subjects showed the well- 
established delayed clearance of dietary lipid when compared to normal individuals 
in agreement with previous studies (Malmstrom et al., 1997; Mero et al., 2000; Tan 
et al., 1995). This was despite there being only modest fasting hypertriglyceridaemia 
in the diabetic subjects. There are at least four possible mechanisms, acting singly or 
in combination, that may explain the exaggerated postprandial lipaemia. These are:
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( 1 ) an effect on the receptor-mediated uptake o f triglyceride-rich lipoproteins 
remnants particles, 2 ) competition between intestinal and hepatic lipoproteins for the 
available lipase activity caused by abnormal VLDL production in type 2 diabetic 
dyslipidaemia, 3) insulin-dependent effects on VLDL synthesis, 4) abnormal 
lipoprotein remodelling processes and apo lipoprotein trafficking.
Results from previous studies, and the present one, suggest that delayed clearance o f 
dietary fat is due to a combined effect of both increased VLDL production by the 
liver and competition between chylomicron remnants and VLDL remnants for the 
hepatic uptake receptors (Cooper et al., 1996). It has been shown that suppression of 
hepatic apo-BlOO production by insulin is impaired in type 2 diabetes and results in 
increased synthesis and secretion of VLDL particles in the fasting and postprandial 
phase (Packard et al., 2000). The normal suppression of NEFA release by insulin 
from the adipose tissue is also impaired in the insulin-resistant state. This increases 
the substrate available to the liver for triglyceride synthesis which results in 
continued VLDL synthesis and secretion at a rate greater than would be expected if 
the adipose tissue lipase was inhibited to the normal degree (will be discussed in 
Chapter 4) (Amer et al., 2002; Staehr et al., 2003).
In the postprandial phase, the increase in chylomicron and chylomicron 
remnants causes abnormal competition with VLDL and its remnants particles for the 
available lipoprotein lipase activity and uptake by common hepatic receptor (will be 
discussed further in Chapter 5). The delayed clearance of intestinal and hepatic 
triglyceride-rich lipoprotein remnant particles increases the potential for lipoprotein 
remodelling mediated by LCAT / CETP / PLTP (Jones et al., 1996).
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3A.2.2 The effect of insulin sensitization on lipid clearance in type 2 diabetic 
patients compared with normal subjects
After treatment with the insulin sensitizer (pioglitazone) major changes were 
observed the in postprandial clearance o f total plasma triglyceride, chylomicron, 
chylomicron remnants and the triglyceride content of IDL, and LDL to levels not 
longer significantly different from control subjects.
The mechanism by which chylomicron and chylomicron remnant clearance could be 
improved by insulin sensitization may involve a decrease in the competition for the 
lipolytic processes caused by the reduced extent of VLDL synthesis after treatment. 
Some evidence in favour of this is given by our finding that the responses o f plasma 
NEFA content, as judged by AUC, showed a trend to decrease after treatment with 
pioglitazone which was not seen with glibenclamide treatment. Thus a restriction of 
a supply o f NEFA may well reflect the overall reduction in plasma triglyceride seen 
after pioglitazone treatment but not after glibenclamide treatment. Other possible 
mechanisms involving abnormal assembly, secretion and constitution of 
chylomicron which are corrected by TZDs treatment can not be ruled out. Recent 
studies in mice lacking adipose tissue have shown that TZD treatment reduced 
plasma triglyceride concentration (Chao et al., 2000). From this it may be inferred 
that TZD treatment does not only act on adipose tissue to control the supply o f 
NEFA to the liver but has other complementary actions that may contribute to the 
reduced hepatic triglyceride synthesis.
Indirect mechanisms arising from an overall reduction in insulin resistance 
may cause the improved clearance of dietary lipid associated with e.g., an increase o f 
mass or activity o f lipoprotein lipase (this will be discussed in Chapter 5).
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The postprandial increase in IDL and LDL triglyceride, which is not reflected 
in an increase in IDL or LDL cholesterol, implies that there is either a failure o f 
lipolysis or other lipoprotein remodelling mechanisms, this is likely to be an indirect 
effect of the competition between intestinal and hepatic lipoprotein for e.g., lipases 
and lipid transfer protein. The effect of pioglitazone is to reduce this competition by 
reducing the VLDL output by the liver and hence permit the normal processing o f 
IDL and LDL by hydrolysis o f the triglyceride content. It seems unlikely that the 
reduction o f IDL and LDL triglyceride is due to a fall in particle numbers because 
we did not observe any postprandial changes in the cholesterol content of these 
lipoproteins and no change in apolipoprotein B.
Our data showed that the administration o f glibenclamide had no apparent 
effect on postprandial triglyceride metabolism. It has been reported in one study that 
glibenclamide reduced postprandial triglyceridaemia due to fall in triglyceride o f 
intestinal origin compared to placebo. This may be related to the amelioration o f 
postprandial glycaemia rather than to a direct action of the drug itself (Skrapari et al., 
2001). In this study we did not find any significant improvement in the chylomicron 
and chylomicron remnant clearance with a treatment regime designed to maintain 
glycaemic control constant.
3.4.2.3 LDL subfractions
In our study we have found that in general, when a negative correlation was found 
between any o f the fasting and postprandial metabolic indices and %  LDL-I and 
LDL-II, a positive correlation was found between LDL-III and these parameters. The 
opposite occurred when positive correlation was found for LDL-I and LDL-II.
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Fasting triglyceride concentrations had a significant negative correlation with 
%  LDL-I, one of the main constituents of the non-atherogenic type A phenotype; it 
had a positive correlation with LDL-ffl. Thus the lower the fasting triglyceride 
content the greater the %  LDL-I. This is consistent with the correlation found with 
the clearance o f postprandial triglyceride. In confirmation o f this is our finding that 
one of the main aspects of fasting diabetic hypertriglyceridaemia is excess VLDL 
which correlated negatively with % LDL-I and %  LDL-II and positively with % 
LDL-ni.
We also found a negative correlation between insulin resistance estimated by HOMA 
and %  LDL-I and a positive correlation between HOMA and %LDL-III. This pattern 
is reflected in the correlation between insulin, proinsulin and split proinsulin 
showing that any improvement in insulin sensitivity and p-cell function, as gauged 
by release o f partially processed insulin species, will favour type-A phenotype. No 
significant correlation in the enzymes and transfers proteins responsible for 
lipoprotein remodelling. The negative correlation between %  LDL-III and HDL may 
well be due to the overall diabetic dyslipidaemia.
The result o f abnormal lipolytic remodelling processes leads to the presence 
of triglyceride-rich lipoprotein relatively enriched of triglyceride which are 
precursors o f small dense LDL. The presence o f atherogenic phenotype was not an 
inclusion requirement in this study and too few of the patients had a predominance o f 
small dense LDL, presumably because the patients studied had only modest 
hypertriglyceridaemia, to permit an assessment of the effect o f insulin sensitization. 
Our results, however, indicate that any improvement of fasting 
hypertriglyceridaemia by insulin sensitization well be expected to favour a greater 
%LDL-I and a lower % of LDL-III.
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CHAPTER 4
EFFECT OF INSULIN SENSITIZATION THROUGH THE PPARy 
RECEPTOR PATHWAY IN TYPE 2 DIABETES AND CONTROL SUBJECT: 
EFFECTS ON GLYCAEMIA, INSULIN RELEASE AND PROCESSING IN 
THE FASTING AND POSTPRANDIAL STATE.
4.1 SECRETION AND PROCESSING OF INSULIN
Type 2 diabetes is associated with both deficient pancreatic islet P-cell function and 
resistance o f peripheral tissues to the action o f insulin (insulin resistance). Pancreatic 
(3-cells normally compensate for insulin resistance by increasing basal and 
postprandial insulin secretion. As long as the hyperinsulinaemia is adequate to 
overcome the insulin resistance, glucose tolerance remains normal. In patients that are 
destined to develop type 2 diabetes, the (3-cell compensatory response declines and 
relative and absolute insulin deficiency develops. At this point, insulin secretion 
cannot keep pace with the underlying insulin resistance and consequently glucose 
intolerance and eventually type 2 diabetes occur. Chronic stimulation o f the P-cells by 
the requirement to secrete more and more insulin leads to the release of immature 
secretory vesicles containing abnormally high amounts of insulin precursors e.g. 
proinsulin. The increase in proinsulin levels with worsening glucose tolerance is 
greater than the increase in insulin concentration, suggesting a worsening defect in 
proinsulin processing with worsening glucose tolerance (Haffiier et al., 1994; 
Wareham et al., 1999). Pancreatic function in type 2 diabetes can be affected by gross 
histological changes such as a loss in the mass o f secretory cells present and 
amyloidosis.
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The processing o f proinsulin to active insulin proceeds via the action of 
endopeptidases which cleave proinsulin between residues 32-33 and 65-66 to yield 
the active insulin molecule. With the availability o f  highly specific insulin assays 
recognising proinsulin, it has become possible to study the contribution of “true” 
insulin relative to its precursors (intact and 32-33 split proinsulin) to various 
components of the insulin resistance syndrome. Under physiological conditions, only 
small amounts of proinsulin and 32-33 split proinsulin are co-secreted with insulin. It 
is now thought that true hyperinsulinaemia in type 2  diabetes is not as severe as 
previously suggested; instead there is an increase in plasma content of insulin 
precursors with 32-33 split proinsulin being the predominant species and 65-66 split 
proinsulin present at only trace concentrations (Temple et al., 1989).
Several studies have suggested that proinsulin concentration may be more 
strongly related to cardiovascular risk factors such as increased blood pressure and 
higher triglyceride levels, than are insulin concentrations (Haffiier et al., 1994, 2002).
4.2 THE EFFECT OF INSULIN ON LIPID METABOLISM
One of the most important functions of insulin is to inhibit the release o f NEFA from 
adipose tissue. This is brought about by inhibition of hormone-sensitive lipase (HSL) 
and through an increase in the re-esterification o f fatty acids within adipose tissue 
(Coppack et al., 1997). In the postprandial period when insulin is secreted in response 
to the meal, inhibition of HSL is most marked with a substantial fall in plasma NEFA 
concentrations (Ferrannini et al., 1997). In a state of insulin resistance, such as type 2 
diabetes, the suppressive effect o f insulin on the mobilisation o f NEFA from adipose 
tissue by the hormone-sensitive lipase is impaired, and there is also reduced NEFA re- 
esterification. This leads to increased supply o f NEFA to the liver and abnormally
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high hepatic VLDL secretion during the postprandial period (Adeli et al., 2001; Byrne 
et al., 1997).
Insulin acutely inhibits hepatic VLDL secretion in hepatocyte preparations and 
also insulin increases the degradation o f newly synthesised apo-BlOO (Carpentier et 
al., 2001; Lewis et al., 2002; Duerden et al., 1989; Bartlett et al 1988). Thus during 
the early postprandial period, the rise in the portal concentration of insulin enhances 
the hepatic degradation of apo-BlOO, reducing VLDL particle secretion. In 
euglycaemic hyperinsulinaemic clamp studies designed to raise insulin concentrations 
to postprandial levels, a 50% reduction in VLDL apo-BlOO production was observed 
in control individuals, which was not seen in the hyperinsulinaemic obese subjects 
(Lewis et al 1993). This suggests that hyperinsulinaemic subjects are resistant to the 
effect o f insulin on inhibition of apo-BlOO synthesis.
4.3 AIMS AND OBJECTIVES
The objective o f this part of the study was to determine the effect of insulin 
sensitization through the PPARy receptor pathway with pioglitazone and compare it 
with sulphonylurea treatment (glibenclamide) on the fasting glycaemia, and resultant 
release o f insulin and precursor species in type 2  diabetic patients compared with a 
group o f control subjects.
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4.4 THE EFFECT OF INSULIN SENSITIZATION ON FASTING GLUCOSE, 
INSULIN AND INSULIN PRECURSOR SPECIES IN TYPE 2 DIABETIC 
SUBJECTS
4.4.1 Baseline fasting plasma glucose, insulin and insulin precursor 
concentrations in the diabetic groups compared to control subjects
Fasting plasma glucose, insulin, proinsulin and 32-33 split proinsulin concentrations 
are shown in Table 11. By definition fasting plasma glucose in the baseline condition 
was significantly greater in the diabetic subjects than in controls. After treatment with 
pioglitazone fasting glucose concentration fell significantly from the baseline level 
but remained significantly higher than the control values; glibenclamide treatment did 
not reduced fasting glycaemia.
Baseline fasting insulin levels were higher in the diabetic group compared to 
control subjects. After treatment with pioglitazone there was a reduction in insulin 
levels to values not significantly different from the control subjects. As expected 
glibenclamide treatment increased fasting insulin concentration from baseline level.
In the baseline fasting state, both groups of diabetic patients had significantly 
higher levels o f proinsulin than control subjects. The effect o f glibenclamide 
treatment was to increase proinsulin significantly from the baseline value. 
Pioglitazone treatment showed a trend for proinsulin concentrations to fall but this 
was not statistically significant. Control subjects had significantly lower proinsulin 
levels than either the pioglitazone or glibenclamide treated group.
Baseline fasting 32-33 split proinsulin concentrations were significantly 
higher in both diabetic groups than in control subjects. Glibenclamide treatment 
slightly increased 32-33 split proinsulin from the baseline. Pioglitazone treatment
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reduced concentrations o f 32-33 split proinsulin significantly to a level that did not 
differ from the controls values.
Table 11: Fasting insulin, proinsulin, 32-33 split proinsulin and insulin resistance 
estimated by HOMA model
Glibenclamide Pioglitazone Control
G lucose (mmol/L) Baseline 
Post-treatment 
% Change
9.39* (2.0) 
9.84*(1.8) 
4.80%
9.5* (1.8) 
7.5* (1.5) 
-21%
5.28 (0.8)
HbA1C% Baseline 
Post-treatment 
% Change
7.21* (0.6) 
7.28* (0.5)
7.40* (0.5) 
7.29* (0.5) 5.30 (0.2)
Insulin (pmo/L) Baseline 
Post-treatment 
% Change
70.6 *(31.5) 
93.9*** (41.6) 
32.90%
79.6 (58.3) 
62.35 (33.5) 
-21.70%
44.1(12.9)
Proinsulin (pmol/L) Baseline 
Post-treatment 
% Change
12.05* (7.5) 
19.4* *(17.5) 
60.80%
9.58 *(6.9) 
7.57* (5.8) 
-20.90%
3.31(2.0)
32-33 Split proinsulin (pmol/L) Baseline 
Post-treatment 
% Change
16.68** (7.9) 
20.8** (13.7) 
24.40%
15.91**(12.0) 
10.6* (10.6) 
-33%
3.9 (0.6)
Insulin Resistance (IR) Baseline 
Post-treatment 
% Change
4.04*** (1.4) 
5.97*** (2.7) 
32.30%
4.96* (3.8) 
2.99*t (1.6) 
-39.80%
1.54 (0.53)
Patient groups vs control subjects: * p <0.05., **p< 0.005, ***p<0.0005. 
Baseline vs post-treatment for each group: t  P <0.05.
Glibenclamide treated vs pioglitazone treated patients:^ p< 0.05.
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4.4.2 The effect of glibenclamide and pioglitazone on insulin resistance assessed 
by the HQMA model
In the baseline state, both groups o f diabetes were significantly more insulin 
resistance than the control subjects using the HOMA model. Treatment with 
glibenclamide slightly increased insulin resistance in these patients in contrast to 
pioglitazone which significantly reduced insulin resistance but, nevertheless remained 
higher than in the control group.
Insulin Resistance
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B aseline Post-treatm ent
■  Glibenclamide 
□  Pioglitazone
■  Control
* P < 0.05 patient group versus control subject.
P < 0.05 Baseline versus post-treatment 
Figure 23: HOMA estimate of insulin resistance before and after treatment with 
pioglitazone or glibenclamide in type 2 diabetic patients compared to control subjects.
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4.5 EFFECT OF INSULIN SENSITIZATION THROUGH THE PPARy 
RECEPTOR PATHWAY ON POSTPRANDIAL GLUCOSE, INSULIN AND 
INSULIN PRECURSORS IN TYPE 2 DIABETIC PATIENTS AND CONTROL 
SUBJECTS
4.5.1 Postprandial Glucose Clearance
Plasma glucose increased slightly after the high fat mixed meal in control subjects. By 
contrast, in both groups of diabetics there was pronounced glycaemia with peak 
concentrations being about 3-5 mmol/L higher than in the fasting state. In control 
subjects, peak glycaemia occurred within the first hour postprandial but peak 
glycaemia in both diabetic groups occurred later. At baseline, both diabetics groups 
had significantly greater area-under curves (AUC) than that o f the control subjects 
(Table 12).
Baseline postprandial glucose
16
14
12 -
_J 10.
o
E 8
E
4
2
0
-as ft -6 a
0 1 2 3 4 5 6 7 8  
Time (hr)
Post-treatment postprandial 
glucose
16
14
12
10 i
o
E 8
E 6 i
4
2
0
0 1 2 3 4 5 6 7 8  
Time (hr)
Figure 24 : The postprandial glucose response to the test meal before and after 
treatment with pioglitazone or glibenclamide in type 2 diabetic patients compared to 
control subjects.
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After treatment with glibenclamide there was no reduction in the AUC for glucose 
but, by contrast, treatment with pioglitazone caused a significant decrease in the AUC 
indicating an improvement in the ability to handle postprandial glucose but still not as 
effectively as by control subjects.
4.5.2 Postprandial Insulin Clearance
B aseline postprandial Insulin
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Time (hr)
Figure 25 : The postprandial insulin response to the test meal before and after 
treatment with pioglitazone or glibenclamide in type 2 diabetic patients compared to 
control subjects.
In control subjects, plasma insulin rose to a peak 30 minutes after the test meal and 
then declined to the fasting level. In contrast both diabetic groups had an exaggerated 
insulin response. Peak insulin concentrations occurred approximately 2 hours after the 
meal and declined only slowly to baseline levels. This was reflected in the area-under 
curves (AUCs) which were significantly greater than in the control subjects. Not 
surprisingly the effect of glibenclamide treatment was to increase insulin levels. By
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contrast, treatment with pioglitazone reduced the AUC but this was still significantly 
higher than for the control subjects.
Table 12: Integrated responses (AUC) of plasma insulin, proinsulin and 32-33 
split proinsulin after the test meal
Gibendam'de Pioglitazone Control
Gucose AUC (mmol/l/8lv) Baseline 
Post-treatrrert 
% Change
76.7*** (15.3) 
73.4*** (14.8) 
■4.30%
81.8*** (18.8) 
61.4 *^ (118 ) 
-24.90%
40.2(6.9)
Insulin AUC (pmol/l/8hr) Baseline 
HDSHreatmert 
% Change
1449** (510) 
1906*** (738) 
31%
1254** (560) 
988*1(468) 
-21.20%
639(119)
Proinsiiin AUC (pmoi/I/8ti) Baseline 
Rost-treatrnent 
% Change
279** (156) 
345 **(236) 
23.60%
165* (144) 
113«:(95) 
-31.50%
50(23)
32-33 Split proinsiiin AUC (pmot/l/8hr) Baseline 
Most-trestrnert 
% Change
344*** (145) 
382*** (179) 
11%
251** (163) 
16711(149) 
-33.50%
70(17)
Patient groips vs control streets: * p 0.05., **p< 0.005, ***p<0.0005 
Baseline vs post-treatment for each gnxp: f  p 0.05.
Qibendam'de treated vs poglitazone treated patients! pO.05
4.5.3 Postprandial Proinsulin Clearance
Proinsulin concentrations in control subjects showed a small peak coinciding with the 
peak of insulin secretion. In both groups o f diabetic patients maximal concentrations 
of proinsulin occurred about 2 hours postprandial. After glibenclamide treatment the 
AUC for proinsulin increased whereas after pioglitazone treatment, there was a 
significant fall in the proinsulin AUC to that of the control subjects.
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Figure 26: The postprandial proinsulin response to the test meal before and after 
treatment with pioglitazone or glibenclamide in type 2 diabetic patients compared to 
control subjects.
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Figure 27 : The postprandial 32-33 split proinsulin response to the test meal before and 
after treatment with pioglitazone or glibenclamide in type 2 diabetic patients compared 
to control subjects.
Baseline split proinsulin
0
0 1 2 3 4 5 6 7 8  
Time (hr)
133
4.5.4 Postprandial 32-33 Split Proinsulin Clearance
Plasma 32-33 split proinsulin in control subjects showed a similar pattern to 
proinsulin (Figure 27). In both groups o f diabetic patients after treatment with 
glibenclamide or pioglitazone the AUC showed the same pattern as for proinsulin. 
With pioglitazone the amount of 32-33 split proinsulin secreted fell such that it no 
longer differed significantly from control subjects (Table 12).
4.6 Relationship of Basal Beta-Cell Function to Fasting and Postprandial 
Lipaemia
To investigate possible relationships between fasting insulin, proinsulin, 32-33 split 
proinsulin level, insulin resistance, fasting lipoproteins and postprandial lipaemia, 
Spearman rank correlation coefficients were calculated. No correlation was found 
between fasting insulin levels and postprandial lipaemia (Table 13). Both fasting 
proinsulin and 32-33 split proinsulin levels correlate with fasting triglyceride, 
triglyceride AUC and negatively with plasma HDL cholesterol (Table 13) when the 
data from all subjects were included in the analyses. However, within each study 
group (diabetic and control subjects) this correlation did not reach statistical 
significance.
The integrated response of insulin over the postprandial period correlated 
positively with chylomicron RP (AUC) and chylomicron remnant RP (AUC) in the 
diabetic groups when the data from all subjects were included in the analyses (Table
14). Both the integrated proinsulin and 32-33 split proinsulin response over the 
postprandial period correlated with triglyceride AUC (Table 14). Both fasting 
triglyceride, proinsulin and split proinsulin correlate with insulin resistance estimated 
by HOMA model when data from all subjects were included in the analyses (Table
15).
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Table 13: Relationships between fasting insulin, proinsulin and 32-33 split
proinsulin levels and fasting and postprandial lipaemia
INSULIN Diabetics Control All subjects
Fasting TG (mmol/L) -0.02 0.21 0.16
HDL-C (mmol/L) -0.16 0.13 -0.17
TG AUC (mmol/L/8hr) -0.2 0.23 0.07
C-RP AUC (mmol/L/8hr) -0.36 -0.26 -0.31
CR-RP AUC (mmol/L/8hr) -0.13 -0.36 -0.21
PROINSULIN
Fasting TG (mmol/L)
Diabetics
0.21
Control
0.53
All subjects 
0.52**
HDL-C (mmol/L) -0.36 -0.33 -0.35*
TG AUC (mmol/L/8hr) 0.28 0.53 0.55**
C-RP AUC (mmol/L/8hr) -0.25 0.21 -0.11
CR-RP AUC (mmol/L/8hr) -0.33 0.57 0.17
32-33 SPLIT PROINSULIN
Fasting TG (mmol/L)
Diabetics
0.37
Control
0.09
All subjects 
0.54**
HDL-C (mmol/L) -0.41 -0.21 - 0.39*
TG AUC (mmol/L/8hr) 0.23 0.25 0.56*
C-RP AUC (mmol/L/8hr) -0.36 0.36 -0.15
CR-RP AUC (mmol/L/8hr) -0.33 0.71* 0.21
Spearman rank correlation coefficient *p < 0.05, ** p< 0.01. 
C-RP Chylomicron Retinyl Palmitate.
CR-RP Chylomicron Remnant Retinyl Palmitate.
135
Table 14: Relationships between integrated response of insulin, proinsulin and
32-33 split proinsulin levels and postprandial lipaemia
Insulin (AUC) (mmol/L/8hr) Diabetics Control All subjects
TG (AUC) (mmd/L/8hr) -0.32 -0.03 0.32
C-RP (AUC) (mmol/LV8hr) - 0.57** 0.24 -0.29
CR-RP (AUC) (mmol/L/8hr) - 0.45* -0.09 0.05
Proinsulin (AUC) (pmol/L/8hr) Diabetics Control All subjects
TG (AUC) (mmol/L/8hr) 0.11 0.53 0.54**
C-RP (AUC) (mmol/L/8hr) -0.31 0.19 -0.13
CR-RP (AUC) (mmol/L/8hr) -0.34 0.38 0.21
Split Proinsulin (AUC) (pmol/L/8 hr) Diabetics Control All subjects
TG (AUC) (mmol/U8hr) 0.17 0.16 0.56**
C-RP (AUC) (mmol/Ly8hr) -0.41 0.47 -0.15
CR-RP (AUC) (mmol/Ly8hr) -0.4 0.18 0.16
Spearman rank correlation coefficient *p < 0.05, ** p< 0.01. 
C-RP Chylomicron Retinyl Palmitate.
CR-RP Chylomicron Remnant Retinyl Palmitate.
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Table 15 : Relationships between insulin resistance (HOMA model) and
postprandial lipaemia
Diabetics Control All subjects
(Fasting)
TG (mmol/L) -0.04 0.22 0.35*
HDL-C (mmol/L) -0.21 0.18 -0.21
Proinsulin (pmol/L) 0.52* 0.33 0.73**
32-33 split proinsulin (pmol/L) 0.71** 0.07 0.81**
(AUC)
TG (mmol/L/8 hr) -0.04 0.22 0.34
C-RP (mmol/L/8 hr) -0.44 -0.22 -0.28
CR-RP (mmol/L/8 hr) -0.44 -0.07 0.05
Spearman rank correlation coefficient *p < 0.05, ** p< 0.01. 
C-RP Chylomicron Retinyl Palmitate.
CR-RP Chylomicron Remnant Retinyl Palmitate.
137
DISCUSSION
4.7.1 The effect of insulin sensitization on the fasting plasma glucose, insulin, 
proinsulin and 32-33 split proinsulin plasma concentration.
Insulin resistance plays a major role early in the development of type 2 diabetes. It is 
associated with clusters o f cardiovascular risk factors (e.g. hypertension and 
dyslipidaemia) that contribute to the increased risk of coronary heart disease in these 
patients. Directly targeting insulin resistance in the peripheral tissues by novel 
pharmacological agents is a relatively new approach for treating type 2  diabetes.
In the present study, both diabetic groups had the same glycaemic control as 
shown by HbAlC at baseline (Table 11). In the fasting state there was a significant 
fall in fasting glucose levels after treatment by sensitization to insulin through the 
PPARy receptor pathway with pioglitazone. This may will be due to decreased 
hepatic gluconeogenesis (Fujiwara et al., 1995; Ikeda et al., 1998) coupled with 
increased glucose disposal by peripheral tissues. Treatment with glibenclamide, 
which augments insulin secretion, caused no effect on the fasting glycaemia. This is 
because its chief pharmacological effect is to overcome relative insulin deficiency 
and promote glucose disposal rather than reducing hepatic gluconeogenesis.
In the fasting state, both groups of diabetic patients were not significantly 
hyperinsulinaemic when compared to control subjects but had disproportionate 
amounts of intact proinsulin and 32-33 split proinsulin present. Thus our results 
confirm the finding that hyperinsulinaemia in type 2  diabetic patients is due to the 
secretion o f greater amounts o f insulin precursor species. This demonstrates the 
presence o f an impairment of P-cell function with the result that the contents of 
immature vesicles are released into the circulation. The major immature species o f 
insulin present in the circulation is 32-33 split proinsulin.
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Following treatment with pioglitazone there was a significant improvement in p-cell 
function as manifested by a significant reduction in proinsulin and 32-33 split 
proinsulin concentrations in the circulation. As expected sulphonylurea treatment 
with glibenclamide treatment caused a significant increase in basal insulin 
concentrations and also in proinsulin and split proinsulin secretion. Over stimulation 
of the p-cell could be a mechanism whereby immature secretory vesicles are released 
into the circulation thus explaining the increased amount of insulin precursor present 
after glibenclamide treatment, and the reduced amount present when the stress on the 
pancreas is reduced by improving insulin resistance with thiazolidinedione.
4.7.2 The effect of insulin sensitization on postprandial glycaemia and p-cell 
function in type 2 diabetic patient compared to normal subjects.
4.7.2.1 Baseline postprandial glycaemia and insulin release in diabetic and 
control subjects
Postprandial glycaemia in control subjects was far less than that in the diabetic 
patients. Prolonged glycaemia in the diabetic subjects cause chronic stimulation of 
the p-cells as shown by the greatly prolonged secretion o f insulin, proinsulin and 
split proinsulin that did not occur in the control subjects. This clearly demonstrates a 
defect in the glucose uptake by the peripheral tissues caused by the presence of 
insulin resistance and o f inadequate insulin secretion.
The effect o f test meal was to induce a severe hyperinsulinaemic state in the 
postprandial period in both groups of diabetic subjects which was associated with the 
presence o f a four-fold increase in the amounts o f insulin precursor species released. 
In this respect it is important to note that non-diabetic subjects secrete approximately 
15% of the total pancreatic insulin output as proinsulin and 32-33 split proinsulin. In
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type 2 diabetic subjects this increases to approximately 30%. This difference could 
be caused by chronic glycaemia in the diabetic subjects that stimulates the pancreas 
to secrete insulin for longer periods than would occur in control subjects. However, it 
cannot be ruled out that the development of type 2  diabetes is associated with a 
change in the protein processing and export apparatus.
4.7.2.2 The effect of treatment on postprandial glycaemia and insulin release in 
diabetic and control subjects
The effect of insulin sensitization with pioglitazone in type 2 diabetic patients was 
far more evident in the postprandial state when compared to the fasting results. 
Hyperinsulinaemia and hyperglycaemia were greatly reduced after insulin 
sensitisation. The overall p-cell response was reduced to that of control subjects 
showing a significant reduction in the glycaemic stimulus experienced by the p-cell. 
A plausible explanation for this could be that a reduction o f insulin resistance in the 
peripheral tissues and improved glucose disposal lowers the glycaemic stimulus to 
secrete insulin. In addition, indirect effects of improved clearance of postprandial 
lipid could result in reduced glycaemia as predicted by the Randle cycle (Randle et 
al., 1963). Not surprisingly, stimulation o f insulin release by glibenclamide showed 
the opposite effect to treatment with pioglitazone in that the glycaemic stimulation 
caused a very large release of insulin and insulin precursors.
The results suggest that the use o f a pioglitazone induces qualitative and 
quantitative changes in insulin secretion. These effects cannot be explained solely by 
the elimination of chronic stimulation by hyperglycaemia on p-cell secretion because 
similar results have been reported in normoglycaemic insulin resistant subjects 
(Berkowitz et al., 1996; Cavaghan et al., 1997). Other possible explanations could be
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the elimination o f toxic effects of free fatty acids on P-cell secretion, and direct 
effects of the thiazolidinedione on P-cells (Saltiel et al., 1996; Kaiyala et al., 1999).
4.7.2.3 The effect of insulin sensitisation on the HOMA model estimate of insulin 
resistance in type 2 diabetic patients compared to normal subjects.
The HOMA model estimate gives a usable indication o f an individual’s insulin 
resistance based on fasting insulin and fasting glucose measurements. Although this 
is not the best technique for measuring insulin resistance, it is the most practical for 
detailed study where clamps or insulin infusion sensitivity tests would be 
impractical. However, despite the drawbacks of the model, when performed on the 
subjects pre- and post-treatment it provide a valid index o f any changes that might 
occur.
Diabetic patients in the baseline state were more insulin resistant than the 
controls as judged by the HOMA estimate. Treatment with the insulin sensitizer 
pioglitazone was effective in reducing insulin resistance, which clearly had an effect 
on p-cells causing them to secrete less insulin to cope with the glycaemic stimulus 
and decreased the secretion of partially processed insulin species. HOMA scores 
were reduced by 39% in the pioglitazone treated patients. Whereas by contrast 
glibenclamide treatment did not improve insulin resistance. The magnitude o f the 
change in the HOMA scores caused by treatment with pioglitazone in this study is in 
agreement with those reported in the European Multicenter Trial using troglitazone 
(Gomez-Perez et al., 2002).
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4.7.2.4 The relationships between fasting and postprandial p-cell function and 
fasting and postprandial lipaemia.
The basal fasting plasma insulin concentration had no strong correlation with the 
extent of the lipaemia in the fasting and the postprandial state when data from all 
subjects were combined. By contrast, when fasting proinsulin and 32-33 split 
proinsulin concentrations were subjected to similar analyses, a significant correlation 
with fasting and postprandial lipaemia were found. The reason for this is most likely 
due to the much greater half-life o f proinsulin and 32-33 split proinsulin (40 min) in 
the circulation compared to that of insulin (5 min) (Temple et al., 1992). This allows 
for a more stable measurement of the insulin precursors than for insulin itself. It 
would seem from our result that measurement of proinsulin and 32-33 split 
proinsulin have some predictive value for the occurrence o f abnormal postprandial 
lipaemia.
The results o f this study clearly demonstrate an association between insulin 
resistance and the clearance of dietary lipid that can be improved by sensitization to 
insulin. Both overall triglyceride and in particular the clearance o f triglyceride-rich 
remnant particles are improved by sensitization to insulin through PPARy pathway. 
This could have an important therapeutic role in the prevention of atherosclerosis, 
since remnant particles clearance has been implicated in atherogenesis and this could 
be important in atherogenesis (Reaven et al., 1987; Zilversmit et al., 1979).
The improvement in insulin sensitivity seen with pioglitazone treatment in this 
study could involve a general action of TZDs causing increased peripheral glucose 
disposal and reduced hepatic glucose production acting together to reduce fasting 
glycaemia and consequently lowering the HOMA estimate of insulin resistance. This 
effect would be reinforced by the improvement in p-cell function and reduced insulin 
secretion to deal with the same stimulus.
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CHAPTER 5
INSULIN SENSITIZATION THROUGH THE PPARy RECEPTOR PATHWAY 
IN TYPE 2 DIABETIC AND CONTROL SUBJECTS: EFFECTS ON LIPASES, 
LCAT, CETP AND PLTP IN THE FASTING AND POSTPRANDIAL STATE.
5.1 Lecithin:cholesterol acyl transferase
LCAT is a key component in the reverse cholesterol transport pathway. This pathway 
serves to remove excess free cholesterol from peripheral tissues and transport it to the 
liver or to steroidogenic tissues in the form of cholesteryl ester for excretion as bile salts 
or steroid hormone synthesis (Jonas et al., 2000; Dobiasova et al., 1999). Phospholipid 
serves as the donor of the acyl group from the C2 position of phosphatidylcholine while 
free cholesterol originates from tissues and is passed to HDL by the action of the 
ABCA1 transporter. The importance of LCAT in lipoprotein metabolism is shown in 
individuals with mutations of the LCAT gene. Established mutations are associated with 
partial or complete absence of plasma LCAT activity, leading to fish eye disease (FED) 
or familial LCAT deficiency (FLD). FLD is characterized by hypertriglyceridaemia, 
markedly reduced HDL levels, cloudy corneas, haemolytic anemia and renal disease. 
Both groups of patients have reduced plasma concentrations of apo-AI and apo-AII but 
synthesis of these proteins is normal and the decreased plasma content results from 
increased catabolism of nascent HDL particles (Peelman et al., 2000; Santamarina et al., 
2000).
Of particular interest is a recent report that, in addition to having an effect on the 
metabolism of HDL, LCAT modulates the metabolism of the apo-BlOO containing 
lipoproteins by upregulating the LDL-receptor pathway. Thus it is proposed that LCAT
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beneficially modifies the plasma lipid profile by raising HDL and lowering LDL 
concentrations (Brousseau et al., 1997). However, studies in LCAT transgenic animal 
models have demonstrated that raising plasma HDL does not always confer protection 
against the development of atherosclerosis and, in the absence of CETP, LCAT over­
expression in mice leads to the formation of abnormal HDL with an impaired facility for 
reverse cholesterol transport (Tall et al., 1998). Expression of CETP, as well as apo-AI, 
corrects the dysfunctional properties of HDL from LCAT transgenic mice. However, in 
humans the effect of LCAT expression on plasma levels of LDL has not been 
extensively studied.
5.2 Lipid Transfer Proteins: CETP and Phospholipid Transfer Protein
Cholesteryl ester transfer protein (CETP) and phospholipid transfer protein (PLTP) play 
a central role in HDL metabolism. PLTP and CETP belong to a family of lipid 
transfer/lipopolysaccharide-binding proteins (LBP) and share sequence homologies, 
(Bruce et al., 1998). Their function is to facilitate the redistribution of lipids and by 
doing so enable cholesterol to be returned to the liver from peripheral tissues.
PLTP also plays an important role in plasma lipoprotein metabolism. It mediates 
the transfer of phospholipids to HDL from triglyceride-rich lipoproteins undergoing 
lipolysis by lipoprotein lipase. Surface fragments from chylomicrons and VLDL during 
lipolysis are important precursors of plasma HDL. PLTP can also remodel HDL 
particles. The interaction of PLTP with typical HDL results in the release of small, lipid- 
poor pre-p-HDL particles, and at the same time produces HDL2  particles by a process
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that involves particle fusion (Fielding et al., 2001). Pre-(3-HDL particles are efficient 
acceptors of free cholesterol from peripheral cells.
In fasting plasma, CETP is associated mainly with HDL and redistributes LCAT- 
derived cholesteryl esters from HDL3 to the apo-BlOO, containing lipoproteins (such as 
VLDL) and apo-B48 containing lipoproteins (chylomicrons and their remnants) in 
exchange for triglycerides (Eisenberg et al., 1985). The redistribution of cholesteryl ester 
by CETP to lipoproteins destined for hepatic uptake provides a mechanism for the 
transfer of peripheral tissue free cholesterol from the plasma to the liver. In addition to 
this role, CETP activity in conjunction with the hepatic lipase, provides a mechanism for 
the remodelling of LDL and HDL into smaller particles (Hopkins et al., 1986; Zambon 
et al., 1993).
PLTP also has an indirect role in the reverse cholesterol transfer pathway. An 
overexpression of PLTP in transgenic mice increases the pre P-HDL particle number 
which can then act as a source of ester synthesized from free cholesterol acquired from 
peripheral tissues through the ABCA1 transporter (Francone et al., 2003; Schlitt et al., 
2003). Variation in the plasma level of PLTP activity would be expected to be associated 
with variations in the cholesterol efflux capacity from the tissues.
5.3 Relationship of CETP and PLTP activity to lipid and glucose metabolism
Plasma CETP activity is highly variable being affected by a variety of metabolic 
conditions and dietary factors. Both CETP activity and mass are increased in obesity but 
not in weight-matched type 2  diabetic patients, and these levels correlate with total and 
LDL cholesterol concentrations (Morton et al,. 2003). Earlier studies have shown that
145
CETP mass and activity levels are increased in diet-induced hypercholesterolaemia. The 
CETP promoter gene contains a sterol regulatory element presumed to be responsible for 
sterol induction of CETP expression .
A partial understanding of these complex regulatory events has been gained in recent 
studies of type 2 diabetes patients and in Type Ha and lib hyperlipidaemic individuals, 
and through comparisons with phospholipid transfer protein. PLTP activity and mass are 
elevated in obese individuals with or without type 2 diabetes (Desrumaux et al., 1999). It 
has been reported that PLTP values correlate with insulin resistance, fasting glycaemia 
and HbAlC levels but not with plasma lipid parameters, however the mechanisms that 
underlie these elevated levels in diabetic patients are not well understood (Riemens et 
al., 1998). Elevated PLTP activity is often associated with increased VLDL turnover rate 
and inhibition of VLDL synthesis by insulin infusion results in decreased PLTP 
activities (Dullaart et al., 2001). Hypertriglyceridaemic patients have higher PLTP 
activity, but also a lower PLTP mass (Jonkers et al., 2003). During a hyperinsulinaemic 
euglycaemic clamp, PLTP, but not CETP activity, decreases acutely (Riemens et al., 
1998; Maclean et al., 2001). Collectively, these studies illustrate that PLTP activity is 
related in some fashion to glucose metabolism whereas CETP is related to lipid 
metabolism (Morton et al., 1999). A linkage of PLTP activity to glucose metabolism is 
consistent with the finding that PLTP is universally expressed in the plasma of all 
species studied, whereas CETP expression is highly species specific .
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5.3.1 Cholesteryl ester transfer protein and atherogenesis
Much attention has been focused on the potential benefit or liability of CETP activity in 
the process of atherogenesis since it is clear from numerous studies that CETP activity 
strongly influences HDL levels, its lipid and protein content, and the size and 
concentration of individual subfractions (Bruce et al., 1998). For example, recent studies 
in transgenic mice and individuals with low levels of CETP have clearly illustrated that 
under some conditions CETP activity is anti-atherogenic, even though the expression of 
CETP is accompanied by reductions in HDL cholesterol (Bruce et al., 1998; Hirano et 
al., 1997; Inazu et al., 2000; Tall et al., 1997). Similarly individuals with a CETP amino 
acid polymorphism (Bruce et al., 1998) associated with lower plasma CETP activity and 
higher HDL levels were found, to have an increased prevalence of CHD. Together these 
studies suggest that CETP can have a protective role. However, CETP deficiency is not 
necessarily pro-atherogenic if very high levels of HDL exist (Tall et al., 1998; Moriyama 
et al., 1998). In a survey of Japanese with high HDL levels (>2 mmol/L), it was found 
that 25-40% of these individuals were CETP deficient, but the prevalence of CHD was 
the same regardless of the presence or absence of CETP (Moriyama et al., 1998).
Inhibition of CETP has been proposed as a strategy to raise HDL cholesterol 
levels. The effects of torcetrapib, a potent inhibitor of CETP, on plasma lipoprotein 
levels in patients with low levels of HDL cholesterol (<1.0 mmol/L) increased plasma 
concentrations of HDL cholesterol by up to 106% depending on the dose and also 
reduced LDL cholesterol levels by 17% (Brouseau et al., 2004). This finding is 
consistent with the fact that patients with homozygous defects in the CETP gene have
r
reduced levels of LDL cholesterol (Inazu et al., 1990) and this is related to the increased
147
clearance of LDL cholesterol from the plasma (Ikewaki et al., 1995) suggesting that the 
LDL receptor pathway may be up-regulated in CETP deficiency. The mean particle size 
of both HDL and LDL was significantly increased by torcetrapib and this in agreement 
with recent report that CETP polymorphism (replacement of isoleucine with valine at 
position 405) that is linked to reduced CETP activity is significantly associated with 
longevity and large HDL and LDL particle size.
The relationship of CETP activity to the risk of coronary heart disease remains 
controversial (Barter et al., 2003). It is not clear whether CETP-deficient persons are 
protected from CHD; they may even be at increased risk (Zhong et al., 1996). In the 
Honolulu Heart program, a subgroup of subjects with a heterzygous CETP mutation who 
had HDL cholesterol levels in the range of 1- 1.6 mmol/L appeared to be at increased 
risk for coronary heart disease (Zhong et al., 1996). However, a recent analysis of seven 
year prospective data from this study did not reveal a significant relation between 
heterozygosity for CETP mutations and CHD or stroke (Barter et al., 2003). At the 
population level, that a common CETP genetic variant (Taq B2) is associated with 
reduced CETP activity, increased HDL cholesterol levels, and a reduced risk of CHD 
(Ordovas et al., 2000; Brousseau et al., 2002). Moreover, inhibition of CETP in rabbits 
has been found to result in reduced atherosclerosis.
Just as CETP expression is protective in some cases, in others it appears 
proatherogenic. In mice, where expression of either the apolipoprotein E or the LDL 
receptor gene has been knocked out, concomitant expression of high levels of CETP 
accelerates lesion development (Plump et al., 1999). By contrast rabbits fed on an 
atherogenic diet showed a suppression of CETP activity, concomitant decrease in LDL
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and VLDL cholesterol levels, increases in HDL cholesterol concentrations and 
decreased aortic content of cholesterol (Sugano et al., 1998). The results of these studies 
suggest that under conditions where VLDL remnants and LDL accumulate (either by 
reduced clearance and/or increased production), CETP activity enhances atherogenesis. 
These and other studies illustrate that the balance of individual HDL species, which 
results from the complex interaction of cholesterol esterification and lipid transfer 
proteins, and not necessarily absolute HDL levels, define the protection generally 
afforded by high HDL levels (Berard et al., 1997; Hoeg et al., 1996).
Overall, these data strongly suggest that the dynamics of cholesterol movement 
through HDL underlie its anti-atherogenic potential (Bruce et al., 1998). This process, a 
key component of reverse cholesterol transport, is protective under normal conditions, 
but appears to be injurious when catabolism of the acceptor lipoproteins, VLDL and 
LDL, is compromised. In instances where HDL levels are very high, the absence of 
CETP activity appears to be adequately compensated by other mechanisms.
5.3.2 CETP activity and insulin resistance
The results of several studies of type 2 diabetic patients have suggested a link between 
plasma CETP activity and insulin resistance. When undergoing euglycaemic clamps 
type 2 diabetics showed a decrease in plasma CETP in response to exogenous 
hyperinsulinemia than did healthy control subjects (Sutherland et al., 1994, 2001; 
Riemens et al., 1998).
Animal studies have shown that CETP from hamster adipose tissue is increased 
during fasting and decreased with feeding (Jiang et al., 1991). These results suggest that
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insulin action in adipose tissue and muscle may be controlling CETP levels by indirect 
effects. It is known that insulin activates lipoprotein lipase and this enhances remnant 
clearance. Another possible explanation is that insulin action in adipose tissue and 
muscle decreases CETP and PLTP gene expression in these tissues. In turn, CETP 
expression in peripheral tissues could increase the effectiveness of insulin signal. CETP 
action on HDL promotes efflux of cholesterol from plasma membranes, improving 
insulin signalling by maintaining membrane cholesteroliphospholipid ratio in an 
appropriate range (Jonas et al., 1998).
5.4 Lipoprotein lipase and Hepatic lipase
Lipoprotein lipase (LPL) plays an essential role in the hydrolysis of plasma triglyceride. 
LPL activity is impaired in diabetes (Eckel et al., 1989; Pulawa et al., 2002), in obesity 
and other states of insulin resistance (Cominacini et al., 1993). Direct estimation of LPL 
action by measuring the extraction of plasma TG in subcutaneous fat showed that the 
enzyme is increased postprandial, but this response is blunted or absent in obese subjects 
(Coppack et al., 1992) and it has been suggested that the postprandial activation of LPL 
results from an increase in the specific activity of the enzyme and not from increased 
transcription and secretion (Coppack et al., 1992; Sakayama et al., 1992).
Impaired postprandial activation of LPL has several consequences. First, it 
prolongs the postprandial elevation of plasma triglyceride concentrations. Second, 
lipolysis of triglyceride-rich lipoproteins is impaired; this inhibits the entry of 
cholesterol into HDL pool, which occurs via the transfer of excess redundant surface 
material (including cholesterol) to HDL during the lipolysis of triglyceride-rich
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lipoproteins. Third, the prolonged residence time of triglyceride-rich lipoproteins in the 
circulation leads to increased exchange of their triglyceride with cholesterol ester in 
HDL through the action of CETP.
Hepatic lipase does not seem to be concerned with the supply of NEFA to the 
tissues to the same extent as the LPL. Its role would seem to be more involved with the 
remodelling of lipoproteins particularly HDL and LDL. In the case of HDL, HL is active 
in the hydrolysis of triglyceride enriched HDL species, remodelling them to a small 
particles possibly ready to participate in further cholesteryl ester synthesis or 
alternatively be excreted as apo-AI through the kidney. In addition to these effects, LDL 
remodelling by HL can give rise to small dense particles which are known to be 
atherogenic (see Chapter 1).
5.5 Aims of the study
The aims of this part of the study were to assess the effect of insulin sensitization and 
postprandial lipaemia on the rates of plasma cholesterol esterification by LCAT, 
cholesteryl ester transfer by CETP, phospholipid transfer by PLTP, LPL and HL 
activity. LCAT, CETP and PLTP were measured in the fasting state and 4 hours after the 
test meal (according to the methods described in Chapter 2). And before and after 
treatment with pioglitazone in order to establish the extent to which postprandial 
lipaemia influences their activities.
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5.6 Results
5.6.1 The effect of insulin sensitization on fasting and postprandial LCAT activity 
in type 2 diabetic patients and control subjects
Result of LCAT measurement in diabetic subjects compared to the control subjects are 
shown in Table 16. It can be seen that there were no differences in LCAT activity 
between the diabetic patients and the control subjects at baseline and after either 
treatment. Four hours after the test meal, plasma cholesterol esterification by LCAT 
increased significantly from the fasting level in both diabetic groups in the baseline 
conditions, but not in the control subjects (Paired t-test glibenclamide p<0.04, 
pioglitazone p<0.01, controls p = NS).
Table 16: Fasting and postprandial plasma LCAT activity in diabetic and control 
subjects before and after treatment
LCAT activity (nmole free cholesterol esterfied/L/hr)
Glibenclamide Pioglitazone Control
Baseline Fasting 49.0118.1 37.9112.5 42.819.2
4-hr postprandial 58.6*113.3 51.9*115.8 46.0110.7
Post-treatment Fasting 50.5113.3 41.1113.8
4-hr postprandial 48.4120.8 51.6120.0
Values are mean ± S.D 
Fasting vs 4 hr: * p < 0.05.
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After treatment with either pioglitazone or glibenclamide there was no change in the 
fasting activity of LCAT from the baseline conditions, but 4 hours postprandial, by 
contrast to the baseline condition, there was no longer statistically significant increase in 
LCAT activity in either group of patients.
5.6.2 The effect of insulin sensitization on fasting and postprandial CETP activity 
in type 2  diabetic compared to control subjects
Results of CETP analyses in diabetic subjects compared to the control group are shown 
in Table 17.
At baseline in all three groups, there was a significant increase in the 
postprandial rates of net cholesteryl ester transfer by CETP (Paired t-test glibenclamide 
P<0.01, pioglitazone p<0.003, control p< 0.002). There was no significant difference in 
CETP activity between the 3 groups in the fasting state or 4 hour after the test meal.
Table 17: Fasting and postprandial CETP activity in diabetic and control subjects 
before and after treatment
CETP activity (jumole cholesterol ester transfered/L/hr)
Glibenclamides Pioglitazone Control
Baseline Fasting 10.5 ±9.7 8 .0 ± 6 . 1 8.213.7
4-hr postprandial 24.0f ± 15.7 23.0t t ±13.2 20.4* f ± 8.9
Post-treatment Fasting 6.4 ±2.9 8.7 ±4.9
4-hr postprandial 20. l f f ±9.8 18.2f ±11.9
Values are mean ± S.D.
Fasting vs 4 hr:t p < 0.02; p < 0.002
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Both groups of diabetic subjects after treatment showed the same pattern of 
increase in cholesteryl ester transfer by CETP after the test meal (Glibenclamide p < 
0.0005, pioglitazone p < 0.002, control p < 0.002). As at baseline Insulin sensitization 
did not change the activity of CETP and neither did glibenclamide treatment.
No correlation’s were found between the fasting rate of plasma cholesterol 
esterification and fasting triglyceride, total cholesterol, HDL cholesterol and 
measurements of glycaemic control. The fasting rate of net cholesteryl ester transfer did 
not correlate with fasting lipids, fasting glucose or HbAlC concentrations in the diabetic 
subjects (data not shown). A LCAT, A CETP did not correlate with the AUC of 
triglyceride, chylomicron RP, and chylomicron remnant RP.
5.6.3 The effect of insulin sensitization on fasting and postprandial PLTP mass in 
type 2 diabetic compared to control subjects
The result of PLTP analyses in diabetic subjects compared to the control group are 
shown in Table 18.
Fasting PLTP mass in the baseline condition was significantly less in both 
groups of diabetic subjects when compared with control subjects. There were no 
significant changes in PLTP mass postprandialy in the diabetic groups or control 
subjects.
After treatment with the insulin sensitizer pioglitazone, fasting PLTP mass was 
increased significantly from the baseline and became not significantly different from the 
control subjects. Glibenclamide treatment showed no effect on fasting PLTP mass and 
remained significantly lower than the control subjects.
154
Table 18: Fasting and postprandial PLTP activity in diabetic and control subjects 
before and after treatment
PLTP MASS
Glibenclamide Pioglitazone Control
Baseline Fasting 1.64* ±0.24 1.56* ±0.22 1.86± 1.72
4-hr postprandial 1.52 ±0.27 1.48 ±0.28 1.62 ±0.08
Post-treatment Fasting 1.59 *±0.33 1.691 ±0.17
4-hr postprandial 1.52 ±0.27 1.51f ± 0.25
Values are mean ± S.D.
Patient groups vs control subjects: *p < 0.05.
Fasting vs 4 hr t p < 0.05. Baseline vs post-treatment for each group: *p < 0.05
There was a significant correlation between PLTP mass and HDL cholesterol 
content when analysed by Spearman rank (r = 0.58, p < 0.05), no correlation were found 
with fasting and triglyceride AUC, NEFA, insulin resistance (HOMA), glucose and 
HbAlC.
5.6.4 The effect of insulin sensitization on fasting LPL and HL activities in type 2 
diabetic compared to control subjects
The result of lipase analyses in diabetic subjects compared to the control group are 
shown in Table 19.
Post-heparin plasma LPL activity was similar in all three groups both at baseline 
and after treatment. Hepatic lipase activity was higher in the diabetic groups than the 
control subjects. No statistically significant changes in the plasma concentration of 
hepatic lipase were observed after either treatment and remained significantly higher in 
both diabetic groups of patients compared to control subjects (Table 19).
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No significant correlation’s between LPL or HL with the postprandial parameters was 
observed at baseline or after treatment with glibenclamide or pioglitazone (Table 20).
Table 19: Post-heparin lipoprotein lipase and hepatic lipase activities (pmol NEFA 
released/ml/hr)
Glibenclamide Pioglitazone Controls
LPL Baseline
Post-treatment
9.6 ±2.6 
11.4 ±4.5
9.5 ±4.3 
8.3 ±2.7 8 . 8  ±3.5
HL Baseline
Post-treatment
2 1 .2 * ± 1 1 . 8  
20.6* ± 9.8
24* ± 10.8 
23.4* ± 12.2 13.8 ±6.2
Values are means ± SD
Diabetic group vs controls: * P < 0.05.
Table 20: Relationships between LPL and HL activities (pmol NEFA 
released/ml/hr) with postprandial lipaemia AUC (mmol/L)
Glibenclamide Pioglitazone Controls
TG (AUC) -0.48 -0 . 1 -0 . 1 0
LPL C-RP (AUC) -0 . 0 1 -0.34 -0.29
CR-RP (AUC) -0.08 -0.09 -0.09
TG (AUC) 0.35 0.25 0.53
HL C-RP (AUC) -0 . 0 2 -0.34 0.64*
CR-RP (AUC) 0.41 0.38 0.29
Spearman rank correlation: * P < 0.05.
C-RP Chylomicron retinyl palmitate.
CR-RP Chylomicron remnant retinyl palmitate.
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DISCUSSION
5.7.1 Lecithin: cholesterol acyl transferase activity
In this study I have demonstrated that the rate of fasting free cholesterol esterification is 
similar in diabetic and control subjects. This is in agreement with previous findings 
(Durlach et al., 1996). Four hours postprandial there was a significant increase in LCAT 
activity in the diabetic patients but not in the control subjects. This finding supports a 
direct or indirect role for triglyceride on LCAT activity. One possible explanation is that 
lipolysis of triglyceride-rich lipoproteins gives rise to an excess of phospholipid which is 
then transferred to HDL by PLTP and so providing additional acyl group-containing 
substrates as donors for LCAT (Marcel et al., 1980). Postprandial LCAT activity did not 
increase in control subjects which may be due to a much smaller rise in the 
concentration of postprandial triglyceride-rich lipoproteins. In this study I did not find 
any correlation between LCAT activity and triglyceride. However, previous studies have 
reported that LCAT activity correlates positively with the concentration of plasma 
triglyceride (Durlach et al., 1996). It has also been reported that LCAT activity is greater 
in type 2 diabetic subjects (Riemens et al., 1998) in contrast to my results. The reasons 
for these differences are uncertain but would seem to be related to the extent of 
hypertriglyceridaemia. If the data from hypertriglyceridaemic subjects are excluded, 
there was no longer a significant difference in LCAT activity in the diabetic patients 
than from the controls as I found in my study. The patients in my study were not as 
severely hypertriglyceridaemic.
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No significant relationship was found between LCAT activity and the HOMA 
estimate of insulin resistance (Data not shown). Given this lack of association, it is not 
surprising that insulin sensitization through the PPARy pathway had no effect on the 
LCAT activity. Similarly glibenclamide had no effect.
5.7.2 Cholesteryl ester transfer protein
In this study fasting CETP activity was similar in the diabetic and control subjects. This 
finding is at variance with the earlier findings of Fielding et al (Fielding et al., 1984; 
Riemens et al., 1998) which showed a lowered fasting rate of net cholesteryl ester 
transfer in diabetic subjects compared to normal individuals. One possible explanation 
for this discrepancy is the difference in glycaemic control in the subjects studied by 
Fielding et al. The patients in their study were poorly controlled with fasting glucose in 
the range of 13-16 mmol/1, whereas the patients in the present study had fasting glucose 
< 9.0 mmol/L.
In this study, a highly statistically-significant postprandial increase in the rate of 
CETP activity was demonstrated in control and diabetic subjects. The postprandial 
increase was of a similar order of magnitude (2-3 fold increase) in the diabetic patients, 
before and after treatment, and the control subjects. The effect of postprandial lipaemia 
on CETP activity could depend on the balance between the transfer of surface 
components from chylomicrons to make new HDL that subsequently esterify free 
cholesterol by LCAT and export it by CETP.
The relative proportion of both donor and acceptor lipoprotein particles are known to 
significantly influence cholesteryl ester transfer mediated by CETP (Guerin et al., 1996,
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2002; Bagdade et al., 1993; Mann et al., 1991). An earlier study has reported increased 
cholesteryl ester transfer from HDL to VLDL in patients with hypertriglyceridaemia. 
Similarly, other studies have reported elevated cholesteryl ester transfer from HDL to 
LDL in patients with hypercholesterolaemia (Mann et al., 1991). It has also been shown 
that during postprandial lipaemia in normolipidaemic subjects, CETP mediated an 
enhanced rate of cholesteryl ester transfer from HDL to both chylomicron and VLDL-I 
but LDL remained the major cholesterol acceptor of the apo-B containing lipoproteins in 
the fasting state (Lassel et al., 1999). In addition to these observations, an increase in the 
relative triglyceride content of the lipoprotein acceptor particles has been shown to 
increase its capacity to accept cholesteryl ester transferred by CETP (Liu et al., 1995).
Treatment with pioglitazone or glibenclamide had no effect on CETP activity either 
in the fasting state or 4 hour postprandial. No correlations were found between p-cell 
function, HOMA or lipaemia. It cannot be ruled out that glycaemic control exerts an 
influence on CETP activity because in this study it was deliberately maintained by the 
treatment regime.
5.7.3 Phospholipid transfer protein
In this study fasting PLTP mass was found to be significantly lower in diabetic patients 
compared with control subjects at baseline and did not change postprandial. This finding 
is in agreement with previous reports (Elchebly et al., 1996; Jonkers et al., 2003). In 
agreement with other reports we found only a correlation between PLTP mass and HDL 
and not with HOMA or indices of beta-cell function and lipaemia. However other 
reports have indicated that PLTP activity, but not mass, is related to insulin resistance in
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type 2 diabetic patients, but in the present study PLTP activity was not measured 
(Jonkers et al., 2003).
Sensitization to insulin had the effect of increasing PLTP mass present to that of 
the control subjects despite there being no correlation with the HOMA estimate. By 
contrast glibenclamide treatment had no effect on fasting and postprandial PLTP mass. 
The positive correlation between PLTP mass and HDL cholesterol is not unexpected 
given that the PLTP protein is intimately associated with HDL particles.
5.7.4 Lipoprotein and hepatic lipase activity.
No differences were found in lipoprotein lipase activity before and after treatment with 
glibenclamide or pioglitazone and neither did the activity in the patient groups differ 
from that of the control subjects. The values obtained were in good agreement with 
published values using this method. In addition, the pre- and post-treatment samples 
were assayed at the same time using the same batch of substrate and should have 
revealed any changes when analysed by paired t-test. The activities of HL and LPL in 
post-heparin plasma were assayed under condition of substrate excess and it cannot be 
ruled out that this does not reflect substrate availability in vivo. Similarly the availability 
of apo-CII (LPL activator) and apo-CIII (LPL inhibitor) may modulate in vivo activity 
that is not reflected in the in vitro activity measured in the presence of excess apo-CII as 
in this study. Further studies on the concentration of these co-factors in post- heparin 
plasma from patients pre- and post-treatment may reveal differences not seen in in vitro 
measurements.
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Previous studies have reported an increase in LPL activity after treatment with 
TZDs (Kageyama et al., 2003; Kletzien et al., 1992; Lefebvre et al., 1997). This is not 
unexpected since the synthesis of the protein is thought to be one of the targets of 
PPARy and also influenced by insulin. The reasons why our result are at variance with 
previous report could be because of: 1) differences in the severity of lipaemia, 2) 
differences in the severity of insulin resistance. Our data does not support any 
relationship between postprandial lipaemia and lipase activity but again an assessment of 
lipase activity in vivo may well demonstrate a relationship. Further studies are required 
to resolve this issue.
Unlike LPL, hepatic lipase activity is not known to require the presence of 
apolipoprotein to regulate activity. Post-heparin plasma samples were assayed as before 
at the same time and with the same substrate and were found to be significantly higher in 
the diabetic patients compared with control subjects in agreement with previous reports 
(Rashid et al., 2003; Tan et al., 2001). No effects of TZDs on reducing the HL activity 
have been reported in agreement with our results. Indirect evidence is however available 
from studies on the effect of TZDs treatment on small dense LDL. Reduced 
concentrations of these particles have been reported with TZDs and HL activity is 
thought to be a major determinant for the production of small dense LDL. However, 
since the extent of hypertriglyceridaemia is a critical determinant for the generation of 
small dense LDL and the patients in this study were only modestly 
hypertriglyceridaemic with only few showing the atherogenic profile, it is perhaps not 
surprising that we found no effect of treatment with pioglitazone that are evident in more 
severely hypertriglyceridaemic patients.
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CHAPTER 6 
CONCLUDING REMARKS
6.1 PPARy ACTIONS
Thiazolidinediones are a class of oral anti-diabetic agents that selectively 
enhance or partially mimic certain actions of insulin. These effects have been 
documented in a variety of genetic and animal models of insulin resistance, as 
well as in numerous clinical trials in patients with insulin resistance. Increasing 
sensitivity to insulin is achieved by modulating the activity of the PPARy 
receptor. In the nucleus, PPARy exists as a heterodimer with the nuclear retinoid 
X receptor (RXR). The heterodimer binds to PPAR response elements within the 
promoter regions of target genes. In the unliganded state, the PPARy-RXR 
heterodimer is associated with a multiprotein corepressor complex that has 
histone deacetylase activity. Deacetylated histone keeps the nucleosome in a state 
in which transcription is inhibited. This histone is important in chromatin 
remodelling, which facilitates gene transcription (Glass et al., 2000). When 
ligand binds to the receptor, the co-repressor complex dissociates and a co­
activator complex with histone acetylase activity is recruited to the PPAR-RXR 
heterodimer (Saltiel et al., 1996). The activation of PPARy by ligands correlates 
well with the antidiabetic action of TZDs. The physiological role of PPARy is to 
maintain an appropriate level of expression of key glucose and liporegulatory 
molecules, as well as other proteins that are involved in the transduction of the 
insulin signal, which ultimately facilitates a state of normal insulin sensitivity.
The reversal of insulin resistance with PPARy activation could be 
explained by a variety of different mechanisms:
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• PPARy up regulates the synthesis of signalling proteins in mature fat cells 
both in vitro and in vivo (Baumann et al., 2000; Ribon et al., 1998) that are 
linked to the insulin receptor. Tyrosine phosphorylation then initiates a 
signaling pathway that is essential for insulin-stimulated glucose transport 
(Baumann et al., 2000).
• Thiazolidinedione treatment has been associated with a decrease in 
circulating non-esterified fatty acid concentrations (Saltiel et al., 1996). 
However, it is unclear whether the lowering of NEFA by TZDs represents a 
direct action on adipocytes or whether this is secondary to a general 
improvement in insulin sensitivity due to the enhancement of the anti­
lipolytic effects of insulin. Given the relatively high level of expression of 
PPARy in fat cells and that TZDs are strongly adipogenic, it is possible that 
the primary actions of TZDs are exerted on fat cells that in someway 
feedback to stimulate the skeletal muscle and improve insulin action. This 
could involve a TZD-mediated effect on adipocytes such as decrease in 
circulating free fatty acid levels, or altered of peptide secretion such as TNF- 
a  (Shibasaki et al., 2003; Marx et al., 2002) and they have been shown to 
increase adiponectin (Satoh et al., 2003; Stumvoll et al., 2003).
• It has also been proposed that TZDs act directly on skeletal muscle to 
increase glucose uptake, rather than the effects being secondary to an action 
on adipocytes. In vitro studies have revealed that TZDs directly enhance 
glucose transport in cultured muscle cells (Vidal-Puig et al., 1997). Studies in 
transgenic mice in which deficient in adipose tissue have shown that these 
animals are insulin resistant and treatment with TZDs resulted in a striking
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improvement in insulin sensitivity (Burant et al., 1997). This suggests that 
TZDs act directly on skeletal muscle.
In an attempt to elucidate the role of PPARy in glucose homeostasis and insulin 
resistance, the gene encoding PPARy has been knocked out in mice but complete 
deletion of both alleles (PPARy'7') is not compatible with life and the animals die 
in utero. However heterozygous knockout mice PPARy +/\  which lack one 
PPARy allele are viable. These PPARy +/' mice were expected to be insulin 
resistant and possibly diabetic but, on the contrary, studies on these animals, 
including oral glucose tolerance tests and euglycaemic clamp, revealed that a 
50% reduction in PPARy expression led to enhanced peripheral and hepatic 
insulin sensitivity (Barak et al., 1999; Miles et al., 2000). These results have led 
to the hypothesis that the normal role of PPARy, through its natural ligands, 
might be to reduce or dampen insulin action, thereby promoting a state of insulin 
resistance.
The decreased expression of PPARy that is seen in these mice would 
partially alleviate this effect and lead to increase insulin sensitivity. This also 
implies that inhibiting PPARy function might render animal less susceptible to 
the endogenous and exogenous causes of insulin resistance. This finding is 
supported by studies of a mutation in the human PPARy gene in which the 
patient exhibited decreased plasma content of insulin, enhanced insulin 
sensitivity and had lower body mass index (Deeb et al., 1998). Other reported 
mutations in the ligand-binding domain of PPARy have been described in three 
patients but these patients were insulin resistant and hypertensive (Barroso et al., 
1999) presumably because the natural ligand does not have a high affinity for the
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mutated receptor. These data provide strong evidence that PPARy is involved in 
the control of insulin sensitivity, glucose homeostasis and hypertension -  
important factors in CHD risk.
It is a paradox that PPARy expression increases insulin resistance while 
TZDs ligands for the PPARy receptor reduce insulin resistance. The concept of 
TZDs as partial agonist/antagonist has been supported by several studies and it is 
clear, from experimental studies that there is likely to be considerable 
heterogeneity of actions within the TZDs class (Olefsky et al., 2000). This 
depends on whether the compounds are full or partial agonists for the PPARy 
receptor. In studies using a prompter/ reporter assay troglitazone behaved as a 
partial agonist whereas pioglitazone and rosiglitazone behaved as full agonists 
(Camp et al., 2000). As discussed above, studies in knockout mice heterozygous 
for PPARy deficiency surprisingly showed enhanced insulin sensitivity in 
peripheral tissue and liver. The TZDs may displace endogenous ligands, which 
presumed to act as pure agonists. Therefore, TZD-induced insulin sensitivity may 
reflect the ability of these compounds to inhibit the dampening effect on insulin 
action of endogenous ligands (Olefsky et al., 2000). In addition to differences 
between TZDs in term of full or partial agonist, differences have been reported in 
the sets of genes induced or suppressed by troglitazone, pioglitazone and 
rosiglitazone together with overlapping effects (Camp et al., 2000). For these 
reasons, each compound is likely to have individual effects as well as common 
effects of the class. Each TZD has different binding affinity, with different 
residence times on the receptor. This indicate that the conformation of the TZD- 
PPARy complex differ according to which ligand is bound (Fig 27 ).
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A recent study has compared the effects of pioglitazone and rosiglitazone 
monotherapy and combination therapy on fasting blood lipid levels and HbAlc 
in patients with type 2 diabetes (Olansky et al 2003). In a multi-centre 
retrospective chart review of 1115 records of patients with type 2 diabetes who 
received pioglitazone or rosiglitazone, alone or in combination with other 
antidiabetic agents, between August 1, 1999, and August 31, 2000.
The demographic characteristics, co-morbidities, and concomitant drug use 
were similar in both treatment groups. O f the patients who received pioglitazone, 
83% also received anti-hyperglycaemic agents and 59% received some form of 
anti-hyperlipidaemic therapy. Among those who received rosiglitazone, 81% 
received concomitant anti-hyperglycaemic medication and 60% received some 
form of anti-hyperlipidaemic therapy. With pioglitazone, mean concentrations of 
serum triglyceride, total cholesterol, and LDL-cholesterol decreased and HDL 
cholesterol increased in most patients, with or without concomitant anti- 
hyperglycaemic medications. Treatment with rosiglitazone, with or without other 
antidiabetic agents, decreased plasma triglyceride and HDL cholesterol 
concentrations, whereas total cholesterol and LDL cholesterol levels increased in 
most patients. Reductions in HbAlc levels and increases in body weight related 
to each study drug were comparable. It was concluded that in both monotherapy 
and combination treatment regimens, pioglitazone was associated with greater 
beneficial effects on lipids than was rosiglitazone. Similar results suggesting 
greater beneficial effects of pioglitazone on fasting lipids when compared to 
rosigltazone have been observed in other independent comparative studies 
(Gegick et al., 2001; Khan et al., 2001; King et al., 2000; 2001). Further
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dedicated studies comparing the long term effects of both drugs may provide 
more information on their effectiveness with regard to cardiovascular effect.
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Figure 28: A model for TZDs action on PPARy to explain different effects. Different 
ligands (1, 2, 3) bind to the ligand-binding domain of PPARy. Each ligand-receptor 
complex assumes a different conformation that leads to unique and differential 
interactions with co-factors, histones, other transcription factors, etc. As a result of these 
differential interactions, each PPARy ligand-receptor complex leads to a differential, but 
overlapping, pattern of gene expression, i.e. each ligand activates (or represses) a 
certain set of genes, some of which are common to other ligands and some of which are 
not. Adapted from TEM Vol. 11, No. 9, 2000.
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6.2 MAJOR FINDINGS OF THE EFFECTS OF INSULIN 
SENSITISATION BY PIOGLITAZONE IN THIS STUDY
This study is the first to investigate the effect of pioglitazone on postprandial 
lipid clearance compared to the effect of sulphonylurea treatment (glibenclamide) 
in a group of patients with type 2  diabetes in a treatment regimes designed to 
keep the glycaemic control the same.
The most striking effects found by treatment TZD patients with the insulin 
sensitizer pioglitazone were evident in:
1) Triglyceride management: a reduction in fasting triglyceride, VLDL and 
improved postprandial triglyceride clearance.
2) Improved management of intestinal lipoproteins leading to a more rapid 
clearance of dietary fat.
3) Improved p-cell function with less insulin secreted to deal with the same 
meal and a reduction in the amount of immature secretory granules released.
Effects On Triglyceridaemia
In this study we set out to examine the effect of insulin sensitization on 
postprandial lipid metabolism at the same level of glycaemic control. This was 
achieved as assessed by the fact that there were no significant change in HbAlC 
by either glibenclamide or pioglitazone treatment. Pioglitazone treatment 
generally reduces the circulating concentrations of fasting and postprandial 
triglyceride. This has been attributed to decreased hepatic VLDL synthesis and 
increased peripheral clearance of remnants particles, together with reduced 
lipolysis.
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That insulin sensitization did not have a marked effect in decreasing 
insulin-dependent NEFA release from adipose tissue but made a significant 
improvement in glucose disposal provides some evidence in favour of the theory 
that thiazolidinediones act directly both on skeletal muscle and adipose tissue. 
While PPARy expression in skeletal muscle is only 10% of that in adipose tissue, 
the larger bulk of muscles could make this a significant target for TZDs. In 
addition, low affinity binding of TZDs to other PPARs (PPARa and PPAR5) 
might also occur in muscle and liver resulting in different biological effects to 
those seen in adipocytes (Forman et al., 1995).
A recent study has suggested that pioglitazone can have PPARa activity 
(Ikeda et al., 2001) however our results did not support involvement of PPARa 
since we did not find any changes in the plasma concentrations of apo-AI, known 
to be under the control of PPARa. Supporting this conclusion is our finding that 
HDL cholesterol concentrations were also unchanged by treatment with 
pioglitazone. Previous reports of an effect of pioglitazone on raising HDL levels 
are thus more likely to occur as a secondary effect arising from overall 
improvement in insulin resistance leading to improved HDL remodelling 
processes rather than a direct stimulation of apo-AI synthesis.
A major effect of TZDs is to stimulate adipogensis (Adams et al., 1997; 
Hallakou et al., 1997). Such an effect is reported to cause significant weight gain 
but this was not observed in the patients treated with pioglitazone in the current 
study (Spiegelman et al., 1998; Tordjman et al., 2003).
In this study pioglitazone significantly lowered circulating triglyceride 
and showed a trend to reduce NEFA concentrations. This could cause an increase 
in insulin sensitivity by correcting imbalances in glucose fatty acid cycle (Randle
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cycle). NEFA can impair insulin action and glucose metabolism in several ways. 
A high NEFA level impairs hepatocyte insulin sensitised function, decreased 
hepatic insulin uptake and enhances gluconeogenesis (Storlien et al., 1996). In 
skeletal muscle when NEFA concentrations are high, fatty acids are oxidised by 
muscle cells in preference to glucose. Finally, NEFA may also influence insulin 
production since it is known that long term exposure of p-cells to insulin 
production impairs the insulin secretory response to glucose.
In summary sensitization of the tissue to the action of insulin with 
pioglitazone modifies fasting and postprandial lipid and lipoprotein metabolism 
in type 2  diabetes, resulting in reduced fasting plasma triglyceride concentrations 
and attenuated postprandial lipaemia.
Management and Clearance of Intestinal Lipoproteins
Sensitization to insulin improved the clearance of chylomicron and chylomicron 
remnants. The mechanism by which is this occurs is not known but is unlikely to 
involve effects of glycaemia since glycaemic control was unchanged from the 
baseline test when delayed clearance of intestinal lipoproteins was evident. The 
results of this study indicate that lipolysis by LPL is an unlikely factor in the 
reduced clearance since pioglitazone treatment apparently made no effect on the 
lipase activity. However, these results must be interpreted with caution because 
the activity expressed in vitro under optimal conditions may not reflect the 
situation in vivo caused either by the supply of regulatory apolipoproteins such as 
apo-CII and apo-CIII. Further studies in the apolipoprotein complement of 
chylomicron and chylomicron remnants may well reveal changes in the nature of 
the particles after sensitization to insulin. By attenuating the magnitude and
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duration of postprandial lipaemia, pioglitazone therapy may limit the vascular 
exposure to a potentially damaging environment.
Improved P-Cell Function
Sensitization of peripheral tissue to the action of insulin had a beneficial effect 
on p-cell function. Less insulin was secreted in response to the post-treatment 
test meal compared to the baseline test and, in addition, the fasting 
concentrations was also significantly reduced. While it may be that more 
effective glucose uptake by peripheral tissues and a reduced hepatic glucose 
output is responsible for providing a smaller stimulus to the p-cell resulting in a 
smaller amount of insulin secretion, it can not be ruled out that there is a direct 
effect of pioglitazone on the p-cell causing it to secrete less insulin. In this study 
pioglitazone caused an improvement in p-cell function in both a qualitative and 
quantitative fashion. These results are supported by an earlier trial, the TRIPOD 
study (Troglitazone in prevention of Diabetes), that showed an improvement of 
p-cell function after treatment with troglitazone (Buchanan et al, 2002). It was 
found that chronic administration of troglitazone 400 mg for 30 months reduced 
the incidence of diabetes by > 50% in high-risk Hispanic women with previous 
history of gestational diabetes. These subjects had insulin resistance and poor p- 
cell compensation during pregnancy (Buchanan et al, 1999). The treatment 
preserved p-cell function, for at least 8  months after the drug was stopped as 
assessed by oral glucose tolerance test and intravenous glucose tolerance tests. 
The increase in the whole body tissue insulin sensitivity was most evident in 
women who showed a large reduction in insulin output. Taken together, these 
findings provide strong support for the concept that type 2  diabetes results from
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progressive P-cell dysfunction that is caused at least in part by high secretory 
demands.
Insulin sensitization with pioglitazone did not only reduced the amount of 
insulin secreted but improved the processing of insulin precursor resulting in a 
reduction of the amounts of proinsulin and 32-33 split proinsulin released both in 
the fasting state and postprandial after the test meal. This suggests that there has 
been less pressure on the need to secrete insulin-containing granules or that the 
proteolytic processing mechanisms are more effective after insulin sensitization.
These beneficial therapeutic effects of pioglitazone treatment described in 
this thesis may reduce the risk of vascular disease in type 2  diabetic patients. 
However, this can be only be fully evaluated by further detailed studies and by 
large, long-term, well-designed intervention trials.
Limitations of the study
This study has certain limitations brought about by the strict entrance criteria 
which precluded recruiting patients who were receiving statin therapy and the 
need to bring the study to a conclusion within three years. The result of these 
restraints led to the study groups of diabetic patients being small and of different 
ethnic origin. The control subjects however had no family history of type 2 
diabetes which otherwise have confounded the interpretation of the data.
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